

**PROGRAMME
AND
ABSTRACTS**

Thorax


British Thoracic Society Winter Meeting 2010


The Queen Elizabeth II Conference Centre
Broad Sanctuary
Westminster
London SW1P 3EE


**1 to 3 December 2010
Programme and Abstracts**

Map to QEII Conference Centre


PowerPoint preview facilities will be available throughout the three days of the Meeting in the Thames Room on the first floor of the Centre. All presenters and chairs should report to the Speakers' section of the Registration Desks on arrival.





 The nearest tube stations are St James's Park and Westminster on the District and Circle Lines.

 Bus routes 24, 11 and 511 all stop nearby.

 Parking facilities are available nearby, but are very limited.


 Victoria Station is approximately 15 minutes' walk down Victoria Street from the Conference Centre.

QEII Conference Centre – Ground and First Floors




Full cafe facilities will be open from 8.00am to 4.00pm each day in the Pickwick Suite on the 1st floor. A snack bar, serving hot and cold drinks, sandwiches and confectionery only, will be open in the Whittle & Fleming Rooms on the 3rd floor, also from 8.00am to 4.00pm daily.

QEII Conference Centre – Second and Third Floors




SECOND FLOOR



THIRD FLOOR

Full cafe facilities will be open from 8.00am to 4.00pm each day in the Pickwick Suite on the 1st floor. A snack bar, serving hot and cold drinks, sandwiches and confectionery only, will be open in the Whittle & Fleming Rooms on the 3rd floor, also from 8.00am to 4.00pm daily.

QEII Conference Centre – Fourth, Fifth and Sixth Floors



Full cafe facilities will be open from 8.00am to 4.00pm each day in the Pickwick Suite on the 1st floor. A snack bar, serving hot and cold drinks, sandwiches and confectionery only, will be open in the Whittle & Fleming Rooms on the 3rd floor, also from 8.00am to 4.00pm daily.

PROGRAMME at a glance**WEDNESDAY | DECEMBER 2010**

Time	Details	Location/Floor
8.00am – 9.00am	COFFEE/TEA	Whittle & Fleming Rooms/3 rd
8.45am – 4.00pm	Poster viewing	PI–P13 Work-related respiratory disease
10.00am – 11.00am	Authors present	P14–P27 Clinical and experimental studies in asthma P28–P40 Pulmonary arterial hypertension P41–P53 Pulmonary rehabilitation P54–P62 Changing patterns of mycobacterial disease P63–P70 Investigating pleural disease P71–P82 Paediatric lung diseases
8.45am – 4.00pm	Moderated poster viewing	P83–P95 Respiratory education training issues
10.00am – 11.00am	Authors present	
8.15am – 8.45am	BTS Journal Club	Pulmonary rehabilitation
8.30am – 10.15am	Symposium	The management of difficult asthma
8.30am – 10.15am	Spoken session	S1–S6 Screen, educate and treat – managing the challenge of TB
8.30am – 10.15am	Spoken session	S7–S12 Economics and the burden of respiratory disease
8.30am – 10.30am	Joint BTS/BALR symposium (part I)	The science of danger signalling
8.45am – 10.15am	Spoken session	S13–S17 Assessing the impact of interventions in sleep disordered breathing
8.45am – 10.30am	Spoken session	S18–S23 New assessments in cystic fibrosis
10.00am – 11.00am	COFFEE/TEA	Whittle & Fleming Rooms, Benjamin Britten Lounge/3 rd
10.30am – 12.15pm	Symposium	National Clinical Strategy in England for COPD
10.30am – 12.15pm	Symposium	Frontiers in the control of mycobacterial disease
10.30am – 12.15pm	Spoken session	S24–S29 Paediatric infectious diseases
10.45am – 12.15pm	Spoken session	S30–S34 Linking airways inflammation and remodelling
10.45am – 12.30pm	Spoken session	S35–S40 How should we be investigating suspected lung cancer?
11.00am – 1.00pm	Joint BTS/BALR symposium (part II)	The role of danger signals in respiratory disease
12.15pm – 2.00pm	LUNCH	Cash catering only
12.30pm – 1.15pm	The Snell Memorial Lecture	Lessons from clinical trials' research
12.30pm – 2.10pm	Poster discussion	PI–P13 Work-related respiratory disease
1.00pm – 2.45pm	Poster discussion	P14–P27 Clinical and experimental studies in asthma
1.20pm – 3.00pm	Poster discussion	P28–P40 Pulmonary arterial hypertension
1.30pm – 3.00pm	Moderated poster discussion	P83–P95 Respiratory education training issues
1.30pm – 3.15pm	Joint BTS/BPRS symposium	Cystic fibrosis – how paediatricians can help adult physicians
2.00pm – 3.30pm	Symposium	T1–T6 BTS/BLF/BALR Young Investigators' symposium
2.00pm – 3.40pm	Poster discussion	P41–P53 Pulmonary rehabilitation
2.00pm – 3.45pm	Symposium	Sleep: the young, the elderly, the obese
2.30pm – 3.45pm	Symposium	The future of specialism
3.00pm – 4.30pm	COFFEE/TEA	Whittle & Fleming Rooms, Benjamin Britten Lounge/3 rd and Mountbatten Lounge/5 th (3.15pm–3.30pm)
3.00pm – 4.15pm	Poster discussion	P54–P62 Changing patterns of mycobacterial disease
3.15pm – 4.15pm	Poster discussion	P63–P70 Investigating pleural disease
3.30pm – 5.00pm	Poster discussion	P71–P82 Paediatric lung diseases
4.00pm – 4.30pm	The BTS President's Address	Learning in respiratory medicine
4.30pm – 4.45pm	Presentation	Presentation of the BTS Medal
4.45pm – 5.00pm	The ERS President's Address	Achievements of the Year of the Lung and Vision of the ERS Presidency
5.00pm – 5.30pm	BTS AGM	BTS Annual General Meeting (BTS members only)
5.30pm – 6.30pm	The President's Reception and Award Presentations – All welcome!	Sanctuary Foyer/Ground

Coffee and tea is complimentary **ONLY** during the coffee/tea break times shown above. Outside these times, drinks may be purchased from the cafe in the Pickwick Suite (1st floor), or the snack bar in the Whittle & Fleming Rooms (3rd floor).

THURSDAY 2 DECEMBER 2010

PROGRAMME at a glance

Time	Details	Location/Floor
8.00am – 9.00am	COFFEE/TEA	Whittle & Fleming Rooms/3 rd
8.45am – 4.00pm	Poster viewing	P96–P109 Clinical studies in cystic fibrosis
10.00am – 11.00am	Authors present	P110–P121 COPD: sputum and exacerbations
		P122–P136 Respiratory physiology: old and new concepts
		P137–P151 Clinical interventions in COPD
		P152–P159 Clinical aspects of NIV
		P160–P171 Improving patient outcomes in TB
		P172–P184 Therapeutic interventions in asthma and airways disease
8.45am – 4.00pm	Moderated poster viewing	P185–P190 Challenges in smoking cessation
		P191–P196 Clinical studies in lung cancer
10.00am – 11.00am	Authors present	
8.15am – 8.45am	BTS Journal Club	Interstitial lung disease
8.30am – 10.15am	Joint BTS/BTOG symposium	Developments in lung cancer therapeutics
8.30am – 10.15am	Joint BTS/BPRS symposium	Oxygen – plenty of guidelines, not much evidence
8.30am – 10.15am	Spoken session	S41–S46 Immunity and fibrosis in chronic asthma
8.30am – 10.30am	Spoken session	S47–S53 Inflammation in lung injury: the key mediators
8.45am – 10.15am	Spoken session	S54–S58 Orphan lung diseases
8.45am – 10.30am	Symposium	Novel mechanisms and new therapies for PAH
8.45am – 10.30am	Spoken session	S59–S64 α 1-antitrypsin: what it tells us about COPD
8.45am – 10.30am	Spoken session	S65–S70 NIV: the acute and domiciliary settings
10.00am – 11.00am	COFFEE/TEA	Whittle & Fleming Rooms, Benjamin Britten Lounge/3 rd
10.30am – 12.15pm	Symposium	Plenary scientific symposium
10.30am – 12.15pm	Spoken session	S71–S76 Novel outcomes and interventions in pulmonary rehabilitation
12.15pm – 2.00pm	LUNCH	Cash catering only
12.30pm – 1.15pm	The BTS Lecture	Acute lung injury: new opportunities with cell-based therapy
1.30pm – 2.15pm	Moderated poster discussion	P185–P190 Challenges in smoking cessation
1.30pm – 3.15pm	Poster discussion	P96–P109 Clinical studies in cystic fibrosis
1.45pm – 3.15pm	Poster discussion	P110–P121 COPD: sputum and exacerbations
1.45pm – 3.30pm	Symposium	Nano materials: an emerging health threat?
1.45pm – 3.30pm	Spoken session	S77–S82 Mechanisms of lung infection in the community and hospital setting
1.45pm – 3.45pm	Poster discussion	P122–P136 Respiratory physiology: old and new concepts
2.00pm – 3.45pm	Symposium	Connective tissue disease associated interstitial lung disease
2.00pm – 3.45pm	Spoken session	S83–S88 Pathophysiological mechanisms in childhood asthma
2.00pm – 3.45pm	Spoken session	S89–S94 Basic mechanisms in lung cancer
2.15pm – 3.00pm	Moderated poster discussion	P191–P196 Clinical studies in lung cancer
3.15pm – 4.15pm	COFFEE/TEA	Whittle & Fleming Rooms, Benjamin Britten Lounge/3 rd
3.30pm – 5.30pm	Poster discussion	P137–P151 Clinical interventions in COPD
3.30pm – 5.30pm	Spoken session	S95–S101 Novel disease mechanisms in pulmonary arterial hypertension
3.45pm – 5.30pm	Spoken session	S102–S107 Acute lung injury: what are the causes?
4.00pm – 5.00pm	Poster discussion	P152–P159 Clinical aspects of NIV
4.00pm – 5.30pm	Poster discussion	P160–P171 Improving patient outcomes in TB
4.00pm – 5.40pm	Poster discussion	P172–P184 Therapeutic interventions in asthma and airways disease
4.00pm – 5.45pm	Symposium	What's new in pneumonia in adults and children?
5.45pm – 7.15pm	BLF symposium	BLF 25 th anniversary symposium

Coffee and tea is complimentary **ONLY** during the coffee/tea break times shown above. Outside these times, drinks may be purchased from the cafe in the Pickwick Suite (1st floor), or the snack bar in the Whittle & Fleming Rooms (3rd floor).

PROGRAMME at a glance**FRIDAY 3 DECEMBER 2010**

Time	Details			Location/Floor
8.00am – 9.00am	COFFEE/TEA	Whittle & Fleming Rooms/3 rd		
8.45am – 2.00pm	Poster viewing	P197–P209	Clinical studies in obstructive sleep apnoea	Whittle & Fleming Rooms/3 rd
10.00am – 11.00am	Authors present	P210–P222	Developments in the delivery of lung cancer care	
		P223–P236	Organisation of respiratory care	
		P237–P247	Clinical challenges in diagnosing and managing respiratory infection	
		P248–P254	Outcome determinants in acute lung injury	
8.45am – 2.30pm	Moderated poster viewing	P255–P261	Clinical studies in pulmonary embolism	Caxton Lounge East/2 nd
10.00am – 11.00am	Authors present			
8.15am – 8.45am	BTS Journal Club		Asthma	Fleet Room/2 nd
8.30am – 10.15am	Symposium		COPD: the patient with complex advanced disease	Churchill Auditorium/Ground
8.30am – 10.15am	Spoken session	S108–S113	Epidemiology of lung disease	Westminster Suite/4 th
8.30am – 10.15am	Spoken session	S114–S119	Measurements in patients with chronic cough	Abbey Room/4 th
8.30am – 10.15am	Spoken session	S120–S125	Inflammation: an important regulator of the fibrotic response	Mountbatten Room/6 th
8.45am – 10.15am	Joint BTS/UKRRC symposium		Building an academic career in respiratory research	Elizabeth Windsor Room/5 th
10.00am – 11.00am	COFFEE/TEA	Whittle & Fleming Rooms, Benjamin Britten Lounge/3 rd		
10.15am – 12.00pm	Spoken session	S126–S131	Lung infection: a multi-faceted problem	Henry Moore Room/4 th
10.30am – 12.00pm	Spoken session	S132–S137	Clinical and translational observations in asthma	Westminster Suite/4 th
10.30am – 12.15pm	Symposium		How has imaging changed lung cancer investigation?	Churchill Auditorium/Ground
10.30am – 12.15pm	Symposium		The industry and UK respiratory medicine: time for closer liaisons	Mountbatten Room/6 th
10.30am – 12.15pm	Spoken session	S138–S143	Mechanisms of fibrosis in respiratory disease	St James's Suite/4 th
10.30am – 12.15pm	Spoken session	S144–S149	Smoke and pollution in COPD mechanisms	Abbey Room/4 th
12.15pm – 2.00pm	LUNCH	Cash catering only		Pickwick Suite/1 st Whittle & Fleming Rooms/3 rd
12.30pm – 1.15pm	John Donaldson Asthma UK Lecture		The role of the patient in asthma management	Churchill Auditorium/Ground
1.00pm – 3.00pm	Spoken session	S150–S156	Cell signalling and cell responses in pulmonary vascular disease	Abbey Room/4 th
1.30pm – 2.30pm	Moderated poster discussion	P255–P261	Clinical studies in pulmonary embolism	Caxton Lounge East/2 nd
1.30pm – 3.10pm	Poster discussion	P197–P209	Clinical studies in obstructive sleep apnoea	Westminster Suite/4 th
1.30pm – 3.10pm	Poster discussion	P210–P222	Developments in the delivery of lung cancer care	Henry Moore Room/4 th
1.30pm – 3.15pm	Poster discussion	P223–P236	Organisation of respiratory care	St James's Suite/4 th
1.30pm – 3.15pm	Symposium		Non-CF bronchiectasis: the known knowns, the known unknowns and the unknown unknowns	Mountbatten Room/6 th
1.45pm – 3.30pm	Symposium		'Late breaking news' symposium – The best of BTS Audit	Churchill Auditorium/Ground
2.00pm – 3.45pm	Spoken session	S157–S162	Occupational asthma	Rutherford Room/4 th
2.00pm – 3.45pm	Spoken session	S163–S168	Survival in COPD	Elizabeth Windsor Room/5 th
3.15pm – 4.40pm	Poster discussion	P237–P247	Clinical challenges in diagnosing and managing respiratory infection	Abbey Room/4 th
3.30pm – 4.30pm	Poster discussion	P248–P254	Outcome determinants in acute lung injury	Mountbatten Room/6 th
3.00pm – 4.45pm	COFFEE/TEA	Benjamin Britten Lounge/3 rd		

Coffee and tea is complimentary **ONLY** during the coffee/tea break times shown above. Outside these times, drinks may be purchased from the cafe in the Pickwick Suite (1st floor), or the snack bar in the Whittle & Fleming Rooms (3rd floor).

ADDITIONAL SESSIONS

Other events during the Winter Meeting will include the following sessions. Further details may be found in the leaflets in the conference bags or by reading the screens in the conference centre.

WEDNESDAY 1 DECEMBER 2010

9.00am – 10.00am
Rutherford Room, 4th Floor

OPEN MEETING

Thorax – “Meet the Editors”

Professor Andrew Bush and Professor Ian Pavord

2.30pm – 3.45pm
Elizabeth Windsor Room, 5th Floor

SYMPOSIUM

**THE FUTURE OF SPECIALISM – A DEBATE
WITH THE NHS CONFEDERATION**

THURSDAY 2 DECEMBER 2010

12.30pm – 1.30pm
Elizabeth Windsor Room, 5th Floor

OPEN MEETING

DEPARTMENT OF HEALTH BRIEFING SESSION

5.45pm – 7.15pm
Mountbatten Room, 6th Floor

BRITISH LUNG FOUNDATION 25TH ANNIVERSARY SYMPOSIUM

Chaired by: Professor Sir Malcolm Green (London)

- | | |
|---------------|--|
| 5.45pm | Overview: 25 years of the BLF
<i>Professor Sir Malcolm Green</i> |
| 6.10pm | COPD: a global epidemic
<i>Professor Sonia Buist (Washington)</i> |
| 6.40pm | How pathology links to abnormal
function
<i>Professor Jim Hogg (Vancouver)</i> |
| 7.10pm | Vote of thanks
<i>Professor Peter Barnes (London)</i> |
-

FRIDAY 3 DECEMBER 2010

8.30am – 10.00am
St James's Suite, 4th Floor

OPEN MEETING

DEPARTMENT OF HEALTH BRIEFING SESSION

BRITISH THORACIC SOCIETY OPEN MEETINGS

The programme will also include open meetings of some of the BTS Specialist Advisory Groups (SAGs) and Guideline Groups. Further details may be found in the leaflets in the conference bags or by reading the screens in the conference centre.

WEDNESDAY 1 DECEMBER 2010

Time	Details	Location/Floor
12.30pm – 1.30pm	BTS COPD SAG	Henry Moore Room/4 th
1.15pm – 2.15pm	BTS Interventional Pulmonology SAG and Advanced Bronchoscopy Guidelines	Rutherford Room/4 th
1.30pm – 2.45pm	BTS TB SAG	Fleet Room/2 nd

THURSDAY 2 DECEMBER 2010

Time	Details	Location/Floor
10.45am – 12.15pm	BTS Nurse Advisory Group	Rutherford Room/4 th
11.00am – 12.00pm	BTS Orphan Lung Disease SAG	Abbey Room/4 th
11.00am – 12.15pm	BTS Tobacco SAG	Henry Moore Room/4 th
11.00am – 12.00pm	BTS Pulmonary Vascular Disease SAG	St James's Suite/4 th
12.30pm – 1.30pm	BTS Lung Cancer and Mesothelioma SAG	Abbey Room/4 th
12.30pm – 1.30pm	BTS Cystic Fibrosis SAG	Westminster Suite/4 th
12.30pm – 1.30pm	BTS Pulmonary Infection SAG	Rutherford Room/4 th
4.00pm – 5.00pm	BTS ILD SAG	Rutherford Room/4 th

FRIDAY 3 DECEMBER 2010

Time	Details	Location/Floor
10.45am – 11.45am	BTS Sleep Apnoea SAG	Wesley Room/4 th
12.15pm – 1.15pm	BTS Specialist Trainee Advisory Group	Henry Moore Room/4 th
12.30pm – 1.15pm	BTS Oxygen Champions	Elizabeth Windsor Room/5 th
12.30pm – 1.30pm	BTS Respiratory Critical Care SAG	Rutherford Room/4 th

The British Thoracic Society President's Reception and Award Presentations


Wednesday 1 December, 5.30pm to 6.30pm
Sanctuary Foyer, Ground floor, QEII Conference Centre



All participants are warmly invited to join us on this special occasion. The presentations will be made for the annual BTS/BLF/BALR Young Investigator of the Year Awards, as well as the Medical Student Awards for the medical students who were judged to have submitted the best abstracts.

FLOOR PLAN OF THE EXHIBITION STANDS

Exhibitors and stand numbers



Whittle & Fleming Rooms, 3rd floor

- 10 & 13 Actelion Pharmaceuticals Ltd
- 12 Air Products
- 43 Airsonett
- 27, 28 & 39 AstraZeneca
- 19 Atrium
- 44 Bedfont Scientific Ltd
- 9 Boehringer Ingelheim GmbH & Pfizer Inc
- 45 BOC Healthcare
- 20 Cellestis Ltd
- 30, 36 & 37 Chiesi Ltd
- 22 Cryopal
- 31 Fentons Solicitors LLP
- 6 Fisher & Paykel Healthcare Ltd UK
- 7 & 8 Forest Laboratories UK Ltd
- 17, 23 & 24 GlaxoSmithKline
- 2 Hill-Rom
- 14 Hitachi Medical Systems
- 4 Medela
- 11 Merck Sharp & Dohme Ltd
- 15 Napp Pharmaceuticals Ltd
- 32 & 35 Novartis
- 29 Nutricia UK
- 25 Olympus KeyMed
- 18 Oxford Immunotec
- 3 PARI Medical Ltd
- 26 Pentax
- 16 Pfizer Vaccines
- 38 Pharmaxis
- 1 Philips Respiration
- 5 Rocket Medical PLC
- 33 S-Med Ltd
- 40 & 41 Teva UK Ltd
- 21 Uptake Medical Corporation
- 42 UK Medical
- 34 Vitalograph

Charity and non-commercial stands

Benjamin Britten Lounge, 3rd floor

- C63 Association for Respiratory Technology and Physiology (ARTP)
- C59 Association of Chartered Physiotherapists in Respiratory Care (ACPRC)
- C52 Association of Respiratory Nurse Specialists (ARNS)
- C57 Asthma UK
- C51 British Lung Foundation
- C60 British Thoracic Oncology Group, Mesothelioma UK and UKLCC
- C47 British Thoracic Society
- C49 Department of Health
- C53 Education for Health
- C50 European Respiratory Society
- C55 Healthy Outlook® from the Met Office
- C62 LAM Action
- C65 Lung Improvement Programme
- C54 The NHS Information Centre (The NHS IC)
- C48 Primary Care Respiratory Society UK (PCRS-UK)
- C56 Primary Ciliary Dyskinesia (PCD) Family Support Group UK
- C58 Pulmonary Hypertension Association (PHA) UK
- C64 Respiratory Education UK
- C61 TBAlert

Benjamin Britten Lounge, 3rd floor

- 46 Wisepress Medical Bookshop

Wednesday | December 2010

8.00am – 9.00am

COFFEE/TEA will be served in the Whittle & Fleming Rooms, 3rd floor

8.45am – 4.00pm

Whittle & Fleming Rooms, 3rd floor

POSTER VIEWING

Authors present: 10.00am – 11.00am

PI–PI3

Work-related respiratory disease

Discussion of abstracts will take place from 12.30pm to 2.10pm in the Elizabeth Windsor Room, 5th floor

PI4–P27

Clinical and experimental studies in asthma

Discussion of abstracts will take place from 1.00pm to 2.45pm in the St James's Suite, 4th floor

P28–P40

Pulmonary arterial hypertension

Discussion of abstracts will take place from 1.20pm to 3.00pm in the Abbey Room, 4th floor

P41–P53

Pulmonary rehabilitation

Discussion of abstracts will take place from 2.00pm to 3.40pm in the Henry Moore Room, 4th floor

P54–P62

Changing patterns of mycobacterial disease

Discussion of abstracts will take place from 3.00pm to 4.15pm in the St James's Suite, 4th floor

P63–P70

Investigating pleural disease

Discussion of abstracts will take place from 3.15pm to 4.15pm in the Abbey Room, 4th floor

P71–P82

Paediatric lung diseases

Discussion of abstracts will take place from 3.30pm to 5.00pm in the Mountbatten Room, 6th floor

8.45am – 4.00pm

Caxton Lounge East, 2nd floor

MODERATED POSTER VIEWING

Authors present: 10.00am – 11.00am

P83–P95

Respiratory education training issues

Discussion of abstracts will take place from 1.30pm to 3.00pm in the Caxton Lounge East, 2nd floor

8.15am – 8.45am

Fleet Room, 2nd Floor

THE BTS JOURNAL CLUB

Pulmonary rehabilitation

Professor Sally Singh (Leicester)

SCIENTIFIC PROGRAMME

8.30am – 10.15am

Churchill Auditorium, Ground Floor

SYMPOSIUM

THE MANAGEMENT OF DIFFICULT ASTHMA

Chaired by: Dr Bernard Higgins (Newcastle upon Tyne) and Professor Neil Thomson (Glasgow)

8.30am Epidemiology and predictors of difficult asthma

Dr Robert Niven (Manchester)

8.55am Management of psychosocial aspects of difficult asthma

Dr Paul Gill (Sheffield)

9.20am Assessing and promoting adherence in patients with difficult asthma

Dr Liam Heaney (Belfast)

9.45am Phenotype specific management of severe asthma

Professor Ian Pavord (Leicester)

8.30am – 10.15am

Abbey Room, 4th Floor

SPOKEN SESSION: S1 – S6

Screen, educate and treat: managing the challenge of TB

Chaired by: Dr Ben Marshall (Southampton) and Professor Peter Ormerod (Blackburn)

8.35am **S1**
HIV-1 infection of macrophages modulates host responses to Mycobacterium tuberculosis to contribute to immunopathogenesis and viral propagation
GS Tomlinson, PTG Elkington, M Noursadeghi

8.50am **S2**
Multi-drug resistant tuberculosis (MDR-TB) treatment in the UK: a survey of injectable use and toxicity in practice
A Sturdy, A Goodman, RJ José, A Loyse, M O'Donoghue, OM Kon, MJ Dedicat, T Harrison, L John, M Lipman, G Cooke

9.05am **S3**
Factors for successful treatment completion among MDR TB cases in the UK
LFA Anderson, ST Tamne, JW Watson, IA Abubakar

9.20am **S4**
Evaluation of TB Peer Educators – Essential partners in Metropolitan TB Control
J Hall, S Bethell, S Hellenen, A Story, M Lipman

9.35am **S5**
Prevalence of latent tuberculosis infection in immigrants to the UK: findings from a multi-centre study
M Pareek, JP Watson, OM Kon, G Woltmann, A Lalvani

SCIENTIFIC PROGRAMME

9.50am S6
Sensitivity and specificity of mobile digital chest radiography for the diagnosis of active pulmonary tuberculosis. A cohort study in high risk groups in London
RW Aldridge, A Story, H Stagg, M Lipman, J Knight, D Taubman, K Shaji, D Quinn, J Watson, I Abubaka, A Hayward

8.30am – 10.15am
Mountbatten Room, 6th Floor
SPOKEN SESSION: S7 – S12

Economics and the burden of respiratory disease

Chaired by: Professor Michael Morgan (Leicester) and Professor Sue Hill (Department of Health)

8.35am S7
Annual trends in asthma emergency attendance, hospital admission and readmission
V Kuan, SJ Quantrill

8.50am S8
The National COPD Resources and Outcomes Project (NCROP): action plan achievement since 2007
JF O'Reilly, NA Pursey, CM Roberts, RA Stone

9.05am S9
Feasibility of establishing a regional weaning unit in Scotland: modelling resource implications and costs
NI Lone, D Sorensen, TS Walsh

9.20am S10
Is it cost-effective to replace nurses with lay asthma educators in primary care?
NJ Roberts, K Boyd, A Briggs, A-L Caress, MR Partridge

9.35am S11
The South East Essex (SEE) model of integrated COPD Care and QUIP (Quality Innovation and Productivity) improvements
AG Davison, E Paddison, C Hanna, S Taylor

9.50am S12
Pre-clinic telephone consultations: a costing study
L O'Byrne, NJ Roberts, K Boyd, A Briggs, MR Partridge

8.30am – 10.30am
Westminster Suite, 4th Floor
SYMPOSIUM

JOINT BTS/BALR SYMPOSIUM PART I: THE SCIENCE OF DANGER SIGNALLING

Chaired by: Professor Rachel Chambers (London) and Professor Ann Millar (Bristol)

Wednesday 1 December 2010

8.30am The biology of the toll-like receptors and their signalling pathways
Professor Luke O'Neill (Dublin)

9.00am Non-TLR danger signals: the role of C-type lectins
Professor Gordon Brown (Aberdeen)

9.30am The NALP3 inflammasome in the recognition of pathogenic dust
Dr Isabelle Couillin (Orleans)

10.00am Links between PAMPs, innate immunity and adaptive immunity in allergic airway disease
Professor Bart Lambrecht (Ghent)

8.45am – 10.15am
St James's Suite, 4th Floor
SPOKEN SESSION: S13 – S17

Assessing the impact of interventions in sleep-disordered breathing

Chaired by: Professor John Stradling (Oxford) and Professor Adrian Williams (London)

8.50am S13
The primary results of the MOSAIC trial: does CPAP for minimally symptomatic OSA reduce daytime sleepiness or calculated vascular risk?
SE Craig, M Kohler, D Nicoll, DJ Bratton, AJ Nunn, RJO Davies, JR Stradling

9.05am S14
CPAP improves endothelial function in minimally symptomatic OSA patients: results from the MOSAIC trial
M Kohler, SE Craig, JCT Pepperell, D Nicoll, D Bratton, A Nunn, RJO Davies, JR Stradling

9.20am S15
An office based advanced driving simulator to assess driving performance in Obstructive Sleep Apnoea Syndrome (OSAS): a pilot study
D Ghosh, S Jamson, MW Elliott

9.35am S16
Detection of sleep-disordered breathing in chronic heart failure patients: utility of heart rate variability versus pulse oximetry?
NR Ward, MR Cowie, SD Rosen, VR Roldao, J Hooper, TA McDonagh, AK Simonds, MJ Morrell

9.50am S17
A pilot study of the prevalence of sleep disordered breathing (SDB) and nocturnal hypoxia in symptomatic adults with Sickle Cell Disease (SCD) and its relationship with disease severity
P Murphy, R Dillon, AJ Williams, J Howard, N Hart

Wednesday | December 2010

8.45am – 10.30am

Elizabeth Windsor Room, 5th Floor

SPOKEN SESSION: S18 – S23

New assessments in cystic fibrosis

Chaired by: Professor Stuart Elborn (Belfast) and
Dr Andrew Jones (Manchester)

8.50am **S18**

Longitudinal assessment of biomarkers for clinical trials of novel therapeutic agents; the Run-in Study

EWWF Alton, C Boyd, S Cunningham, JC Davies, SC Hyde, JA Innes, DR Gill, A Greening, U Griesenbach, T Higgins, DJ Porteous

9.05am **S19**

Real time PCR in the identification and management of aspergillus in CF

CG Baxter, AM Jones, AK Webb, DW Denning

9.20am **S20**

The bacterial cytoskeleton – A new antimicrobial target in cystic fibrosis pathogens?

SC Carnell, JD Perry, CMA Khan, A De Soya

9.35am **S21**

Identification of Pseudomonas aeruginosa infection via volatile organic compounds in sputum headspace gases

S Savelev, J Perry, SJ Bourke, R Taylor, AJ Fisher, M Petrie, PA Corris, A De Soya

9.50am **S22**

Lung Clearance Index, FEV1 and CT findings in Cystic Fibrosis: Data from the UK CF Gene Therapy Consortium Run-In Study

HS Sheridan, NJ Bell, KA Macleod, PA Reid, AR Horsley, G Davies, C Saunders, S Cunningham, JA Innes, JC Davies, EW Alton

10.05am **S23**

A comparative study of polymicrobial diversity in CF and non-CF bronchiectasis

SP Cummings, A Nelson, PJ Purcell, A De Soya, SJ Bourke, JD Perry

10.00am – 11.00am

COFFEE/TEA will be served in the Whittle & Fleming Rooms and Benjamin Britten Lounge, 3rd floor

10.30am – 12.15pm

Churchill Auditorium, Ground Floor

SYMPOSIUM

NATIONAL CLINICAL STRATEGY IN ENGLAND FOR COPD

To be confirmed

SCIENTIFIC PROGRAMME

10.30am – 12.15pm

Mountbatten Room, 6th Floor

SYMPOSIUM

FRONTIERS IN THE CONTROL OF MYCOBACTERIAL DISEASE

Chaired by: Dr Marc Lipman (London) and
Dr Alistair Story (London)

10.30am What's "latent" about latent TB infection?
Professor Robert Wilkinson (Cape Town)

10.55am New drugs for TB and the challenge of resistance
Professor Peter Davies (Liverpool)

11.20am Managing TB in a resource poor country: what can the UK learn?
Dr Alison Grant (London)

11.45am New developments in the biology of non-tuberculous mycobacteria
Dr Andres Floto (Cambridge)

10.30am – 12.15pm

St James's Suite, 4th Floor

SPOKEN SESSION: S24 – S29

Paediatric infectious diseases

Chaired by: Professor Alan Smyth (Nottingham) and
Dr Anne Thomson (Oxford)

10.35am **S24**

Differentiated Primary Bronchial Epithelial Cell (pBECs), Monocyte derived Macrophages (MdMs) and Monocyte derived dendritic cells (MODCs) Transwell co-culture: Respiratory Syncytial Virus (RSV) infection of the apical and basolateral surfaces
KB Ugonna, K Plant, ML Everard

10.50am **S25**

IL 17 production in primary and secondary Respiratory Syncytial Virus (RSV) infection and neutrophil transmigration
KB Ugonna, K Plant, ML Everard

11.05am **S26**

Recurrent respiratory tract infections and specific antibody deficiency in children
MTC Lim, K Jeyarajah, H Pandya, M Browning, E Gaillard

11.20am **S27**

Should routine screening for Vitamin D deficiency be incorporated into current guidelines for treatment of paediatric TB patients?
A Ting, M Jiki, C Bell, C Murray, Z Mughal, F Child

11.35am **S28**

Clinical predictors of admission in infants with acute bronchiolitis
M Marlais, J Evans, E Abrahamson

SCIENTIFIC PROGRAMME

11.50am S29

Mannose binding lectin deficiency in children with respiratory infection
S Prudon, J Wake, D Barge, C Simmister, S Tremble, V Stevenson, T Flood, DA Spencer

10.45am – 12.15pm

Abbey Room, 4th Floor

SPOKEN SESSION: S30 – S34

Linking airways inflammation and remodelling

Chaired by: *Professor Peter Bradding (Leicester) and Dr David Singh (Manchester)*

10.50am S30

TRUSS is a regulator of TNF α -TNF-R1 induced NF- κ B activation
IP Horan, AJ Langton, S Farrow, DW Riches, ER Chilvers, H Parfrey

11.05am S31

Characterisation of cell adhesion molecule-1 in lung mast cells
EP Moiseeva, M Leyland, P Bradding

11.20am S32

Cyclical mechanical stretch enhances the pro-fibrotic responses of primary embryonic fetal fibroblasts, but not ADAM33 expression
A Noto, W Manuyakorn, HM Haitchi, F Bucchieri, D Davies

11.35am S33

Suppression of constitutive and stimulated secretion of histamine from human lung mast cells by a secreted factor from lung epithelial cells
N Martin, GK Arthur, WYH Wan, L Woodman, CE Brightling, ID Pavord, P Bradding

11.50am S34

Effects of the cyclin-dependent kinase inhibitor R-roscovitine on eosinophil survival and clearance
N Farahi, L Uller, JK Juss, AJ Langton, AS Cowburn, A Gibson, MR Foster, SN Farrow, A Sobolewski, AM Condliffe, ER Chilvers

10.45am – 12.30pm

Elizabeth Windsor Room, 5th Floor

SPOKEN SESSION: S35 – S40

How should we be investigating suspected lung cancer?

Chaired by: *Mr Sion Barnard (Newcastle upon Tyne) and Dr Pallav Shah (London)*

10.50am S35

A randomised controlled trial comparing combined EBUS/EUS followed by surgical

Wednesday 1 December 2010

staging versus surgical staging alone in non-small cell lung cancer: the ASTER study
RC Rintoul, KG Tournoy, C Dooms, P De Leyn, AG Nicholson, E Deschepper, OM Dekkers, KF Rabe, JP van Meerbeeck, JT Annema

11.05am S36

Novel in vivo real time imaging of the bronchial mucosa using an endo-cytoscopy
K Shibuya, N Okada, H Kohno, N Iwai, M Noro, B Akikusa, H Hoshino, I Yoshino

11.20am S37

Comparison of Dynamic Contrast Enhanced MRI (DCE-MRI) parameters with integrated PET-CT and serum mesothelin in the baseline assessment of malignant pleural mesothelioma
C Hooper, D Hall, P Virgo, P White, M Darby, T Hall, J Braybrooke, J Searle, I Lyburn, N Maskell

11.35am S38

Fourier Transform Infra-Red (FTIR) spectroscopy on sputum from lung cancer patients, healthy controls and a high-risk cohort
R Ghosal, KE Lewis, P Kloer, S Bayliss, L Mur, PD Lewis

11.50am S39

Sub typing of non small cell carcinoma in EBUS-TBNA samples
M Gautam, K Mohan, T Giles, S Forrest, C Smyth, M Walshaw, B Sukumaran

12.05pm S40

Early experience of endobronchial ultrasound – miniprobe (EBUS-MP) for investigation of peripheral pulmonary mass lesions
JF Tiernan, W Wallace, KM Skwarski

11.00am – 1.00pm

Westminster Suite, 4th Floor

SYMPOSIUM

JOINT BTS/BALR SYMPOSIUM PART II: THE ROLE OF DANGER SIGNALS IN RESPIRATORY DISEASE

Chaired by: *Dr Deborah Clarke (Cambridge) and Professor Ian Sabroe (Sheffield)*

11.00am TLR polymorphisms and susceptibility to lung disease

Professor Nicholas Gay (Cambridge)

Opportunities for therapeutic intervention

11.35am Matrix regulation of lung inflammation and fibrosis: location matters

Professor Paul Noble (Durham, NC)

Wednesday 1 December 2010

12.10pm Therapeutic strategies targeting PAMPs and DAMPs
Dr Matthew Robinson (MedImmune)

12.15pm – 2.00pm

LUNCH will be available to purchase in the Cafe in the Pickwick Suite, 1st floor, and the Snack Bar in the Whittle & Fleming Rooms, 3rd floor

12.30pm – 1.15pm

Churchill Auditorium, Ground Floor
SNELL MEMORIAL LECTURE

Lessons from clinical trials' research

Professor Jeffrey Drazen (Boston)

Introduced by: Dr Ed Neville (Portsmouth)

12.30pm – 2.10pm

Elizabeth Windsor Room, 5th Floor
POSTER DISCUSSION: P1 – P13

Work-related respiratory disease

Chaired by: Professor Sherwood Burge (Birmingham) and Professor Paul Cullinan (London)

- P1** Quality of life related to COPD and occupational exposures
AC Darby, JC Waterhouse, V Stevens, CG Billings, SE Hickman, A Seriki, J Wight, D Fishwick
- P2** Outbreak case definitions for extrinsic allergic alveolitis due to metal working fluids
CM Burton, PS Burge, AS Robertson, W Robertson, CAC Pickering, DJ Hendrick, CM Barber
- P3** COPD causation; an assessment of agreement between expert clinical raters
AC Darby, R Barraclough, PS Burge, NS Hopkinson, JL Hoyle, RA Lawson, RM Niven, SC Stenton, CJ Warburton, CM Barber, PD Blanc, AD Curran, D Fishwick
- P4** Breathlessness and work performance in older adults in Kent
J Szram, SJ Schofield, APM Woods, P Cullinan
- P5** Airway responsiveness measurements in asthmatic recruits to emergency services
S Wiscombe, V Jeebun, SC Stenton
- P6** Work-related respiratory symptoms in the UK; do primary care physicians miss diagnostic opportunities in occupational asthma?
J Hoyle, L Hussey, R Barraclough, R Agius
- P7** Occupational eosinophilic constrictive bronchiolitis with asthma in a foam cutter caused by Soya bean products
J Hoyle, K Ballance, H Francis, CAC Pickering, RMc Niven
- P8** Unique outbreak of occupational asthma in toolmakers caused by chrome
GI Walters, VC Moore, AD Vellore, AS Robertson, PS Burge

SCIENTIFIC PROGRAMME

- P9** The evaluation of an improved method of occupational asthma diagnosis from timepoint analysis of serial PEF records
CBSG Burge, VC Moore, AS Robertson, CFA Pantin, PS Burge
- P10** Asbestos-induced diffuse pleural thickening – a continuing problem
V Jeebun, SC Stenton
- P11** Cardio-respiratory fitness at work; the effects of public health guidance?
M Naughton, JSS Gaynor, L Bradshaw, A Curran, S Till, D Fishwick
- P12** Alarming ignorance about the dangers of asbestos among UK homeowners
N Eiser, I Jarrold, H Richardson, K Huntly
- P13** Clinical, radiographic and pulmonary function findings in silicosis
CD Lucas, N Hirani, AJ Simpson, PT Reid
-
- 1.00pm – 2.45pm**
St James's Suite, 4th Floor
POSTER DISCUSSION: P14 – P27
Clinical and experimental studies in asthma
Chaired by: Professor Andrew Greening (Edinburgh) and Dr Liam Heaney (Belfast)
- P14** Does Vitamin D axis have an effect on the severity of asthma?
R Sathyamurthy, S Manney, A Wood, G Perkins, C Webster, MT Krishna, AH Mansur
- P15** Concerns about corticosteroids among people with asthma: implications for clinical interventions
V Cooper, L Metcalf, J Upton, S Walker, J Versnel, R Horne
- P16** Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently: a randomised controlled trial
D Bumbacea, A Dymek, H Mansikka
- P17** Self reported physical activity levels and attitudes towards a structured exercise programme in adults with difficult asthma
A Singapuri, SJ Singh, B Hargadon, M Shelley, D Desai, R Carter, CE Brightling, ID Pavord, P Bradding, AJ Wardlaw, RH Green
- P18** Experimental infection with low dose rhinovirus in asthma
DJ Jackson, J Del Rosario, SL Johnston
- P19** Psychosocial factors and the morbidity of severe asthma
A Pooler, A Caress
- P20** The eligibility of patients with difficult asthma for omalizumab since the change to the treatment criteria

SCIENTIFIC PROGRAMME

- AJ Burton, B Hargadon, AC Murphy, CE Brightling, ID Pavord, AJ Wardlaw, P Bradding, RH Green*
- P21** Success rate of sputum induction in the Leicester paediatric severe asthma clinic using
R Herzallah, KS Staley, M McFeeters, C Brightling, P Bradding, D Parker, H Pandya, E Humphreys, EA Gaillard
- P22** Factors associated with refractoriness to repeat exercise challenge in adults with asthma
N Martin, ID Pavord
- P23** Effect of omalizumab on oral corticosteroid requirements of young children with severe asthma; results of a UK survey
A Kirk, D Spencer, A Radwan
- P24** Fluticasone propionate/formoterol fumarate combination therapy has a more rapid onset of action than fluticasone propionate/salmeterol xinafoate in the treatment of asthma: a randomised controlled trial
A Bodzenta-Lukaszyk, A Dymek, H Mansikka
- P25** Relationships between airway hyper-responsiveness, airway inflammation and airway calibre in asthmatic subjects
PM Short, SIW Lipworth, BJ Lipworth
- P26** Home serial spirometry as an adjunct in the diagnosis of vocal cord dysfunction
SY Barnett, B Ziso, SJ Quantrill
- P27** Personal allergen exposures are increased by changes in sleep position and improved by Temperature-Controlled Laminar Airflow
RB Gore, RJ Boyle, H Hanna, A Custovic, C Gore, P Svensson, JO Warner

1.20pm – 3.00pm

Abbey Room, 4th Floor

POSTER DISCUSSION: P28 – P40

Pulmonary arterial hypertension

Chaired by: *Professor Paul Corris (Newcastle upon Tyne) and Dr John Wort (London)*

- P28** Inflammatory profiling of adventitial fibroblasts in pulmonary hypertension
AC Church, A Melendez, RM Wadsworth, AJ Peacock, DJ Welsh
- P29** Endothelial cell NF-κB activation is increased in human idiopathic PAH
LC Price, G Caramori, P Dorfmüller, F Perros, J Zhu, D Shao, M Humbert, I Adcock, SJ Wort
- P30** The changing face of pulmonary hypertension: the role of heart and lung disease
SF Crawley, MK Johnson, AJ Peacock
- P31** Disease targeted therapies and effect on survival in idiopathic, heritable and anorexigen-associated Pulmonary Arterial Hypertension (PAH)
Y Ling, M Johnson, A Peacock

Wednesday 1 December 2010

- P32** Delivering pulmonary hypertension services – 5 year experience from a satellite centre
S Sturney, S Reddecliffe, H Davies, G Robinson, J Easaw, J Suntharalingam, G Coghlan
- P33** Iron deficiency independently predicts survival in idiopathic pulmonary arterial hypertension
CJ Rhodes, LS Howard, M Busbridge, D Ashby, E Kondili, JSR Gibbs, J Wharton, MR Wilkins
- P34** Characterising T cell sub-populations in pulmonary hypertension
AJ Shepherd, K Hopkinson, DG Kiely, CE Elliot, R Condliffe, DC Crossman, AG Pockley, A Lawrie
- P35** Elevated tricuspid regurgitation jet velocity on echocardiogram in Sickle Cell Disease is associated with raised inflammatory mediators and low steady state haemoglobin but not other markers of haemolysis
H Ranu, E Connell, C Hunt, F Boa, J Lee, L Brown, F Willis, H Buyck, BP Madden
- P36** Functional class and gas transfer are useful tools in the assessment of pulmonary hypertension associated with Sickle Cell Disease
H Ranu, L Brown, J Lee, BP Madden
- P37** Flying – safer than we thought? A questionnaire-based study of 156 individuals with hereditary haemorrhagic telangiectasia; 95 with pulmonary AVMs
CG Mason, CL Shovlin
- P38** Which patients with pulmonary arteriovenous malformations are dyspnoeic? Retrospective analysis of a single centre 2005 – 2010 cohort
V Santhirapala, JT Springett, H Wolfenden, HC Tighe, CL Shovlin
- P39** Pulmonary Hypertension (PH) associated with lung disease/hypoxia
J Hurdman, RA Condliffe, CA Elliot, I Sabroe, DG Kiely
- P40** A comparison of the value of oxygen shunt studies and cardiac bubble echo as screening tools for pulmonary arteriovenous malformations in patients with suspected hereditary haemorrhagic telangiectasia
JW Donaldson, K Pointon, T Mathew, AW Fogarty

1.30pm – 3.00pm

Caxton Lounge East, 2nd Floor

MODERATED POSTER DISCUSSION: P83 – P95

Respiratory education and training issues

Chaired by: *Dr Ian Forrest (Newcastle upon Tyne) and Dr Duncan Powrie (Southend)*

Wednesday 1 December 2010

- P83** Validation of a novel porcine – resin thorax model for chest drain insertion training
TR Naicker, EA Hughes, DT McLeod
- P84** The impact of a multidisciplinary educational programme on the prescribing of oxygen in an Acute Trust
H Khachi, M Burman, L Walters, R Sinha-Ray, S Antoniou, S Mandal
- P85** Pictorial representation of respiratory examination in hospital notes
N Mahmood, C Gobbett, S Malik, C Houghton, G Ng Man Kwong
- P86** Chest drain insertion training; is simulation training the answer?
TR Naicker, DT McLeod
- P87** Evidence based emergency oxygen guidelines are not being followed in the emergency department
SM Wallace, LE Doy, EN Kedgley, WM Ricketts
- P88** The Aintree Hospital Pleural Disease Training Programme: achieving competency in intercostal drain insertion and in management of pleural problems on the “acute take”
B Chakrabarti, LG Spencer, A Kwok, P Albert, CJ Warburton, JE Earis
- P89** A decade on still not enough time for asthma
C Mordaunt, SJ Billington, MG Pearson, RM Angus
- P90** Simulated bronchoscopy training delivered by experienced peers improves confidence of new trainees
ARC Patel, S Mandal, JJP Goldring
- P91** Can health care professionals in a respiratory unit correctly set an oxygen flow rate on a standard oxylitre medical regulator?
SJ Billington, C Mordaunt, RM Angus, LG Spencer
- P92** Training opportunities in thoracic ultrasound for respiratory specialist trainees in the West Midlands Deanery
TS Jordan, F Choudhary, R Heinink, S Mathew, I Hussain, M Allen
- P93** A simulated bronchoscopy course for new specialist trainees
S Mandal, ARC Patel, JJP Goldring
- P94** Do health care professionals have sufficient knowledge of inhaler techniques in order to educate their patients effectively in their use?
M Baverstock, N Woodhall, V Maarman
- P95** Oxygen delivery in an acute hospital setting
J Maycock, K Ellis, P Mullholland, L Bate, V Sadananda, D Nazareth, S Agarwal, P Stockton

SCIENTIFIC PROGRAMME

1.30pm – 3.15pm

Mountbatten Room, 6th Floor

SYMPOSIUM

JOINT BTS/BPRS SYMPOSIUM: CYSTIC FIBROSIS – HOW PAEDIATRICIANS CAN HELP ADULT PHYSICIANS

Chaired by: *Dr Steven Conway (Leeds) and Dr David Honeybourne (Birmingham)*

1.30pm The impact on future CF adults of newborn screening
Dr Kevin Southern (Liverpool)

1.55pm Difficult diagnoses: is it CF?
Dr Stephen J Bourke (Newcastle upon Tyne)

2.20pm Practical lessons from iatrogenic disease
Dr Alan Smyth (Nottingham)

2.45pm Newer therapies, drugs and genes
Dr Jane Davies (Brompton)

2.00pm – 3.30pm

Westminster Suite, 4th Floor

SYMPOSIUM: T1–T6

BTS/BLF/BALR YOUNG INVESTIGATORS SYMPOSIUM

Chaired by: *Professor Andrew Fisher (Newcastle upon Tyne) and Professor Nicholas Morrell (Cambridge)*

Judging panel: *Professor Andrew Fisher (Newcastle upon Tyne), Dr Sam Janes (London), Professor Ann Millar (Bristol) and Professor Nicholas Morrell (Cambridge)*

2.00pm T1
Rev-erb α , a novel anti-inflammatory target, modifies the circadian oscillation of pulmonary inflammation
J Blaikley, L Green, J Gibbs, S Farrow, A Loudon, D Singh, D Ray

2.15pm T2
Blockade of intraalveolar p55 TNF-receptor signalling by a domain antibody decreases inflammation and oedema in an in vivo mouse model of ventilator-induced lung injury
S Bertok, MR Wilson, PJ Morley, R de Wildt, A Bayliffe, M Takata

2.30pm T3
Tissue inhibitor of Metalloproteinase-3 (TIMP3) protects against inflammatory processes in Interstitial Lung Disease (ILD)
MJ Heightman, HL Booth, GJ Laurent, MR Hill, RM McNulty

2.45pm T4
Increased reticular basement membrane thickness but NOT airway smooth muscle in endobronchial biopsies of severe preschool wheezers
R O'Reilly, T Oates, J Zhu, PK Jeffery, A Bush, S Saglani

SCIENTIFIC PROGRAMME

3.00pm T5
KCa3.1 ion channel blockers restore corticosteroid sensitivity in cytokine-treated airway smooth muscle (ASM) cells from both COPD and asthmatic patients
L Chachi, A Shikotra, A Sutcliffe, C Brightling, P Bradding, Y Amrani

3.15pm T6
Acute exacerbations of chronic obstructive pulmonary disease: identification of phenotype-specific biomarkers and biological clusters
M Bafadhel, S McKenna, S Terry, V Mistry, C Reid, P Haldar, M McCormick, K Haldar, T Kebabdz, A Duvoix, K Lindbald, P Rugman, P Dodson, M Jenkins, P Newbold, P Venge, RH Green, DA Lomas, MR Barer, SL Johnston, ID Pavord, CE Brightling

2.00pm – 3.40pm

Henry Moore Room, 4th Floor

POSTER DISCUSSION: P41 – P53

Pulmonary rehabilitation

Chaired by: Dr William Man (London) and Professor Sally Singh (Leicester)

P41 The COPD Assessment Test (CAT) used to evaluate outcome in pulmonary rehabilitation
QC Jones, DW Eyre, J Young, E Tucker, J Riley, M Hardinge

P42 Comparison of a one and two walk protocol for the Endurance Shuttle Walk Test when measuring change due to therapeutic intervention in COPD patients
SE Roberts, M Stern, FM Schreuder, T Watson

P43 Do changes in objective outcome measures match patient-reported experience of pulmonary rehabilitation?
RP Fowler, KA Ingram, AL Clark, CM Nolan, WD Man

P44 COPD patients derived benefits from attending PR: "This has given me my life back"
L Matheson, J O'Connor, T Cartwright, CH Blunt, A Clow, C Lee, S Elkin

P45 Outcomes following pulmonary rehabilitation for patients with restrictive lung diseases with or without oxygen therapy
VL Warrington, J Scullion, L Sewell, J Williams, S Singh

P46 Effects of Physical Activity Top Up "PAT on the back" programme on exercise capacity and healthcare utilisation for people with Chronic Obstructive Pulmonary Disease (COPD)
G Arbane, A Douiri, L Enright, L Haggis, T Poulter, R Garrod

P47 Outcomes of static versus continuous rolling community pulmonary rehabilitation (PR) programmes
JL Tomkinson, M Rosedale

Wednesday 1 December 2010

P48 Attendance rates and response to pulmonary rehabilitation
CM Nolan, KA Ingram, RP Fowler, AL Clark, WD Man

P49 Seasonal effect upon attendance at a pulmonary rehabilitation programme
GE Walker, C Lee, SL Elkin

P50 Facilitation of continued exercise via patient volunteers with Chronic Obstructive Pulmonary Disease (COPD) following a pulmonary rehabilitation programme: a feasibility study
CA Langley-Johnson, E Jenkin, CAE Dyer, K Gruffydd-Jones, N Harris, M Reed, G Taylor

P51 Group-based pulmonary rehabilitation delivered to the home via the Internet – a feasibility study
DJ Godden, J Colligan, A Aitken, A Taylor

P52 Is a Pulmonary Rehabilitation (PR) programme effective in reducing severe symptoms of anxiety and depression in patients with COPD?
S Harrison, N Greening, J Williams, S Singh

P53 The effect of co-morbidities on response to pulmonary rehabilitation
KA Ingram, RP Fowler, AL Clark, CM Nolan, WD Man

2.00pm – 3.45pm

Churchill Auditorium, Ground Floor

SYMPOSIUM

SLEEP: THE YOUNG, THE ELDERLY AND THE OBESE

Chaired by: Professor Sir Neil Douglas (Edinburgh) and Dr Anita Simonds (London)

2.00pm Do children need sleep labs?
Dr Rob Primhak (Sheffield)

2.25pm Obstructive sleep apnoea in older people
Professor Mary Morrell (London)

2.50pm Obesity-related respiratory failure: pathophysiology to clinical outcomes
Dr Nicholas Hart (London)

3.15pm Obstructive sleep apnoea: diabetes and the metabolic syndrome
Dr Sophie West (Newcastle upon Tyne)

3.00pm – 4.30pm

COFFEE/TEA will be served in the

Whittle & Fleming Rooms and Benjamin Britten Lounge, 3rd floor and the Mountbatten Lounge, 5th floor

(3.15pm – 3.30pm)

Wednesday | December 2010

3.00pm – 4.15pm

St James's Suite, 4th Floor

POSTER DISCUSSION: P54 – P62

Changing patterns of mycobacterial disease

Chaired by: Dr John Moore-Gillon (London) and
Dr John Watson (Leeds)

- P54** Do the NICE new entrant TB screening guidelines under-diagnose cases of latent TB infection?
D Thomas, M Jarvis, A Williams
- P55** Post-bronchoscopy sputum: increasing the diagnostic yield in smear negative pulmonary tuberculosis
PM George, M Mehta, J Dhariwal, A Singanayagam, CE Raphael, M Salmasi, DW Connell, P Molyneaux, M Wickremasinghe, A Jepson, OM Kon
- P56** High incidence of tuberculosis in patients with chronic kidney disease in a tertiary referral unit
P Palchadhuri, A Riding, P Begum, M Ostermann, H Milburn
- P57** The London TB Metrics: are targets achievable in a local district hospital clinic?
LSC Lok, L Ridge, J Barrett, DJF Mack, DD Creer
- P58** What does pulmonary tuberculosis (TB) look like in London?
C Brown, S Natas, A Salam, R Breen
- P59** Why do we often fail to meet the gold standard for the diagnosis of active tuberculosis?
S Huq, M Haris, M Gautam, PDO Davies
- P60** Questionable utility of T-SPOT testing in a TB exposure incident on a clinical haematology unit
J Brebner, J Mann, H Jones, W Bladen, N Syed, P Dawkins
- P61** Pulmonary nontuberculous mycobacterial (NTM) culture is common following lung transplantation, and NTM lung disease is associated with poor prognosis
TT Gorsuch, I Crossingham, M Cullen, M Al-Aloul
- P62** Are we missing opportunities to obtain a microbiological diagnosis of TB?
Z Al-Nakeeb, V Gupta, C Bell, M Woodhead

3.15pm – 4.15pm

Abbey Room, 4th Floor

POSTER DISCUSSION: P63 – P70

Investigating pleural disease

Chaired by: Dr Nabeel Ali (Sutton-in-Ashfield) and
Dr Nicholas Maskell (Bristol)

SCIENTIFIC PROGRAMME

- P63** A prospective observational trial examining the diagnostic utility of serum and pleural fluid procalcitonin in the initial investigation of unilateral pleural effusions
CE Hooper, AJ Morley, JE Harvey, NA Maskell
- P64** Course and variation of the intercostal artery by computed tomography
NM Rahman, EJ Helm, O Talakoub, RJO Davies, FV Gleeson
- P65** Is serum N-terminal pro B type natriuretic peptide (NT-proBNP) measurement useful in the investigation of unilateral pleural effusions? A prospective observational study
CE Hooper, I Rider, RS Finn, AJ Morley, JE Harvey, A Skyrme-Jones, NA Maskell
- P66** Histone deacetylase inhibitor CBHA attenuates the expression of plasminogen activator inhibitor-1 in human pleural mesothelial cells
C-L Chung, W-L Chen, Y-W Cheng, Y-C Chou, M-J Hsu, C-J Hsiao, J-R Sheu, G Hsiao
- P67** Outcomes from surgical management of pleural infection: 12 year experience from a tertiary cardiothoracic centre
DJB Marks, M Fisk, CY Koo, SF Lee, D Lawrence, RF Miller, A Zumla
- P68** Surgery for mesothelioma: the case for macroscopic complete resection
KKW Lau, A Nakas, DA Waller
- P69** Mesothelioma in the 21st Century. A one year survey of malignant mesothelioma in the South West of the UK
R Bhatnagar, S Earl, K Lansdell, TJ Howell
- P70** Talc slurry pleurodesis: does mixing talc with 50% dextrose rather than normal saline increase success rate?
A Khanna, C Mackinlay, A Kerry

3.30pm – 5.00pm

Mountbatten Room, 6th Floor

POSTER DISCUSSION: P71 – P82

Paediatric lung diseases

Chaired by: Dr Stephen Turner (Aberdeen) and
Dr David Spencer (Newcastle upon Tyne)

- P71** Reduced airway beta-defensin 2 levels in children with cystic fibrosis and Vitamin D-deficiency
K Naderi, J Donovan, S Brown, N Leaver, H-L Tan, EFW Alton, A Bush, JC Davies
- P72** Feasibility of recruiting newborn babies with cystic fibrosis diagnosed by newborn screening to a clinical study with invasive outcome measures
J Chudleigh, A-F Hoo, SA Prasad, D Ahmed, A Bush, C Wallis, J Stocks

SCIENTIFIC PROGRAMME

- P73** The complexities of defining atopy in severe childhood asthma
J Frith, L Fleming, C Bossley, N Ullmann, A Bush
- P74** British Asthma Guideline revision does affect prescribing patterns in children
H Elkout, JS McLay, CR Simpson, PJ Helms
- P75** Clinical predictors of continuous positive airway pressure requirement in bronchiolitis
J Evans, M Marlais, E Abrahamson
- P76** General and respiratory health outcomes in adult survivors of bronchopulmonary dysplasia: a systematic review
A Gough, D Spence, MA Linden, L McGarvey, H Halliday
- P77** Children's exposure to airborne fine particulate matter at home and asthma outcomes
K Woods, A Apsley, S Semple, SW Turner
- P78** Impact of severe allergic asthma in children: highlighting a role for understanding the family perspective
KG Staley, R Herzallah, H Pandya, E Humphreys, E Gaillard
- P79** Impulse oscillometry for the assessment of lung function deficits associated with preschool wheezing
U Banerjee, S Goldring, J Kirkby, J Stocks, JO Warner, RJ Boyle
- P80** Pre-operative assessment of children undergoing scoliosis surgery
AL Ross Russell, S Charlton, ER Mooney, C Ward, RI Ross Russell
- P81** The changing incidence of paediatric empyema in NE England 2006 – 2010
MF Thomas, C Simmister, SP Rushton, DA Spencer
- P82** What is the role of chest computed tomography in children with parapneumonic effusion?
A Parmar, G Peek, R Firmin, H Pandya, E Gaillard

Wednesday 1 December 2010

4.00pm – 4.30pm
Churchill Auditorium, Ground Floor
THE PRESIDENT'S ADDRESS
Learning in respiratory medicine
Dr Ed Neville (Portsmouth)

4.30pm – 4.45pm
Churchill Auditorium, Ground Floor
PRESENTATION OF THE BTS MEDAL

4.45pm – 5.00pm
Churchill Auditorium, Ground Floor
THE ERS PRESIDENT'S ADDRESS
Achievements of the Year of the Lung and Vision of the ERS Presidency
Professor Marc Decramer (Leuven)

5.00pm – 5.30pm
Churchill Auditorium, Ground floor
BTS ANNUAL GENERAL MEETING
(BTS members only)

5.30pm – 6.30pm
Sanctuary Foyer, Ground Floor
THE PRESIDENT'S RECEPTION – YOUNG INVESTIGATORS AND MEDICAL STUDENT AWARDS

Thursday 2 December 2010

8.00am – 9.00am

COFFEE/TEA will be served in the Whittle & Fleming Rooms, 3rd floor

8.45am – 4.00pm

Whittle & Fleming Rooms, 3rd floor

POSTER VIEWING

Authors present: 10.00am – 11.00am

P96–P109

Clinical studies in cystic fibrosis

Discussion of abstracts will take place from 1.30pm to 3.15pm in the Henry Moore Room, 4th floor

P110–P121

COPD: sputum and exacerbations

Discussion of abstracts will take place from 1.45pm to 3.15pm in the St James's Suite, 4th floor

P122–P136

Respiratory physiology: old and new concepts

Discussion of abstracts will take place from 1.45pm to 3.45pm in the Abbey Room, 4th floor

P137–P151

Clinical interventions in COPD

Discussion of abstracts will take place from 3.30pm to 5.30pm in the St James's Suite, 4th floor

P152–P159

Clinical aspects of NIV

Discussion of abstracts will take place from 4.00pm to 5.00pm in the Westminster Suite, 4th floor

P160–P171

Improving patient outcomes in TB

Discussion of abstracts will take place from 4.00pm to 5.30pm in the Elizabeth Windsor Room, 5th floor

P172–P184

Therapeutic interventions in asthma and airways disease

Discussion of abstracts will take place from 4.00pm to 5.40pm in the Abbey Room, 4th floor

8.45am – 4.00pm

Caxton Lounge East, 2nd Floor

MODERATED POSTER VIEWING

Authors present: 10.00am – 11.00am

P185–P190

Challenges in smoking cessation

Discussion of abstracts will take place from 1.30pm to 2.15pm in the Caxton Lounge East, 2nd floor

P191–P196

Clinical studies in lung cancer

Discussion of abstracts will take place from 2.15pm to 3.00pm in the Caxton Lounge East, 2nd floor

8.15am – 8.45am

Fleet Room, 2nd Floor

THE BTS JOURNAL CLUB

Interstitial lung disease

Dr Toby Maher, London

SCIENTIFIC PROGRAMME

8.30am – 10.15am

Churchill Auditorium, Ground Floor

SYMPOSIUM

BTS/BTOG JOINT SYMPOSIUM: DEVELOPMENTS IN LUNG CANCER THERAPEUTICS

Chaired by: Dr Paul Beckett (Burton upon Trent) and Dr Denis Talbot (Oxford)

8.30am EGRF targeted therapies: from promise to practice

Professor David Ferry (Wolverhampton)

9.10am Radiofrequency ablation – its role in lung cancer

Dr Paras Dalal (London)

9.40am Stereotactic radiotherapy – will it make surgery for early lung cancer redundant?

Dr Matthew Hatton (Sheffield)

8.30am – 10.15am

St James's Suite, 4th Floor

SYMPOSIUM

JOINT BTS/BPRS SYMPOSIUM: OXYGEN – PLENTY OF GUIDELINES, NOT MUCH EVIDENCE

Chaired by: Dr Rupert Jones (Plymouth) and Dr Rob Primhak (Sheffield)

8.30am Home oxygen for adults – new issues

Professor Wisia Wedzicha (London)

8.55am Home oxygen for children – unanswered questions

Dr Ian Balfour-Lynn (London)

9.20am Emergency oxygen for adults – controversies

Dr Ronan O'Driscoll (Salford)

9.45am Oxygen for neonates – benefits and harm

Professor Ben Shaw (Liverpool)

8.30am – 10.15am

Henry Moore Room, 4th Floor

SPOKEN SESSION: S41 – S46

Immunity and fibrosis in chronic asthma

Chaired by: Professor Fan Chung (London) and Professor Donna Davies (Southampton)

8.35am S41

Expression of functional receptor activity modifying protein (RAMP)-1 by airway epithelial cells with dysregulation in asthma
AB Kay, K Bonner, HH Kariyawasam, FR Ali, P Clark

SCIENTIFIC PROGRAMME

- 8.50am S42**
Airway epithelial toll receptor expression in asthma and its relationship to disease severity
L Cottey, N Jayasekera, H-M Haitchi, B Green, C Grainge, P Howarth
- 9.05am S43**
The expression of CRACM ion channels in human lung mast cells
I Ashmole, SM Duffy, M Leyland, P Bradding
- 9.20am S44**
Increased expression of immunoreactive thymic stromal lymphopoetin in severe asthma
A Shikotra, B Hargadon, M Shelley, J Bennett, C Brightling, C Austin, DF Choy, LC Wu, JR Arron, P Bradding
- 9.35am S45**
Functional KCa3.1 K⁺ channels are required for human fibrocyte migration
SM Duffy, G Cruse, S Singh, C Doe, R Saunders, CE Brightling, P Bradding
- 9.50am S46**
Activation of TGF- β by airway smooth muscle cells via the α V β 5 Integrin in asthmatic airway remodelling
AL Tatler, AE John, L Jolly, AJ Knox, L Pang, G Jenkins

8.30am – 10.30am

Westminster Suite, 4th Floor

SPOKEN SESSION: S47 – S53

Inflammation in lung injury: the key mediators

Chaired by: *Dr Mark Griffiths (London) and Dr Cecilia O’Kane (Belfast)*

- 8.35am S47**
RAGE-mediated cytokine release from leukocytes: implications for systemic inflammation
M Kaneshamoorthy, BC Creagh-Brown, A Burke-Gaffney
- 8.50am S48**
NGAL inhibits cytoskeletal re-organisation, MMP-2 production and invasion in alveolar epithelial cells in an in vitro model of acute lung injury
CM O’Kane, E Moran, DF McAuley
- 9.05am S49**
Is the development of acute lung injury influenced by increased levels of IL17 as a result of Treg/TH17 imbalance?
RCA Dancer, V D’Souza, L Jeffery, D Sansom, CR Bassford, G Perkins, DR Thickett

Thursday 2 December 2010

- 9.20am S50**
Evaluation of Secretory Leucoprotease Inhibitor (SLPI) as an anti-inflammatory therapy for donor lung inflammation
HR Walden, DM Karamanou, CR Fox, AJ Rostron, JA Kirby, AJ Simpson, JH Dark, AJ Fisher
- 9.35am S51**
Thioredoxin modifies MIF release from human monocytes following stimulation with LTA and LPS
SK Leaver, GJ Quinlan, TW Evans, A Burke-Gaffney
- 9.50am S52**
The role of the receptor for advanced end products (RAGE) in acute lung injury (ALI)
BA Thompson, CW Stitt, DF McAuley, CM O’Kane
- 10.05am S53**
Nanoparticles cause pulmonary inflammation through IL-1 α and partial activation of the NLRP3 inflammasome
NR Riteau, AY Yazdi, LB Baron, AG Gombault, GG Guarda, JT Tschopp, IC Couillin

8.45am – 10.15am

Elizabeth Windsor Room, 5th Floor

SPOKEN SESSION: S54 – S58

Orphan lung diseases

Chaired by: *Dr Howard Branley (London) and Dr Simon Johnson (Nottingham)*

- 8.50am S54**
Characterising sarcoidosis using a web-based registry: a pilot study
RK Coker, C Wang, A Sepahzad, NJ Roberts, MR Partridge
- 9.05am S55**
Pulmonary fibrosis with and without co-existing connective tissue disease: does it affect survival?
V Navaratnam, N Ali, CJP Smith, A Fogarty, RB Hubbard
- 9.20am S56**
Flat trachea syndrome – an under-diagnosed and under-treated condition?
G Niranjan, JFK Marzouk
- 9.35am S57**
Evaluation of circulating biomarkers in lymphangioliomyomatosis
WYC Chang, LM Magowan, SR Johnson

Thursday 2 December 2010

9.50am S58

Pulmonary Langerhans' Cell Histiocytosis (PLCH): a new national register
RH Mason, NM Foley, MR Hetzel, H Branley, J Suntharalingam

8.45am – 10.30am

Mountbatten Room, 6th Floor

SYMPOSIUM

NOVEL MECHANISMS AND NEW THERAPIES FOR PULMONARY ARTERIAL HYPERTENSION (PAH)

Chaired by: Dr David Kiely (Sheffield) and Professor Andrew Peacock (Glasgow)

8.45am Inflammation and PAH: lessons from schistosomiasis

Professor Nicholas Morrell (Cambridge)

9.10am The role of cell-based therapies in the treatment of PAH

Dr Duncan Stewart (Ottawa)

9.35am Manipulating the cyclic GMP signalling pathway in PAH

Professor Martin Wilkins (London)

10.00am On the TRAIL of new biomarkers in PAH

Dr Allan Lawrie (Sheffield)

8.45am – 10.30am

Rutherford Room, 4th Floor

SPOKEN SESSION: S59 – S64

α 1-antitrypsin: what it tells us about COPD

Chaired by: Dr Ravi Mahadeva (Cambridge) and Professor Robert Stockley (Birmingham)

8.50am S59

A α -Val360: a plasma marker of neutrophil elastase activity and COPD disease severity

R Carter, MJ Ungurs, RA Stockley

9.05am S60

Cigarette smoke induced oxidation of alpha-1 antitrypsin amplifies the pulmonary inflammatory response

S Alam, Z Li, R Mahadeva

9.20am S61

Cigarette smoke promotes polymerisation of Z α 1-antitrypsin

S Alam, Z Li, S Janciauskiene, R Mahadeva

9.35am S62

Characterisation of a novel 'pseudo-Z' variant of α 1-antitrypsin

M-P Nyon, L Segu, B Roussel, N Kalsheker, DA Lomas, K Thalassinou, B Gooptu

SCIENTIFIC PROGRAMME

9.50am S63

Use of NMR spectroscopy and nanospray mass spectrometry to characterise binding of lead compounds for drug design in α 1-antitrypsin deficiency

M-P Nyon, G Levy, J Kirkpatrick, U Ekeowa, DA Lomas, LD Cabrita, J Christodoulou, A McKay, B Gooptu

10.05am S64

Changes in physiological phenotypes of α 1-antitrypsin deficiency with time

H Ward, MR Miller, RA Stockley

8.45am – 10.30am

Abbey Room, 4th Floor

SPOKEN SESSION: S65 – S70

NIV: the acute and domiciliary settings

Chaired by: Dr Mark Elliott (Leeds) and Dr Anita Simonds (London)

8.50am S65

Interim data from a randomised controlled trial of average volume-assured pressure support (AVAPS) versus spontaneous-timed (ST) pressure support in obesity hypoventilation syndrome (OHS)

P Murphy, AC Davidson, AJ Williams, J Moxham, A Simonds, M Hind, MI Polkey, N Hart

9.05am S66

A randomised crossover trial of Pressure Support Ventilation (PSV) vs Pressure Controlled Ventilation (PCV) in stable hypercapnic Chronic Obstructive Pulmonary Disease (COPD)

KA Brignall, PB Murphy, J Moxham, M Polkey, AC Davidson, N Hart

9.20am S67

Phenotypic differences between obese patients with eucapnic and hypercapnic sleep-disordered breathing (SDB)

KK Lee, E Suh, J Peisch, A McGlone, A Mistry, P Murphy, A J Williams, A C Davidson, N Hart

9.35am S68

Evaluation of noninvasive ventilation in management of acute severe asthma

D Chaudhry, M Indora, V Sangwan, IPS Sehgal, A Chaudhry

9.50am S69

HOT HMV UK: Prevalence of persistent significant hypercapnia following acute exacerbation of COPD (AECOPD) requiring non-invasive ventilation (NIV)

P Murphy, GJ Gibson, MI Polkey, N Hart

SCIENTIFIC PROGRAMME

10.05am S70

Non-invasive ventilation (NIV) in chronic obstructive pulmonary disease (COPD) exacerbations with acute hypercapnic respiratory failure (AHRF) with pH
A Thomas, B Beauchamp, B Chakraborty, E Gallagher, A Ali, R Mukherjee, D Banerjee

10.00am – 11.00am

COFFEE/TEA will be served in the Whittle & Fleming Rooms and Benjamin Britten Lounge, 3rd floor

10.30am – 12.15pm

Churchill Auditorium, Ground Floor

SYMPOSIUM

PLENARY SCIENTIFIC SYMPOSIUM

Chaired by: Professor Edwin Chilvers (Cambridge) and Professor Andrew Fisher (Newcastle upon Tyne)

10.30am Genetic and molecular mechanisms in the pathogenesis of COPD

Professor David Lomas (Cambridge)

10.55am The epidemiology of chronic lung disease: what does it teach us?

Professor Richard Hubbard (Nottingham)

11.20am The lungs at work: future directions?

Dr David Fishwick (Sheffield)

11.45am Pulmonary AV malformations: from patient, to bench, to bedside

Dr Claire Shovlin (London)

10.30am – 12.15pm

Elizabeth Windsor Room, 5th Floor

SPOKEN SESSION: S71 – S76

Novel outcomes and interventions in pulmonary rehabilitation

Chaired by: Ms Julia Bott (Surrey) and Dr Michael Steiner (Leicester)

10.35am S71

Ambulatory oxygen improves the effectiveness of pulmonary rehabilitation (PR) in selected patients

FJ Dyer

10.50am S72

The utility of the modified BODE index (incorporating the incremental shuttle walking test) in assessing survival in patients with COPD screened for Pulmonary Rehabilitation (PR)

JEA Williams, V Warrington, SJ Singh, R Green

11.05am S73

4-metre gait speed as a functional outcome measure in patients with Chronic Obstructive Pulmonary Disease (COPD)

AV Donaldson, BE Garfield, MS Patel, AL Clark, MI Polkey, WD Man

11.20am S74

Effect of pulmonary rehabilitation on the Short Physical Performance Battery (SPPB) in COPD

MS Patel, AL Clark, KA Ingram, RP Fowler, AV Donaldson, SS Kon, MI Polkey, WD Man

11.35am S75

Is a practice incremental shuttle walk test always necessary and is it influenced by MRC dyspnoea grade?

AK Dhaliwal, L Sewell, R Collier, SJ Singh

11.50am S76

The COPD assessment test score (CAT) – a multicentre, prospective study of response to pulmonary rehabilitation

JW Dodd, L Hogg, J Nolan, H Jefford, VM Lord, R Garrod, MI Polkey, PW Jones, WD-C Man, NS Hopkinson

12.15pm – 2.00pm

LUNCH will be available to purchase in the Cafe in the Pickwick Suite, 1st floor, and the Snack Bar in the Whittle & Fleming Rooms, 3rd floor

12.30pm – 1.15pm

Churchill Auditorium, Ground Floor

THE BTS LECTURE

Acute lung injury: new opportunities with cell-based therapy

Professor Michael Matthay (San Francisco)

Introduced by: Professor Michael Morgan (Leicester)

1.30pm – 2.15pm

Caxton Lounge East, 2nd Floor

MODERATED POSTER DISCUSSION: P185 – P190

Challenges in smoking cessation

Chaired by: Dr Elin Roddy (Shrewsbury) and

Dr Michael Ward (Sutton-in-Ashfield)

P185 Public attitudes to smoking in cars

E De Lacy, R Morrison, M Dockrell, T Buchanan, KE Lewis

P186 Public attitudes to the UK smoking ban

M Dockrell, E DeLacy, R Morrison, T Buchanan, KE Lewis

P187 Parents support ban of smoking in cars where minors are present

I Jarrold, K Huntly, T Turkel, N Eiser

P188 An evaluation of a novel semi-quantitative saliva test for cotinine and other nicotinic metabolites

GF Cope, GV O'Donovan, B Savage, HJ Milburn

P189 Smoking status predicts benefit from breathing retraining for hyperventilation

CA Maguire, AG Robson, J Pentland, D McAllister, JA Innes

Thursday 2 December 2010

- P190** Attitudes of health care professionals towards smoking cessation
S Pearce, J Maycock, C McCauley, D Nazareth, P Stockton

1.30pm – 3.15pm

Henry Moore Room, 4th Floor

POSTER DISCUSSION: P96 – P109

Clinical studies in cystic fibrosis

Chaired by: *Dr Mary Carroll (Southampton) and Dr Daniel Peckham (Leeds)*

- P96** Haplotype variability in *Pseudomonas aeruginosa* (Psa) strains in the adult CF population
A Ashish, J Fothergill, E Mowat, J Greenwood, C Winstanley, M Walshaw
- P97** Do intravenous antibiotics influence arterial stiffness in adults with cystic fibrosis?
JH Hull, R Garrod, TB Ho, RK Knight, JR Cockcroft, DJ Shale, CE Bolton
- P98** Accuracy of routine antibiotic susceptibility testing of sputum samples in adult cystic fibrosis patients colonised with *Pseudomonas aeruginosa* (Psa)
A Ashish, J Fothergill, E Mowat, S Huq, M Harris, C Winstanley, M Walshaw
- P99** Social deprivation and clinical outcomes in adult CF patients
A Ashish, D Nazareth, A Tsoukani, G Priona, M Harris, M Ledson, M Walshaw
- P100** An investigation of mutator *Pseudomonas aeruginosa* in chronically infected cystic fibrosis patients treated for pulmonary exacerbation
T Gouliouris, CR Laughton, DM Pearce, V Athithan, JE Foweraker
- P101** Surface parasternal intercostal electromyogram (sEMGpara) as a monitoring tool in cystic fibrosis
C Reilly, C Jolley, C Elston, G F Rafferty, J Moxham
- P102** Quantitative biological imaging of plasmid DNA in live human airway epithelial cells following non-viral gene transfer
C Singh, FM Munkonge, SN Smith, U Griesenbach, R Carzaniga, P Tillmann, S Cheng, A Rogers, A Dewar, EFWF Alton
- P103** Oral contraceptive use does not affect CF disease severity
NG Kernan, P Cullinan, EFWF Alton, D Bilton, U Griesenbach
- P104** T Helper 1 and T Helper 22 cell responses against *Pseudomonas aeruginosa* infections
HK Bayes, T Evans

SCIENTIFIC PROGRAMME

- P105** *Burkholderia latens* – a new infection in CF patients
A Horsley, C Perry, K Martin, K Webb, D Kenna, A Jones
- P106** Inflammatory markers: data from the UK CF Gene Therapy Consortium Run-in study
JA Innes, J Donovan, S Soussi, N Newman, J Leiton, K Campbell, J Gibson, A Doherty, EFWF Alton, C Boyd, U Griesenbach, JC Davies
- P107** Pulmonary imaging techniques to identify suitable patients and act as outcome measures in the UK CF Gene Therapy Consortium clinical programme
JC Davies, JH Conway, J Fleming, M Dewar, N Voase, EFWF Alton, A Greening, D Hansell, JA Innes
- P108** Phenotypic changes in *Pseudomonas aeruginosa* (Psa) populations during exacerbations in adult cystic fibrosis patients infected with non-epidemic strains
A Ashish, J Fothergill, E Mowat, M Gautam, C Winstanley, M Walshaw
- P109** Exercise capacity and physical activity in patients with CF: data from the UK CF Gene Therapy Consortium (UKCFGTC) ‘Run-In’ Study
CJ Saunders, G Davies, NJ Bell, PA Reid, HS Sheridan, SC Hyde, JA Innes, EFWF Alton

1.45pm – 3.15pm

St James’s Suite, 4th Floor

POSTER DISCUSSION: P110 – P121

COPD: sputum and exacerbations

Chaired by: *Dr John Hurst (London) and Dr Tom Wilkinson (Southampton)*

- P110** Quantitative PCR-based detection and quantification of atypical bacteria at baseline and exacerbation of COPD
DS Garcha, SJ Thurston, ARC Patel, JJP Goldring, TD McHugh, GC Donaldson, JA Wedzicha
- P111** FTIR spectroscopic profiling of COPD sputum: identification of distinct spectral signatures and correlation to COPD status
N Patel, P Coleborn, A Hampton, V Campbell, M Allen, A Gahkani, M Spiteri
- P112** Association of sputum *Pseudomonas aeruginosa* (Psa) isolation and length of hospital stay in patients with Chronic Obstructive Pulmonary Disease (COPD)
A Ali, M Bhattacharya, J Corcoran, B Chakraborty, A Thomas, M Raza, R Mukherjee
- P113** Procalcitonin (PCT) is a safe and reliable biomarker of bacterial infection in exacerbations of COPD – So why is it

SCIENTIFIC PROGRAMME

- so challenging to introduce it into a large UK hospital?
L Burke, M Alhajji, N Todd, JS White
- PI14** C-reactive protein at onset predicts symptom resolution in acute exacerbations of COPD
AJ Mackay, GC Donaldson, ARC Patel, JR Hurst, JA Wedzicha
- PI15** Vitamin D binding protein in COPD exacerbations
M Newnham, R Carter, L Sapey, RA Stockley, AM Wood
- PI16** Serum PARC (CCL18) and exacerbation frequency in COPD
CG George, JK Quint, RJ Sapsford, GC Donaldson, JA Wedzicha, JR Hurst
- PI17** Comparison of indices of nutritional status in prediction of in-hospital mortality and early readmission of patients with acute exacerbations of COPD
J Steer, E Norman, GJ Gibson, SC Bourke
- PI18** Predicting survival in patients admitted to hospital with an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
K Williamson, A Sullivan, N Folland, S Rees, S Gompertz
- PI19** COPD assessment test scores: short term changes during recovery from COPD exacerbation
S Chandramouli, S Huq, J Lagan, L Davies
- PI20** Observational study of acute admissions with non-infective asthma and COPD to Perth Royal Infirmary following the eruption of Icelandic volcano Eyjafjallajökull and subsequent ash cloud formation
MEM Wilkie, M Anderson, S Schembri
- PI21** Feasibility of performing valid spirometry in rural India: preliminary results from a population study assessing the prevalence of COPD
R Mukherjee, V C Moore, S Purkait, P Goon, C J Warburton, B Chakrabarti, P M A Calverley

1.45pm – 3.30pm

Mountbatten Room, 6th Floor

SYMPOSIUM

NANO MATERIALS: AN EMERGING HEALTH THREAT?

Chaired by: *Dr Chris Barber (Sheffield) and Dr Chris Warburton (Liverpool)*

- 1.45pm** Nano-materials – uses (benefits) and exposures in the real world
Professor Andrew Maynard (Michigan)
- 2.10pm** Nano-tubes and health – another asbestos?
Professor Ken Donaldson (Edinburgh)

Thursday 2 December 2010

- 2.35pm** Nano-particles and health – just air pollution magnified?
Professor Jon Ayres (Birmingham)
- 3.00pm** Should we be concerned about exposures to nano-materials?
Professor Robert Maynard (London)

1.45pm – 3.30pm

Elizabeth Windsor Room, 5th Floor

SPOKEN SESSION: S77 – S82

Mechanisms of lung infection in the community and hospital setting

Chaired by: *Dr Rosemary Boyton (London) and Dr David Dockrell (Sheffield)*

- 1.50pm S77**
Compartmentalisation of surface Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) in Ventilator-Associated Pneumonia (VAP)
V Grover, P Kelleher, D Henderson, N Soni, S Singh
- 2.05pm S78**
Determinants of macrophage responses to *Streptococcus pneumoniae*
G S Tomlinson, S Khandavilli, J Cohen, C Hyams, J Brown, M Noursadeghi
- 2.20pm S79**
Potential diagnostic significance of neutrophil proteases in ventilator-associated pneumonia
A Conway Morris, K Kefala, TS Wilkinson, K Dhaliwal, IF Laurenson, T Walsh, DF McAuley, C O'Kane, AJ Simpson
- 2.35pm S80**
The role of MyD88 in rhinovirus IB infection
CA Stokes, EP Dick, JA Bennett, S Ismail, MR Edwards, I Sabroe, LC Parker
- 2.50pm S81**
Primary type II alveolar epithelial cells respond differentially to bacterial virulence factors
OL Moncayo Nieto, M Brittan, TS Wilkinson, A Conway Morris, K Dhaliwal, WS Walker, AJ Simpson
- 3.05pm S82**
Survival of HIV-infected patients admitted to the intensive care unit
A G Adlakha, M Pavlou, D Walker, A J Copas, S Batson, S G Edwards, M Singer, R F Miller

1.45pm – 3.45pm

Abbey Room, 4th Floor

POSTER DISCUSSION: P122 – P136

Respiratory physiology: old and new concepts

Chaired by: *Dr William Kinneer (Nottingham) and Professor John Gibson (Newcastle upon Tyne)*

Thursday 2 December 2010

- P122** The use of impulse oscillometry (IOS) to study fractal scaling and sample entropy in airway resistance time series in severe asthma
I Umar, D Desai, S Corkill, M Shelley, A Singapuri, C Brightling, S Siddiqui
- P123** Impulse oscillometry (IOS) indices in severe asthma and healthy controls after deep breath manoeuvres and bronchodilator administration
I Umar, D Desai, S Corkill, M Shelley, A Singapuri, C Brightling, S Siddiqui
- P124** Neuroventilatory uncoupling during cycle and treadmill exercise in COPD
CJ Jolley, YM Luo, J Steier, G Rafferty, MI Polkey, J Moxham
- P125** Non-invasive assessment of ventilation distribution in infants using Electrical Impedance Tomography
PA Shah, H Shannon, A-F Hoo, D Ahmed, J Chudleigh, J Stocks
- P126** The influence of breathing pattern on specific airways resistance
JC Kirkby, S Sonnappa, J Stocks
- P127** Does it matter how they breathe? Perceptions in COPD patients when adopting different routes of breathing
AJ Williams, A Pitcher, P Thomas, R Baker
- P128** The challenges of hypertonic saline in non CF bronchiectasis
T M Small, H Groves, P McAlinden, J Davison, A DeSoyza
- P129** Lung Clearance Index is a sensitive marker of early airway changes in smokers with normal spirometry
NJ Bell, AR Horsley, PA Reid, HS Sheridan, M Monaghan, H Connelly, AP Greening, JA Innes
- P130** Limits of agreement for peak expiratory flow measured by mini-Wright's meter and a pneumotachograph
SJ Oliver, E Ingram, D Fynn, DS Urquhart
- P131** Fitness to fly assessment in patients with neuromuscular disease
J Humphreys, S Agarwal, I Cliff, S Mathew, N Mustfa
- P132** Carbon dioxide sensitivity in patients with hyperventilation syndrome
KA Bazin, S Moosavi, K Murphy, A Perkins, M Hickson, LS Howard
- P133** Prediction equations for pulmonary function values in healthy Iranian children (aged 4–10 years)
MH Boskabady, S Tababaei, S Shahmohammadi, O Mohammadi, P Saremi, S Amery, H Esmaili, Z Ghafari

SCIENTIFIC PROGRAMME

- P134** Lung function in post-transplant Hodgkin's lymphoma patients
H McConkey, S Sachchithanatham, M Gillion, K Raj, M Kazmi, P Fields, M Streetly, H Milburn
- P135** Lung function in post-transplant multiple myeloma patients
H McConkey, M Streetly, S Sachchithanatham, M Gillion, M Kazmi, K Raj, HJ Milburn
- P136** Comparison of the ROBD and the Ventimask method of pre-flight evaluation
SE Martin, JM Bradley, JB Buick, JS Elborn

2.00pm – 3.45pm

Churchill Auditorium, Ground Floor

SYMPOSIUM

CONNECTIVE TISSUE DISEASE ASSOCIATED INTERSTITIAL LUNG DISEASE (ILD)

Chaired by: Professor Ann Millar (Bristol) and Professor Athol Wells (London)

- 2.00pm** The pathogenesis of pulmonary fibrosis in scleroderma
Professor Chris Denton (London)
- 2.25pm** The clinical course of connective tissue disease associated ILD
Professor Kevin Brown (Denver)
- 2.50pm** Connective tissue disease associated ILD – should it be treated like IPF?
Dr Ulrich Costabel (Essen)
- 3.15pm** A biologic revolution – emerging therapeutics for rheumatological disease
Dr David d' Cruz (London)

2.00pm – 3.45pm

Westminster Suite, 4th Floor

SPOKEN SESSION: S83 – S88

Pathophysiological mechanisms in childhood asthma

Chaired by: Dr James Paton (Glasgow) and Dr Sejal Saglani (London)

- 2.05pm S83**
Preschool wheezing phenotypes in a representative UK birth cohort
JM Harris, A Bush, N Wilson, P Mills, C White, S Moffat, L Shread, P Cullinan
- 2.20pm S84**
Childhood incident asthma and physical activity: a systematic literature review and meta-analysis with heterogeneity assessments
L Lochte, R Granell, JAC Sterne, AJ Henderson

SCIENTIFIC PROGRAMME

- 2.35pm S85**
The effects of exposure to IL-9 alone or in combination with IL-13 on the mucociliary differentiation of bronchial epithelial cells from normal and asthmatic children
JC Parker, ST Thavagnanam, G Skibinski, MD Shields, LG Heaney
- 2.50pm S86**
Effects of exposure to IL-13, IL-31 and an IL-13/31 combination on mucociliary differentiation of bronchial epithelial cells from normal children
JC Parker, ST Thavagnanam, G Skibinski, LG Heaney, MD Shields
- 3.05pm S87**
Relationship between bronchial reticular basement membrane thickness (RBM) and smooth muscle mass in childhood severe asthma (SA)
CJ Bossley, N Regamey, L Fleming, T Oates, C Lloyd, A Bush, S Saglani
- 3.20pm S88**
Mast cell myositis is associated with persistent airflow limitation (PAL) in childhood severe asthma (SA)
C J Bossley, T Oates, N Regamey, L Fleming, C Lloyd, A Bush, S Saglani

2.00pm – 3.45pm

Rutherford Room, 4th Floor

SPOKEN SESSION: S89 – S94

Basic mechanisms in lung cancer

Chaired by: Dr Sam Janes (London) and Professor Tariq Sethi (Edinburgh)

- 2.05pm S89**
Bimodal iron oxide nanoparticles for hyperthermia therapy and MR imaging in cancer
KL Parcell, TL Kalber, S Walker-Samuel, P Southern, QA Pankhurst, MF Lythgoe, SM Janes
- 2.20pm S90**
Homocysteine levels in non-small cell lung cancer
J Maguire, V Kelly, C Smyth, M Ledson, M Walshaw

- 2.35pm S91**
The role of the vitamin D axis in lung cancer
LA McGowan, AM Wood, P Newby, B Naidu

- 2.50pm S92**
Epithelial mesenchymal transition occurs earlier than previously thought in the development of squamous cell carcinoma of the lung
NM Cummings, DM Rassl, HC Boobier, JR Gosney, AG Nicholson, LD Sharples, RC Rintoul

Thursday 2 December 2010

- 3.05pm S93**
Is Bcl-2 important in small cell lung cancer?
MH Lawson, DM Rassl, SL Vowler, NM Cummings, WJ Howat, G Murphy, RC Rintoul
- 3.20pm S94**
Two novel determinants of etoposide resistance in small cell lung cancer
MH Lawson, NM Cummings, DM Rassl, R Russell, JD Brenton, RC Rintoul, G Murphy

2.15pm – 3.00pm

Caxton Lounge East, 2nd Floor

MODERATED POSTER DISCUSSION:

P191 – P196

Clinical studies in lung cancer

Chaired by: Dr Richard Harrison (Stockton-on-Tees) and Dr Mark Slade (Cambridge)

- P191** Development of a new patient reported experience measure for the Improving Lung Cancer Outcomes Project
S Christie, N Bell, T Malinowski, A Roberts, I Woolhouse
- P192** Fiberoptic bronchoscopic insertion of the Gianturco stent for tracheobronchial obstruction in patients with cancer at a lung cancer tertiary referral centre: 20 year experience
A Collins, T Jordan, M Ledson, M Walshaw
- P193** The value of a regional mesothelioma multidisciplinary team meeting – an audit
A Jeyabalan, A Pillai, S Smith, M Darby, N Ibrahim, NA Maskell
- P194** The Rise of EBUS: the fall of mediastinoscopy?
H Tan, S Binukrishnan, PA Smith, C Smyth, M Walshaw, K Mohan
- P195** Temporal trends and distribution of recurrent disease following lung cancer surgery and relationship to pre-operative PET scan
R Tunney, D Gnananandha, R Shah, SCO Taggart
- P196** Cryo-recanalization via day-case flexible bronchoscopy for central airway obstruction
B Ng, U Oltmanns, C Hardy, C Yip, M Slade

3.15pm – 4.15pm

COFFEE/TEA will be served in the Whittle & Fleming Rooms and Benjamin Britten Lounge, 3rd floor

3.30pm – 5.30pm

St James's Suite, 4th Floor

POSTER DISCUSSION: P137 – P151

Clinical interventions in COPD

Chaired by: Dr Nicholas Hopkinson (London) and Dr William MacNee (Edinburgh)

Thursday 2 December 2010

- PI37** Efficacy and safety of once-daily acclidinium bromide 200 µg in combination with formoterol in patients with COPD
P Sliwinski, D-W Perng, A Chuchalin, PW Jones
- PI38** Efficacy of inhaled pan-selectin antagonist Bimosiamose on ozone-induced airway inflammation in healthy subjects
A Kirsten, H Watz, G Kretschmar, F Pedersen, W Meyer-Sabellek, D Bock, H Magnussen
- PI39** Atelectasis following bronchoscopic lung volume reduction (BLVR) is associated with improved survival in COPD
NS Hopkinson, SV Kemp, TP Toma, DM Hansell, DM Geddes, PL Shah, MI Polkey
- PI40** Thoracoscopic bullectomy for dyspnoea in emphysema : defining new boundaries
DS Stavroulias, KL Lau, IO Oey, AN Nakas, SR Rathinam, DAW Waller
- PI41** Lung volume reduction surgery – the first 200 operations in a UK centre: the benefits of a multidisciplinary strategy and minimally invasive approach
KA Abdul Aziz, IF Oey, DA Waller, MD Morgan, MC Steiner, SJ Singh
- PI42** Inflammatory cells in the quadriceps of COPD patients and response to resistance training
MK Menon, L Houchen, S Harrison, SJ Singh, MDL Morgan, P Bradding, MC Steiner
- PI43** NF-kappa B (NF-κB) and Activator Protein-1 (AP-1) DNA binding in the quadriceps of COPD patients
SA Natanek, RCJ Langen, HR Gosker, GS Marsh, I Slot, NS Hopkinson, WD-C Man, PR Kemp, J Moxham, AMWJ Schols, MI Polkey
- PI44** Muscle fibre atrophy and aerobic to anaerobic fibre type shift in the quadriceps in COPD
SA Natanek, HR Gosker, I Slot, GS Marsh, RCJ Langen, NS Hopkinson, WD-C Man, J Moxham, PR Kemp, AMWJ Schols, MI Polkey
- PI45** Evaluation of a quadriceps muscle endurance leg lift test in patients with Chronic Obstructive Pulmonary Disease
S Hattle, C Hayton, J Elia, AM Wilson
- PI46** Cognitive loss in stable non-hypoxaemic patients with moderate Chronic Obstructive Pulmonary Disease (COPD)
JW Dodd, M Van Den Broek, D Shrikrishna, NS Hopkinson, PW Jones
- PI47** Deprivation is associated with increased healthcare utilisation in patients with chronic obstructive pulmonary disease
PF Collins, RJ Stratton, R Kurukulaaratchy, M Elia

SCIENTIFIC PROGRAMME

- PI48** Correlating changes in lung function with patient reported outcomes in COPD
PW Jones, J Donohue, J Nedelman, G Pinault, S Pascoe
- PI49** Validation of the COPD Assessment Test (CAT) within α-1 antitrypsin deficiency (AIATD)
RG Edgar, D Griffiths, RA Stockley
- PI50** How well do patients with chronic respiratory failure secondary to COPD and their carers adapt to long-term oxygen therapy at home?
C Wrench
- PI51** Reduced mortality with beta blockers when added to stepwise therapy for COPD
PM Short, SIW Lipworth, DH Elder, S Schembri, BJ Lipworth

3.30pm – 5.30pm

Henry Moore Room, 4th Floor

SPOKEN SESSION: S95 – S101

Novel disease mechanisms in pulmonary arterial hypertension

Chaired by: *Dr Luke Howard (London) and Dr David Kiely (Sheffield)*

- 3.35pm S95**
Application of proteomics to explore the pathobiology of pulmonary arterial hypertension
VB Abdul-Salam, J Wharton, MR Wilkins, RJ Edwards
- 3.50pm S96**
Novel biomarkers in idiopathic pulmonary arterial hypertension
CJ Rhodes, J Wharton, LS Howard, JSR Gibbs, MR Wilkins
- 4.05pm S97**
Inflammatory cytokines are elevated in patients with operable chronic thromboembolic pulmonary hypertension and predict outcome post-endarterectomy
E Soon, AM Holmes, L Barker, C Treacy, J Suntharalingham, M Toshner, P Nicklin, C Walker, D Budd, D Jenkins, KK Sheares, J Pepke-Zaba, NW Morrell
- 4.20pm S98**
Ventilatory efficiency in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: physiological differences and implications for disease-specific end-points
Z Zhai, K Murphy, H Tighe, C Wang, M Wilkins, S Gibbs, LS Howard
- 4.35pm S99**
Multiple regression analyses in a cohort of hereditary haemorrhagic telangiectasia

SCIENTIFIC PROGRAMME

- patients suggest a novel role for iron in thrombosis
JA Livesey, JE Jackson, CL Shovlin
- 4.50pm S100**
Change in diastolic pulmonary artery pressure (3 months post surgery compared to pre-surgery value) as a long term prognostic parameter in patients treated with pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension
GC Hagan, C Treacy, K Sheares, DP Jenkins, J PepkeZaba, A Kacprzak
- 5.05pm S101**
Praziquantel prevents progression and reverses pulmonary hypertension and pulmonary vascular remodelling in a mouse model of Schistosomiasis
A Crosby, F M Jones, E Kakolos, M Southwood, I Purvis, G Butrous, DW Dunne, N Morrell
-
- 3.45pm – 5.30pm**
Mountbatten Room, 6th Floor
SPOKEN SESSION: S102 – S107
Acute lung injury: what are the causes?
Chaired by: Dr Daniel McAuley (Belfast) and Professor Moira Whyte (Sheffield)
- 3.50pm S102**
KGF enhances pulmonary production of pro-epithelial repair factors in a human in vivo model of acute lung injury
M Shyamsundar, CM O'Kane, C Calfee, ST McKeown, C Taggart, MA Matthay, DF McAuley
- 4.05pm S103**
A decrease in elafin due to proteolytic cleavage may contribute to alveolar inflammation in patients with ALI
A Kerrin, C O'Kane, M Shyamsundar, T Craig, CC Taggart, DF McAuley
- 4.20pm S104**
Monocyte influx accompanies the early neutrophilic inflammation seen in bronchoalveolar lavage fluid following lipopolysaccharide inhalation
LC Barr, M Brittan, A Conway Morris, S Johnston, F Rossi, R Duffin, N Hirani, K Dhaliwal, AG Rossi, DF McAuley, AJ Simpson
- 4.35pm S105**
Does Vitamin D deficiency increase risk of acute lung injury post oesophagectomy?
RCA Dancer, D Park, V D'Souza, F Gao Smith, GD Perkins, DR Thickett
- 4.50pm S106**
Polymorphisms in genes encoding RAGE or RAGE ligands predispose patients to adverse

Thursday 2 December 2010

- outcomes following surgery necessitating cardiopulmonary bypass
N Zakeri, B Creagh-Brown, LR Hector, RJ Hewitt, AL Lagan, GJ Quinlan, P Pantelidis
- 5.05pm S107**
Comparison of high-stretch versus atelectasis in the pathophysiology of ventilator-induced lung injury using the mouse isolated perfused lung
K Wakabayashi, MR Wilson, KP O'Dea, M Takata
-
- 4.00pm – 5.00pm**
Westminster Suite, 4th Floor
POSTER DISCUSSION: P152 – P159
Clinical aspects of NIV
Chaired by: Dr Naveed Mustfa (Stoke-on-Trent) and Professor Michael Polkey (London)
- P152** Effect of obesity in patients admitted to Non Invasive Ventilation (NIV) unit with acute hypercapnic respiratory failure (AHRF)
CM Thippanna, A Thomas, W Tosh, B Chakraborty, B Beauchamp, D Banerjee, R Mukherjee
- P153** The effect of body mass index on outcomes of acute Non-invasive Ventilation (NIV) in a district general hospital
H Liddicoat, C Zammitt, J Loft, I Moonsie, H Makker
- P154** The patients' experience of NIV.A phenomenological study
H Matthews
- P155** Non-Invasive Ventilation (NIV) in acute hypercapnic respiratory failure in Restrictive Lung Diseases (RLD)
A Thomas, A Ali, B Chakraborty, B Beauchamp, E Gallagher, D Banerjee, R Mukherjee
- P156** Does analysis of patient-ventilator interaction offer benefits in addition to overnight pulse oximetry in patients with motor neurone disease being followed on non-invasive ventilation?
B Chakraborty, H Ando, E Thornton, V Ford, CA Young, RM Angus
- P157** Staff education improves non-invasive ventilation outcomes in COPD patients presenting with acute hypercapnoeic respiratory failure
S Roychowdhury, O Kankam, C Jackson, D Sword, K Prasad, V Stark
- P158** The strength of association between the risk of endotracheal intubation and initial arterial blood (ABG) pH in patients presenting with acute hypercapnic respiratory failure (AHRF) treated with Non-Invasive Ventilation (NIV)
A Thomas, B Beauchamp, B Chakraborty, M Page, S Khanum, E Gallagher, D Banerjee, R Mukherjee

Thursday 2 December 2010

- P159** HOT HMV UK: sleep disruption following initiation of domiciliary NIV in hypercapnic COPD
P Murphy, MI Polkey, N Hart

4.00pm – 5.30pm

Elizabeth Windsor Room, 5th Floor

POSTER DISCUSSION: P160 – P171

Improving patient outcomes in TB

Chaired by: Professor Peter Davies (Liverpool) and Dr Gerrit Woltmann (Leicester)

- P160** Treating TB patients with no entitlement to social support – welcome to the social jungle
S Hemming, P Windish, J Hall, A Story, M Lipman
- P161** Global prevalence of chronic pulmonary aspergillosis (CPA) following pulmonary tuberculosis (PTB)
DW Denning, A Pleuvry, DC Cole
- P162** How many and how much? Assessing resource utilisation in Multi-drug Resistant Tuberculosis (MDR TB) management using routinely-collected hospital data
RJ José, C Smith, R Breen, N Marshall, I Cropley, S Hopkins, MCI Lipman
- P163** Incidence and clinical relevance of non-tuberculous mycobacteria isolates based on 10 years experience at York Hospital, North Yorkshire (UK)
L Burke, A Anderson, S Waring, N Thompson, RA Thomas
- P164** Enabling next day processing of blood samples with T-SPOT.TB
I Durrant, J Radcliffe
- P165** TB-ST Rapid Test for tuberculosis diagnosis in a resource poor setting: are cases of tuberculosis going undiagnosed?
N Javanshir, DS Shah, DE Jennings, J Ivanyi, HJ Milburn
- P166** Quantiferon testing in close contacts of smear positive pulmonary TB identifies people at low risk of secondary progression
P Haldar, H Thuraisingam, H Patel, W Hoskyns, G Woltmann
- P167** Characterisation of tuberculous mediastinal lymphadenopathy on CT and correlation with biomarkers and chest radiograph findings
A Singanayagam, P George, D Connell, S Kaneria, J Dhariwal, P Molyneaux, M Wickremasinghe, A Lalvani, A Wright, OM Kon
- P168** Rifabutin is a useful alternative to rifampicin in the treatment of active TB/HIV co-infection
R Singh, N Marshall, CJ Reynolds, RAM Breen, CJ Smith, L Swaden, S Bhagani, S Hopkins, MA Johnson, MCI Lipman

SCIENTIFIC PROGRAMME

- P169** Subclinical ocular manifestations of pulmonary and extrapulmonary tuberculosis in a Hampshire population
S Beeson, N Wetherill, S Mansour, AK Banerjee, D Rowen, N Hall, BG Marshall
- P170** TB-HIV co-infection: how does the UK compare to Europe?
ME Kruijshaar, L Pimpin, C Ködmön, M Lipman, V Delpech, B Rice, L Drumright, D Manissero, I Abubakar
- P171** The development of a UK national MDRTB service
PDO Davies, DM Cullen

4.00pm – 5.40pm

Abbey Room, 4th Floor

POSTER DISCUSSION: P172 – P184

Therapeutic interventions in asthma and airways disease

Chaired by: Dr Ruth Green (Leicester) and Dr Andrew Menzies-Gow (London)

- P172** Fluticasone/Salmeterol combination confers significant benefits in smoking asthmatics
KL Clearie, L McKinlay, PA Williamson, P Hopkinson, KT Meldrum, BJ Lipworth
- P173** Management of sputum eosinophil-negative patients in a severe asthma clinic
G Tavernier, C Pris-Picard, R Gore, R Niven
- P174** Identifying non-adherence with asthma medication and the relationship to clinical outcomes amongst adults with difficult-to-control asthma
AC Murphy, A Proeschel, ME Linnett, CE Brightling, AJ Wardlaw, ID Pavord, P Bradding, RH Green
- P175** Cross-sectional and longitudinal relationships of self-management behaviours and other psychological factors with outcomes in patients with severe asthma
JR Smith, MJ Noble, BDW Harrison, M Adams
- P176** Evaluating the role of triamcinolone in a difficult asthma service
R Carter, A Murphy, B Hargadon, J Agbetile, I D Pavord, A J Wardlaw, R H Green, P Bradding
- P177** Fluticasone propionate/formoterol fumarate combination therapy is as effective as fluticasone propionate/salmeterol xinafoate in the treatment of asthma: a randomised controlled trial
A Bodzenta-Lukaszyk, A Dymek, H Mansikka
- P178** Validation of a novel Synthetic Absorptive Matrix (SAM) for sampling nasal mucosal lining fluid
D Jackson, Y Clements, SL Johnston, TT Hansel

SCIENTIFIC PROGRAMME

- P179** Lung-based assessment in Anderson Fabry Disease (AFD) demonstrates differential alpha galactosidase A enzyme (GLA) activity at blood and tissue sites
NT Shafi, DA Hughes, R Baker, C Smith, J Hurst, A Mehta, M Lipman
- P180** Sputum eosinophil positivity to tailor steroid management of severe asthmatics
G Tavernier, C Pris-Picard, R Gore, R Niven
- P181** Better asthma control with Montelukast than Salmeterol in arg-I6 homozygous children with asthma
K Basu, HP Donald, BJ Lipworth, R Tavendale, DF Macgregor, SA Ogston, CNA Palmer, S Mukhopadhyay
- P182** Adenosine potentiates human mast cell fibrinolytic activity
MJ Sereda, P Bradding, C Vial
- P183** Global burden of allergic bronchopulmonary aspergillosis (ABPA) complicating asthma
DW Denning, A Pleuvry, DC Cole
- P184** Can we predict asthma exacerbations in working-age adults?
SJ MacNeill, AB Jones, CJP Smith, R Hubbard, P Cullinan

4.00pm – 5.45pm

Churchill Auditorium, Ground Floor

SYMPOSIUM

WHAT'S NEW IN PNEUMONIA IN ADULTS AND CHILDREN?

Chaired by: Dr Jeremy Brown (London) and Dr Wei Shen Lim (Nottingham)

- 4.00pm** Aetiology and diagnosis of hospital/ventilator acquired pneumonia
Professor John Simpson (Newcastle upon Tyne)
- 4.25pm** Beyond the CURB65
Dr Adam Hill (Edinburgh)
- 4.50pm** Lessons from paediatrics
Dr David Spencer (Newcastle upon Tyne)
- 5.15pm** Vaccinating infants and protecting adults: global experience with pneumococcal conjugate vaccines
Professor David Goldblatt (London)

Thursday 2 December 2010

5.45pm – 7.15pm

Mountbatten Room, 6th Floor

BRITISH LUNG FOUNDATION 25TH ANNIVERSARY SYMPOSIUM

Chaired by: Professor Sir Malcolm Green (London)

- 5.45pm** Overview: 25 years of the BLF
Professor Sir Malcolm Green
- 6.10pm** COPD: a global epidemic
Professor Sonia Buist (Washington)
- 6.30pm** How pathology links to abnormal function
Professor Jim Hogg (Vancouver)
- 7.10pm** Vote of thanks
Professor Peter Barnes (London)

Friday 3 December 2010

8.00am – 9.00am

COFFEE/TEA will be served in the Whittle & Fleming Rooms, 3rd floor

8.45am – 2.00pm

Whittle & Fleming Rooms, 3rd floor

POSTER VIEWING

Authors present: 10.00am – 11.00am

P197–P209

Clinical studies in obstructive sleep apnoea

Discussion of abstracts will take place from 1.30pm to 3.10pm in the Westminster Suite, 4th floor

P210–P222

Developments in the delivery of lung cancer care

Discussion of abstracts will take place from 1.30pm to 3.10pm in the Henry Moore Room, 4th floor

P223–P236

Organisation of respiratory care

Discussion of abstracts will take place from 1.30pm to 3.15pm in the St James's Suite, 4th floor

P237–P247

Clinical challenges in diagnosing and managing respiratory infection

Discussion of abstracts will take place from 3.15pm to 4.40pm in the Abbey Room, 4th floor

P248–P254

Outcome determinants in acute lung injury

Discussion of abstracts will take place from 3.30pm to 4.30pm in the Mountbatten Room, 6th floor

8.45am – 2.30pm

Caxton Lounge East, 2nd Floor

MODERATED POSTER VIEWING

Authors present: 10.00am – 11.00am

P255–P261

Clinical studies in pulmonary embolism

Discussion of abstracts will take place from 1.30pm to 2.30pm in the Caxton Lounge East, 2nd floor

8.15am – 8.45am

Fleet Room, 2nd Floor

THE BTS JOURNAL CLUB

Asthma

Dr Philip Ind (London)

8.30am – 10.15am

Churchill Auditorium, Ground Floor

SYMPOSIUM

COPD: THE PATIENT WITH COMPLEX ADVANCED DISEASE

Chaired by: Professor Martyn Partridge (London) and Ms Jane Scullion (Leicester)

8.30am The clinical relevance of systemic manifestations of COPD
Dr Alvar Agusti (Barcelona)

SCIENTIFIC PROGRAMME

8.55am The challenges of managing COPD in the elderly patient
Dr Charlotte Ruse (Sheffield)

9.20am Volume reduction therapies in advanced emphysema
Professor Michael Polkey (London)

9.45am The role of home ventilatory support in advanced COPD
Dr Mark Elliott (Leeds)

8.30am – 10.15am

Westminster Suite, 4th Floor

SPOKEN SESSION: S108 – S113

Epidemiology of lung disease

Chaired by: Dr Andrew Fogarty (Nottingham) and Dr David Hendrick (Newcastle upon Tyne)

8.35am S108

A historical cohort study to determine the prevalence of common chronic respiratory diseases and medication use in drug misusers
F Palmer, M Jaffray, M Moffat, C Matheson, J Haughney, A Coutts

8.50am S109

Current COPD care in the UK; results from 180,000 patients in the POINTS database
A De Soyza, J Roberts

9.05am S110

Employment histories of people with asthma in the 1958 Birth Cohort
R Ghosh, D Jarvis, D Strachan, P Cullinan

9.20am S111

Asthma, puberty and BMI in the 1958 British Birth Cohort
DL Jarvis, L Gnatiuc, RB Newson

9.35am S112

The natural history of wheeze from birth to adult life: a cohort study
ML Burr, FDJ Dunstan, S Hand, KP Jones, S Rolf

9.50am S113

The effect of small airways disease and emphysema on the association between smoking and lung function, and bronchodilator response
BD Patel, HO Coxson, PG Camp, SG Pillai, AG Agusti, PM Calverley, CF Donner, BJ Make, NL Müller, SI Rennard, J Vestbo, EF Wouters, WH Anderson, PD Paré, RD Levy, EK Silverman, DA Lomas

8.30am – 10.15am

Abbey Room, 4th Floor

SPOKEN SESSION: S114 – S119

Measurements in patients with chronic cough

Chaired by: Professor Alyn Morice (Hull) and Professor Ian Pavord (Leicester)

SCIENTIFIC PROGRAMME

- 8.35am S114**
A double blind, placebo controlled, randomised, study to assess the effects of placebo, codeine and Talnetant, on citric acid cough threshold in healthy subjects
S Khalid, A Woodcock, B Haumann, P Ventresca, SJ Langley, JA Smith
- 8.50am S115**
Magnitude of cough response to inhaled capsaicin differentiates between health and disease
EC Young, H Sumner, A Kelsall, AA Woodcock, JA Smith
- 9.05am S116**
Urge-to-cough intensity in chronic cough patients compared to asthmatics and healthy controls
EC Young, H Sumner, A Kelsall, AA Woodcock, JA Smith
- 9.20am S117**
Four hour cough frequency monitoring with the Leicester Cough Monitor
KK Lee, A Savani, S Matos, C Woods, ID Pavord, SS Birring
- 9.35am S118**
Acute hemispheric stroke patients have reduced functional residual capacity and cough flow rates
PR Rao, KW Ward, CR Reilly, GR Rafferty, J Moxham
- 9.50am S119**
Variation in pharyngeal pH in the diagnosis of airway reflux
ID Molyneux, W Jackson, AH Morice

8.30am – 10.15am

Mountbatten Room, 6th Floor

SPOKEN SESSION: S120 – S125

Inflammation: an important regulator of the fibrotic response

Chaired by: Dr Nik Hirani (Edinburgh) and Dr Toby Maher (London)

8.35am S120

IL-1 is a key epithelial alarmin which promotes fibroblast activation
MI Suwara, LA Borthwick, J Mann, AJ Fisher, DA Mann

8.50am S121

Individual cell tracking in a transgenic zebrafish inflammation model reveals the fates of inflammatory neutrophils during inflammation resolution
G Dixon, CA Loynes, X Wang, PW Ingham, MKB Whyte, SA Renshaw

Friday 3 December 2010

- 9.05am S122**
The M1 macrophage phenotype accentuates TGF- β 1 driven epithelial to mesenchymal transition (EMT) via the secretion of TNF α
LA Borthwick, M Brodrie, GE Johnson, C Ward, J Perry, PA Corris, A De Soyza, AJ Fisher
- 9.20am S123**
Mononuclear inflammation and disruption of normal alveolar structure following deletion of G α Q/11, but not G α 12/13, in type II alveolar epithelial cells
AE John, J Porte, L Jolly, AL Tatler, RG Jenkins
- 9.35am S124**
Macrophage deletion of vHL results in alternative activation and enhanced lung fibrosis independent of HIF-1
MA Gibbons, PM Fitch, A MacDuff, AC Mackinnon, SJ Forbes, V Aidinis, RS Johnson, T Sethi, C Haslett, AG Rossi, AJ Simpson, SEM Howie, N Hirani
- 9.50am S125**
Ly6Chi circulating monocytes direct alternatively activated, pro-fibrotic, lung macrophage regulation of pulmonary fibrosis
MA Gibbons, AC MacKinnon, P Ramachandran, R Duffin, K Dhaliwal, C Haslett, SEM Howie, AJ Simpson, N Hirani, J Gaudie, JP Iredale, T Sethi, SJ Forbes

8.45am – 10.15am

Elizabeth Windsor Room, 5th Floor

SYMPOSIUM

**JOINT BTS/UKRRC SYMPOSIUM:
BUILDING AN ACADEMIC CAREER IN
RESPIRATORY RESEARCH**

Chaired by: Professor Stephen Holgate (Southampton) and Dr Samantha Walker (London)

8.45am Starting an academic career in respiratory paediatrics

Dr Malcolm Brodrie (Newcastle upon Tyne)

9.05am Balancing clinical training with building your academic career

Dr Sarah Walmsley (Sheffield)

9.25am Research careers for respiratory nurses

Dr Linda Pearce (Bury St Edmunds)

9.45am Developing an academic career via the NIHR route

Dr William Man (London)

10.00am – 11.00am

COFFEE/TEA will be served in the Whittle & Fleming Rooms and Benjamin Britten Lounge, 3rd floor

Friday 3 December 2010

10.15am – 12.00pm

Henry Moore Room, 4th Floor

SPOKEN SESSION: S126 – S131

Lung infection: a multi-faceted problem

Chaired by: Professor John Simpson (Newcastle upon Tyne) and Dr Mark Woodhead (Manchester)

10.20am **S126**

Measuring quality in pneumonia care. The North West Advancing Quality programme 2008 – 2009

M Woodhead, J Butterworth, L-A Myers

10.35am **S127**

Is healthcare associated pneumonia a distinct clinical phenotype?

J Taylor, J Chalmers, A Singanayagam, A Akram, G Choudhury, P Mandal, A Hill

10.50am **S128**

Analysis of volatile biomarkers within exhaled breath for the diagnosis of pneumonia

PR Boshier, V Mistry, JR Cushnir, S Curtis, S Elkin, OM Kon, N Marczin, GB Hanna

11.05am **S129**

Predicting outcome from HIV-associated Pneumocystis pneumonia

D Armstrong-James, AJ Copas, PD Walzer, SG Edwards, RF Miller

11.20am **S130**

Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis

L White, G Mirrani, M Grover, J Rollason, A Malin, J Suntharalingam

11.35am **S131**

Fatigue in bronchiectasis: its relationship to Pseudomonas colonisation, dyspnoea and airflow obstruction

JG Macfarlane, H Tedd, P McAlinden, T Small, L Rostron, J Newton, A De Soyza

10.30am – 12.00pm

Westminster Suite, 4th Floor

SPOKEN SESSION: S132 – S137

Clinical and translational observations in asthma

Chaired by: Professor Sebastian Johnston (London) and Professor Neil Thomson (Glasgow)

10.35am **S132**

Airway dysfunction and inflammation in pool and non-pool based elite endurance athletes

N Martin, MR Lindley, B Hargadon, W Monteiro, ID Pavord

10.50am **S133**

Eosinophilic airway inflammation is associated with FEV1 decline in severe asthma

J Agbetile, D Desai, B Hargadon, P Bradding, AJ Wardlaw, ID Pavord, RH Green, CE Brightling, S Siddiqui

SCIENTIFIC PROGRAMME

11.05am **S134**

ABSTRACT WITHDRAWN

11.05am **S135**

Can your mobile phone improve your asthma?
D Ryan, H Pinnock, L Tarassenko, A Lee, A Sheikh, D Price

11.20am **S136**

Fungal sputum culture in patients with severe asthma is associated with a reduced post bronchodilator FEV1

J Agbetile, A Fairs, M Bourne, B Hargadon, K Mutalithas, W Monteiro, R Edwards, J Morley, D Desai, CE Brightling, PH Bradding, RH Green, ID Pavord, AJ Wardlaw, CH Pashley

11.35am **S137**

The At-Risk Registers in Severe Asthma (ARRISA) Study: a cluster-randomised controlled trial in primary care

JR Smith, MJ Noble, SD Musgrave, J Murdoch, G Price, A Martin, J Windley, R Holland, BDW Harrison, D Price, A Howe, I Harvey, AM Wilson

10.30am – 12.15pm

Churchill Auditorium, Ground Floor

SYMPOSIUM

HOW HAS IMAGING CHANGED LUNG CANCER INVESTIGATION?

Chaired by: Dr Matthew Callister (Leeds) and Dr Richard Harrison (Stockton-on-Tees)

10.30am Pro-con debate: "PET-CT, EBUS and EUS mean that mediastinoscopy is no longer needed in staging lung cancer"

Pro: Dr Ian Woolhouse (Birmingham) and Con: Mr David Waller (Leicester)

11.10am Pro-con debate: "Conventional TBNA is outmoded in staging the mediastinum since the advent of EBUS"

Pro: Dr Robert Rintoul (Cambridge) and Con: Dr Mark Slade (Cambridge)

11.50am What has the national PET programme delivered for the UK?

Professor Fergus Gleeson (Oxford)

10.30am – 12.15pm

Mountbatten Room, 6th Floor

SYMPOSIUM

THE INDUSTRY AND UK RESPIRATORY MEDICINE: TIME FOR CLOSER LIAISONS

Chaired by: Professor Peter Barnes (London) and Professor Michael Morgan (Leicester)

10.30am Why is the government promoting strong collaborations between the NHS and industry?
Professor Dame Sally Davies (Department of Health)

SCIENTIFIC PROGRAMME

- 10.55am** Making relationships between the NHS, respiratory academia and industry work for patients with lung disease
Dr Richard Marshall (GlaxoSmithKline)
- 11.20am** "This could be something big": create your own respiratory biotech company
Dr Garth Rapeport (RespiVert)
- 11.45am** The pivotal role of NHS respiratory medicine in drug discovery and development
Professor Tim Higenbottam (Chiesi)

10.30am – 12.15pm

St James's Suite, 4th Floor

SPOKEN SESSION: S138 – S143

Mechanisms of fibrosis in respiratory disease

Chaired by: Dr Gisli Jenkins (Nottingham) and

Dr Chris Scotton (London)

10.35am S138

Clara cells inhibit alveolar epithelial wound repair through a TRAIL-dependent apoptosis mechanism

KM Akram, M Spiteri, NR Forsyth

10.50am S139

The K⁺ channel KCa3.1 is a novel target for the treatment of idiopathic pulmonary fibrosis
MC Shepherd, SR Sabir, C McSharry, H Wulff, P Bradding

11.05am S140

The role of Transforming Growth Factor- β Activated Kinase-1 (TAK-1) in the development of airway fibrosis
A Gardner, MJ Brodlie, DA Mann, LA Borthwick, AJ Fisher

11.20am S141

A Disintegrin And Metalloprotease (ADAM)33 protein in patients with pulmonary sarcoidosis
AS Shaffiq, HMH Haitchi, YYP Pang, AA Alangari, MGJ Jones, BGM Marshall, KMAO O'Reilly, DED Davies

11.35am S142

The K⁺ channel KCa3.1 is expressed in human lung fibroblasts
K Roach, G Arthur, C Feghali-Bostwick, W Coward, SM Duffy, P Bradding

11.50am S143

Serum Mannose binding lectin deficiency is present in patients with early onset Interstitial pulmonary fibrosis and those with affected relatives suggesting a genetic risk factor for defects in the innate immune system
VA Varney, J Evans, H Parnell, A Nicholas, B Barjardeen, N Sumar

Friday 3 December 2010

10.30am – 12.15pm

Abbey Room, 4th Floor

SPOKEN SESSION: S144 – S149

Smoke and pollution in COPD mechanisms

Chaired by: Professor Ian Adcock (London) and

Dr Louise Donnelly (London)

10.35am S144

Cigarette smoke dysregulates pro-inflammatory cytokine release from airway epithelial cells and macrophages in response to Haemophilus influenzae

EJ Moisey, LA Borthwick, J Perry, A De Soyza, AJ Fisher

10.50am S145

The impact of cigarette smoke extract on inflammatory responses and Toll-like receptor-4 expression in healthy nasal epithelial cells

D Comer, JS Elborn, V Brown, C McDowell, M Ennis

11.05am S146

Microvascular endothelial cell apoptosis and dysregulation of Vascular Endothelial Growth Factor Receptor 2 (VEGF-R2) in response to cigarette smoke. New insights into the pathogenesis of emphysema

LS Mackay, S Dodd, W Tomlinson, I Dougall, H Walden, B Isherwood, A Gardner, L Borthwick, K Pinnion Brown, M Foster, AJ Fisher, PA Corris

11.20am S147

Diesel exhaust particles alter monocyte differentiation in vitro but have little impact on neutrophil function

H Jary, K Piddock, K Donaldson, LR Prince, LC Parker, I Sabroe, N Chaudhuri

11.35am S148

Regulation of neutrophil apoptosis by phosphoinositide 3-kinases

JK Juss, AM Condliffe, PT Hawkins, L Stephens, ER Chilvers

11.50am S149

Characterization of T cell populations in the lung

R Spruce, G Rankin, J Ward, S J Wilson, C Pickard, J A Warner

12.15pm – 2.00pm

LUNCH will be available to purchase in the Cafe in the Pickwick Suite, 1st floor, and the Snack Bar in the Whittle & Fleming Rooms, 3rd floor

Friday 3 December 2010

12.30pm – 1.15pm

Churchill Auditorium, Ground Floor

JOHN DONALDSON ASTHMA UK LECTURE

The role of the patient in asthma management

Professor Martyn Partridge (London)

Introduced by: Dr Robert Wilson (London)

1.00pm – 3.00pm

Abbey Room, 4th Floor

SPOKEN SESSION: S150 – S156

Cell signalling and cell responses in pulmonary vascular disease

Chaired by: Professor Nicholas Morrell (Cambridge) and Professor Duncan Stewart (Ottawa)

1.05pm **S150**

Smad-dependent and Smad-independent induction of Id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo
J Yang

1.20pm **S151**

TRAIL deficiency is protective in experimental pulmonary arterial hypertension
AG Hameed, J Chamberlain, ND Arnold, SE Francis, CMH Newman, DC Crossman, A Lawrie

1.35pm **S152**

Dexamethasone reverses established monocrotaline-induced pulmonary hypertension in rats and increases pulmonary BMPR2 expression
LC Price, SJ Wort, D Montani, CTcherakian, P Dorfmueller, R Souza, D Shao, G Simonneau, LS Howard, I Adcock, M Humbert, F Perros

1.50pm **S153**

Bone morphogenetic protein receptor-II regulates pulmonary artery endothelial cell barrier function: relevance to heritable pulmonary arterial hypertension
VJ Burton, LI Ciuclan, AM Holmes, D Rodman, C Walker, DC Budd

2.05pm **S154**

Is there a role for IL-33 in the pathogenesis of pulmonary arterial hypertension?
D Shao, F Perros, M Humbert, G Caramori, L Price, I Adcock, S Wort

2.20pm **S155**

The role of ST2 in a model of pulmonary hypertension
A Mahmood, C McSharry, D Xu, AJ Peacock, DJ Welsh

2.35pm **S156**

Chloride intracellular channel protein 4 (CLIC4) in the regulation of human pulmonary endothelial responses to hypoxia
VB Abdul-Salam, MR Wilkins, B Wojciak-Stothard

SCIENTIFIC PROGRAMME

1.30pm – 2.30pm

Caxton Lounge East, 2nd Floor

MODERATED POSTER DISCUSSION:

P255 – P261

Clinical studies in pulmonary embolism

Chaired by: Dr Derek Bell (London) and

Dr Adam Hill (Edinburgh)

P255

Defining a circadian pattern of presentation of pulmonary embolism on CT/VQ imaging
N Shah, AS Jubber, I Syed

P256

Investigating suspected pulmonary embolism as outpatient, the Portsmouth experience
I Shafiq, N Siddique, A J Chauhan, L Albon, V King, SR Alapati

P257

A comparison of scoring systems in the management of a range of pulmonary embolism patients in a university hospital
M Maruthappu, A Manuel, A Christian, A Hollington, M Ramsden, Z Alexopoulou, M Healy, M Giles

P258

Is Chronic Thromboembolic Pulmonary Hypertension (CTEPH) underdiagnosed in the UK?
S Sturney, G Robinson, G Coghlan, J Pepke-Zaba, J Easaw, J Suntharalingam

P259

Incidental findings on computed tomography pulmonary angiography: what should we be looking for?

R Thiagarajah, M Qureshi, A Sahu, R Riordan

P260

Managing the indeterminate CT pulmonary angiogram: Do we get it right?

EL O'Dowd, JD Birchall, RJ Berg

P261

Questionnaire to assess acceptability of venous thromboembolism risk assessment tool by admitting doctors and nurses in the medical assessment unit of a district general hospital
E K Nuttall, F Zaman

1.30pm – 3.10pm

Westminster Suite, 4th Floor

POSTER DISCUSSION: P197 – P209

Clinical studies in obstructive sleep apnoea

Chaired by: Dr Martin Allen (Stoke-on-Trent) and Dr Joerg Steier (London)

P197

The effect of CPAP therapy on insulin sensitivity and CV risk factors in patients with OSA
M Paracha, D Ahearn, W Flight, V Gupta, M Abdelhalim

P198

Effects of oxygen therapy on central sleep-disordered breathing in infants with Prader-Willi Syndrome
DS Urquhart, P Wales, C Parsley, S Suresh

SCIENTIFIC PROGRAMME**Friday 3 December 2010**

- P199** Diabetic Macular Oedema (DME) and Obstructive Sleep Apnoea (OSA) – visual improvement post CPAP therapy. Proof of principle study
RH Mason, CA Kiire, A Bolton, L Smith, V Chong, JR Stradling
- P200** Snoring and carotid atheroma: no association
RH Mason, Z Mehta, PM Rothwell, JR Stradling
- P201** Health literacy and sleep apnoea
R Ghiassi, MR Partridge
- P202** Clinics for Obstructive Sleep Apnoea Hypopnoea (OSAH) – time for a change?
TS Jordan, E Idris, R Haqqee, M Allen
- P203** Management of obesity in respiratory clinics – are we doing enough?
S Mandal, DJ Powrie
- P204** Travel with CPAP machines: how frequent and what are the problems?
S Faruqi, P Carveth-Johnson, AOC Johnson
- P205** Obstructive sleep apnoea screening – cost and clinically effective in a TIA clinic?
M Waller, A Hussey, A Morris, D Hargroves, B Prathibha
- P206** Compliance with CPAP: subjective vs objective methods of assessment and regional variations
A Lal, L Dale, T Lucas, B Chakraborty, D Banerjee, D Brocklebank
- P207** Obstructive sleep apnoea in patients undergoing bariatric surgery – a London teaching hospital experience
CJ Jolley, S Zimmerman, S Shah, N Davison, S Singh
- P208** A prospective observational study to evaluate the effect of social and personality factors on CPAP compliance in OSA
A Gulati, K Jordan, M Ali, R Chadwick, IE Smith
- P209** What might patients mean by “sleepiness”?
R Ghiassi, L O’Byrne, AR Cummin, MR Partridge

1.30pm – 3.10pm**Henry Moore Room, 4th Floor****POSTER DISCUSSION: P210 – P222****Developments in the delivery of lung cancer care**Chaired by: *Dr David Baldwin (Nottingham) and Dr Michael Peake (Leicester)*

- P210** The National Lung Cancer Audit – year 5 completeness and outcomes
P Beckett, I Woolhouse, R Stanley, MD Peake
- P211** Assessment of operability in early stage lung cancer: results from the national lung cancer audit
I Woolhouse, R Stanley, P Beckett, MD Peake

- P212** Screening for lung cancer: a qualitative study of the acceptability of screening and participation in the Lung-SEARCH trial
A Akporobaro, D Patel, N Chinyanganya, R Butawan, A Hackshaw, C Seale, S Spiro, C Griffiths
- P213** Long term results of concurrent chemotherapy and hypofractionated radiotherapy for inoperable NSCLC
J Maguire, V Kelly, C Smyth, M Ledson, M Walshaw
- P214** Pathological staging of malignant pleural mesothelioma – how important is nodal disease in selection for radical surgery?
A Nakas, K Lau, D Waller
- P215** The influence of age on management of lung cancer patients in England
P Beckett, I Woolhouse, MD Peake, R Stanley, RN Harrison
- P216** Lung cancer in young patients: a retrospective study
R Sarkar, G Jones, T Peacock, A de Ramón Casado
- P217** What’s happening to lung cancer in females?
A Ives, J Verne
- P218** Is there any value in obtaining a tissue diagnosis in suspected lung cancer patients with a performance status 3-4?
M Gautam, M Haris, S Huq, M Shaw, M Ledson, M Walshaw
- P219** Is there a role for conventional transbronchial needle aspiration in the endobronchial ultrasound era?
UH Oltmanns, P Perera, M Slade
- P220** High prevalence of malignancy in HIV infected patients with enlarged mediastinal lymphadenopathy
J Alçada, N Navani, M Taylor, P Shaw, RF Miller, SM Janes
- P221** Distal airway bacterial colonisation in patients with lung cancer
P Agarwal, DJ Newberry, J Waller, J Mullings, S Sundaram, PC Russell
- P222** A retrospective study of disease recurrence post thoracotomy for non-small cell lung cancer
J Naqvi, N Navani, S Saeed, M Shastry, A Groves, P Shaw, D Lawrence, S Kolvekar, M Hayward, S Janes

1.30pm – 3.15pm**St James’s Suite, 4th Floor****POSTER DISCUSSION: P223 – P236****Organisation of respiratory care**Chaired by: *Professor Martyn Partridge (London) and Professor Michael Roberts (London)*

Friday 3 December 2010

- P223** One blood gas is not enough to assess a patient for LTOT – how to kiss goodbye to circa £10 million in England
C Loutsios, G Logan, C Deeming, D Powrie, A Davison
- P224** Screening of coronary care inpatients with spirometry to detect early obstructive airways defects
W Alwan, N Stolagiewicz, N Raison, R Saha, P Murray
- P225** First National Survey of the Respiratory Physiotherapy Workforce
C Mikelsons, M Buxton
- P226** Prevalence and treatment of pain in hospital in-patients with respiratory disease
K Matthews, D Brunnen, Y Mahmood, EH Baker
- P227** Disparities in care of adult CF patients in the UK
M Salako, SJ MacNeill, E Gunn, M Baker, D Bilton, P Cullinan
- P228** Patient experience of a nurse led therapeutic pleural aspiration service
N Surange, JA Murray, SCO Taggart
- P229** Choose and Book: not a patient-centred service?
L O'Byrne, N Roberts, MR Partridge
- P230** Inappropriate referrals to the Rapid Access Lung Clinic (RALC)
S Huq, M Gautam, M Haris, A Ashish, M Ledson, M Walshaw
- P231** Audit of pre-hospital oxygen therapy by North West Ambulance Service (NWS) one year after publication of new JRCALC guidance for oxygen use
A Matthews, C Gavin, BR O'Driscoll
- P232** The early detection of chronic obstructive pulmonary disease
A Gupta, S Church, S Lacey
- P233** COPD and me: the development and implementation of an individual patient management plan and hand-held record
T Robinson, S Shires, C Fletcher, J Parrington, J Norell, S Mabbett
- P234** BLF and BTS "Ready for home" survey of the experiences of patients admitted to hospital with COPD. Pt2: – The discharge process
JE Scullion, SJ Singh, MDL Morgan
- P235** BLF and BTS "Ready for home" survey of patients admitted to hospital with COPD; the hospital experience
I Jarrold, N Eiser
- P236** Allergy services at a tertiary referral centre: a one year retrospective review of all referrals
NL Swindlehurst, AM Swindlehurst, S Kaul, C Corrigan

SCIENTIFIC PROGRAMME

1.30pm – 3.15pm

Mountbatten Room, 6th Floor

SYMPOSIUM

NON-CF BRONCHIECTASIS: THE KNOWN KNOWN, THE KNOWN UNKNOWN AND THE UNKNOWN UNKNOWN

Chaired by: Dr Diana Bilton (London) and Dr Anthony De Soyza (Newcastle upon Tyne)

1.30pm Recent insights into the microbiology of non-CF bronchiectasis

Dr Juliet Foweraker (Cambridge)

1.55pm Therapies for bronchiectasis: what works, what does not work and what will work in the future

Dr Alan Barker (Portland)

2.20pm The Bronchiectasis Guideline

Dr Mark Pasteur (Norwich)

2.45pm How can the immunologist help with the management of bronchiectasis?

Dr Elizabeth McDermott (Nottingham)

1.45pm – 3.30pm

Churchill Auditorium, Ground Floor

SYMPOSIUM

'LATE BREAKING NEWS' SYMPOSIUM – The best of BTS Audit

Chaired by: Professor Nick Black (National Clinical Audit Advisory Group)

1.45pm The National Scene

Professor Nick Black

2.00pm The BTS Audit Programme

Dr Christine Bucknall (Glasgow)

2.15pm The 2010 National Pleural Procedures Audit

Dr Nick Maskell (Bristol) and Dr Clare Hooper (Bristol)

2.30pm The 2009/10 Community Acquired Pneumonia in Adults Audit

Dr Wei Shen Lim (Nottingham)

2.45pm The 2009/10 Paediatric Asthma and Paediatric Pneumonia Audits

Dr James Paton (Glasgow)

3.00pm The 2010 Emergency Oxygen Audit

Dr Ronan O'Driscoll (Salford) and Professor Tony Davison (Southend)

3.15pm Discussion/conclusion

2.00pm – 3.45pm

Rutherford Room, 4th Floor

SPOKEN SESSION: S157 – S162

Occupational asthma

Chaired by: Dr David Fishwick (Sheffield) and Dr Jo Szram (London)

SCIENTIFIC PROGRAMME

- 2.05pm S157**
Prevalence of asthma related to employment in the UK
J Szram, SJ Schofield, SJ MacNeill, P Cullinan
- 2.20pm S158**
Occupational asthma; referral patterns from primary care in the UK
JL Hoyle, L Hussey, R Agius
- 2.35pm S159**
Do occupational asthmatics with small changes in PEF at work have less FEV1 decline than those with larger changes?
W Anees, VC Moore, PS Burge
- 2.50pm S160**
The effect of shift work on serial peak expiratory flow measurements used to diagnose occupational asthma
VC Moore, MS Jaakkola, CBSG Burge, CFA Pantin, AS Robertson, PS Burge
- 3.05pm S161**
Reducing exposure to allergens in bakeries
SJ Fraser, HJ Mason, A Thorpe, P Roberts, I Smith, G E Evans, J Morton, D Mark
- 3.20pm S162**
Job categories and risk of adult onset asthma in the 1958 birth cohort from age 16 to age 42 years
R Ghosh, P Cullinan, D Strachan, D Jarvis

2.00pm – 3.45pm

Elizabeth Windsor Room, 5th Floor

SPOKEN SESSION: S163 – S168

Survival in COPD

Chaired by: *Dr Charlotte Bolton (Nottingham) and Dr David Halpin (Exeter)*

- 2.05pm S163**
The 'Obesity Paradox' in chronic obstructive pulmonary disease
PF Collins, RJ Stratton, R Kurukulaaratchy, M Elia
- 2.20pm S164**
Diminished left ventricular end-diastolic dimensions predict an amplified risk of death in chronic obstructive pulmonary disease
M Mendonca, J Brown, M Rashid, HZ Ling, S Kang, A Cheng, E Boston-Griffiths, M Okorie, M Thomas, S Woldman, H Booth, DO Okonko
- 2.35pm S165**
Deprivation is an independent predictor of 1-year mortality in outpatients with chronic obstructive pulmonary disease
PF Collins, RJ Stratton, R Kurukulaaratchy, M Elia
- 2.50pm S166**
The role of clinical, metabolic and cardiac biomarkers in predicting outcome from COPD exacerbations requiring hospital admission: a prospective observational study

Friday 3 December 2010

- G Tack, V Osman-Hicks, A Hicks, Y Perry, RM Angus, PMA Calverley, B Chakrabarti*
- 3.05pm S167**
Expansion of the red cell distribution width and evolving iron deficiency as predictors of poor outcome in chronic obstructive pulmonary disease
M Rashid, J Brown, HZ Ling, M Mendonca, S Kang, R Sofat, M Okorie, M Thomas, S Woldman, H Booth, DO Okonko
- 3.20pm S168**
Evaluation of the MRC dyspnoea scale and a novel extended version in prediction of in-hospital death and early readmission in acute exacerbations of COPD
J Steer, E Norman, G Afolabi, GJ Gibson, SC Bourke
-
- 3.15pm – 4.40pm**
Abbey Room, 4th Floor
POSTER DISCUSSION: P237 – P247
Clinical challenges in diagnosing and managing respiratory infection
Chaired by: *Dr Wei Shen Lim (Nottingham) and Professor John Macfarlane (Nottingham)*
- P237** The utility of the Nottingham Health Profile in exacerbations of non-cystic fibrosis bronchiectasis
MP Murray, J Twiss, SP McKenna, AT Hill
- P238** Characteristics, treatment patterns and outcomes of patients with non-CF bronchiectasis: a single institution district general hospital (DGH) analysis
MJ McDonnell, C Mashamba, A Foden
- P239** Audit of once daily Nebulised Hypertonic 6% Saline (HTS) in adult non-CF bronchiectasis
H Pyne, B Kane, BR O'Driscoll
- P240** Longitudinal study of sputum microbiology in adult non-CF bronchiectasis
JG Macfarlane, P McAlinden, A De Soyza
- P241** Functional impairment in patients with bronchiectasis
NS Gale, JM Duckers, M Munnery, S Enright, DJ Shale
- P242** The treatment of *Pseudomonas Aeruginosa* (PA) in non-CF bronchiectasis
O Hewitt, L Mc Crossan, R Hanna, J Rendall, JM Bradley, JS Elborn
- P243** Duration and choice of antibiotics in hospital admitted community acquired pneumonia patients over a period of 5 years in NHS South East of Scotland
GC Choudhury, PM Mandal, AA Akram, AS Singanayagam, JC Chalmers, AH Hill

Friday 3 December 2010

- P244** Adherence with Department of Health guidelines for the management of pandemic H1N1 influenza in secondary care
MM Khan, RB Gore, SJ Fowler
- P245** Assessment of acute illness severity and radiological extent identify patients at heightened risk of developing major pneumonic progression in influenza A H1N1/2009 infection
J Choy, A Draper, E Ribbons, I Vlahos, S Grubnic, T Bicanic, P Riley, M Wansbrough-Jones, F Chua
- P246** Suspicion-prompted testing reveals missed opportunities for diagnosing new HIV cases amongst patients with community-acquired pneumonia
S Safavi, FJK Chua, P Reilly, GK Russell
- P247** High levels of iron in the soil are associated with an increased incidence of bovine tuberculosis in cattle
GV O'Donovan, HJ Milburn

3.30pm – 4.30pm

Mountbatten Room, 6th Floor

POSTER DISCUSSION: P248 – P254

Outcome determinants in acute lung injury

Chaired by: *Dr Craig Davidson (London) and Dr Nicholas Hart (London)*

- P248** Measuring physical recovery in the critical care population: development of the Chelsea Critical Care Physical Assessment tool (CPAx)
E J Corner, H Wood, C Englebretsen, S Boot, D Nikolettou
- P249** Physicians' opinion: ceilings of therapy in chronic obstructive pulmonary disease (pilot study)
JL Gallagher, B Morton, I Clegg, J Walker, L Davies
- P250** Incidence, clinical profile and outcomes of ventilator-associated pneumonia in a tertiary hospital
RM Panaligan, JP Guiang, MD
- P251** Flow cytometric detection of intracellular activation markers of pulmonary cells during acute lung injury
AC Waite, KP O'Dea, MR Wilson, M Takata
- P252** A physiological characterisation of injury, inflammation and resolution in murine aspiration pneumonitis
BV Patel, MR Wilson, M Takata
- P253** Pulmonary infiltrates in HIV negative immunocompromised patients: outcome and predictive factors
S Chandramouli, M Devine, H Shoo, N Duffy

SCIENTIFIC PROGRAMME

- P254** Investigating HMGB1 as a potential inflammatory mediator in brain death induced lung damage
AE Vallance, HR Walden, DM Karamanou, CR Fox, AJ Rostron, JA Kirby, AJ Simpson, JH Dark, AJ Fisher

3.00pm – 4.30pm

COFFEE/TEA will be served in the Benjamin Britten Lounge, 3rd floor

SPEAKERS' BIOGRAPHICAL DETAILS

Dr Alvar Agustí is Director of the Thorax Institute at Hospital Clinic in Barcelona and Scientific Director of the National Spanish Network for Respiratory Research (www.ciberes.org). His main research interest is COPD. He has a seat at the Royal Academy of Medicine of the Balearic Islands, is an Honorary Fellow of the Royal College of Physicians of Edinburgh (UK) and an Associate Editor of the *American Journal of Respiratory and Critical Care Medicine*.

Professor Jon Ayres is Professor of Environmental and Respiratory Medicine at the University of Birmingham. His research interests are the health effects of environmental exposures especially indoor/outdoor air pollution. He chairs the Department of Health's Committee on the Health Effects of Air Pollutants (COMEAP) and is a member of the Royal Commission on Environmental Pollution.

Dr Ian Balfour-Lynn is a Consultant at the Royal Brompton Hospital as well as the Chelsea and Westminster Hospital. He specialises in all aspects of paediatric respiratory medicine including both tertiary and secondary care. He is past President of the British Paediatric Respiratory Society. Dr Balfour-Lynn's current research interests are pulmonary hypertension in CF, health issues of air travel, and use of home oxygen. He co-chaired the committee who wrote the recent BTS guidelines on home oxygen in children.

Dr Chris Barber is a Consultant Respiratory Physician at the Royal Hallamshire Hospital in Sheffield, and Deputy Chief Medical Officer of the Centre for Workplace Health at the Health and Safety Laboratory in Buxton. He qualified in Medicine from Nottingham University in 1993 and proceeded to train in respiratory and general medicine in Trent and the North West. In addition, he spent two years as a research fellow at HSL dedicated to research into occupational lung disease. Dr Barber has specialist recognition in Respiratory and General Medicine from the GMC, and is an Associate of the Faculty of Occupational Medicine. He is also a member of GORDS, the government funded national group of experts in occupational lung disease, and sits on the advisory committee for SWORD, the national surveillance scheme for occupational lung disease. His main areas of clinical interest relate to the diagnosis and management of all types of occupational lung disease. Current research interests include the national/international approach to the diagnosis/management of occupational airway disease, and occupational lung disease relating to metal working fluid.

Dr Alan Barker has been a member of the faculty of Oregon Health and Science Center, Portland, Oregon since 1976. He serves as Medical Director of Respiratory Care and the Pulmonary Function Laboratory. He also maintains active inpatient and outpatient practices in Pulmonary Medicine. Dr Barker has been recognized as a regional and national expert on AAT deficiency and

has published numerous articles on the subject. He has been the Oregon Principal Investigator for an NIH Rare Lung Disorders network and is involved in studies of AAT deficiency and Lymphangiomyomatosis. He also maintains a longstanding interest in bronchiectasis, specializing in clinical trials involving reducing infection with aerosol antibiotics including tobramycin and more recently aztreonam.

Professor Peter Barnes is Head of Respiratory Medicine at Imperial College London. He has published over 1000 peer-review papers on asthma, COPD and related topics and has been the most highly cited respiratory researcher in the world over the last 20 years. He was elected a Fellow of the Royal Society in 2007.

Dr Paul Beckett is a Consultant Respiratory Physician in Burton-on-Trent. He went to medical school in Cambridge and did his specialist training in Southampton, including an MD in asthma pharmacology. He is one of the clinical leads for the National Lung Cancer Audit and is the current chair of the BTS Lung Cancer and Mesothelioma Specialist Advisory Group. His other interests include patient safety and the use of IT as a tool for service improvement in healthcare.

Dr Diana Bilton is a Consultant at the Royal Brompton Hospital and Honorary Senior Lecturer at Imperial College London. She specialises in cystic fibrosis and non-CF bronchiectasis. She has served on the Non-CF Bronchiectasis guidelines committee as well as the BTS Infection Specialist Advisory Group. She chairs the Medical Advisory Group of the CF Trust. Dr Bilton has research interests in new treatments of both CF and non-CF bronchiectasis.

Dr Stephen J Bourke is a Consultant Physician in Respiratory Medicine at the Royal Victoria Infirmary, Newcastle upon Tyne. He is Director of the Newcastle Adult Cystic Fibrosis Centre and has research interests in clinical aspects of cystic fibrosis.

Dr Malcolm Brodlie is an SpR in Respiratory Paediatrics at The Great North Children's Hospital in Newcastle. He was awarded a Joint MRC/CF Trust Clinical Research Training Fellowship to fund a PhD developing a primary airway epithelial cell culture model from CF lungs removed at transplantation. He is the trainee-representative on the CSAC for paediatric respiratory medicine and BPRS executive committee.

Professor Gordon Brown completed a PhD in microbiology at the University of Cape Town, South Africa. He was a Wellcome Trust travelling postdoctoral fellow at the University of Oxford, UK, then a Wellcome Trust Senior Fellow at the University of Cape Town, South Africa, and is now a Professor of Immunology at the University of Aberdeen. His primary research interests are macrophage receptors and their role in immunity and homeostasis.

SPEAKERS' BIOGRAPHICAL DETAILS

Dr Jeremy Brown is a clinician scientist and a Reader in Respiratory Infection in the Centre for Respiratory Research at UCL. His main research interest is the molecular pathogenesis of *Streptococcus pneumoniae* pneumonia, and his clinical interests are pneumonia, infections in the immunocompromised host and bronchiectasis.

Dr Kevin K Brown is a Professor and Vice Chairman in the Department of Medicine at National Jewish Health, Denver, USA. He has an active clinical practice as well as an NIH-funded translational research programme focused on the development, progression, and control of fibrosing lung diseases. His clinical research interests include the development and progression of lung disease in the connective tissue disorders.

Dr Mat Callister is a Consultant Physician at St James's University Hospital, Leeds. He was previously a Wellcome Clinical Research Fellow at the National Heart and Lung Institute, and is currently a member of the BTS Lung Cancer and Mesothelioma SAG. His research interest is in the early detection of lung cancer.

Professor Rachel Chambers heads a group of basic scientists and physician scientists at University College London (UCL). Her research interests are centred on the elucidation of the pathomechanisms leading to lung inflammation, remodelling and fibrosis; with a particular focus on the contribution of procoagulant signalling pathways. Professor Chambers is also Divisional Postgraduate Tutor (UCL Division of Medicine) and is an Editorial Board member of the American Journal of Respiratory Cell and Molecular Biology. Her research is funded by major peer-reviewed grants awarded from the MRC, the Wellcome Trust, the British Lung Foundation and the European Commission.

Professor Edwin Chilvers is Professor of Respiratory Medicine at the University of Cambridge and Honorary Consultant Physician at Addenbrooke's Hospital, CUHNHSFT and Papworth Hospital NHSFT. His research interests include understanding the molecular basis of neutrophil priming, activation and apoptosis, in particular, the role of the phosphoinositide 3-kinases and the use of radiolabelled autologous granulocytes to define neutrophil kinetics *in vivo*.

Dr Deborah Clarke is a Senior Scientist at MedImmune, a leading biologics company. She obtained her PhD in Respiratory Pharmacology from Imperial College, London in 2003 and since then has continued to focus on the inflammatory signalling pathways activated in asthma.

Dr Steven Conway is Clinical Director for Cystic Fibrosis Services at Leeds Teaching Hospitals NHS Trust caring for both children and adults. He trained at St George's Medical School, London. Dr Conway's interest in cystic fibrosis was first stimulated by a student placement on Dr John Batten's (ex-President of the

UK Cystic Fibrosis Trust) firm, and later as a Registrar in Leeds for Dr Jim Littlewood. He has lectured and presented his work extensively both at International meetings and European meetings with approximately 170 publications. He has been Deputy Chair of the UK CF Trust Medical Advisory Committee, Chair of the UK CF Trust Consensus Committee on Bone Disease, Deputy Chief Editor of the European Cystic Fibrosis Society Journal, and he acts on the Executive Board of the European Clinical Trials Network.

Professor Ulrich Costabel is Professor of Medicine and Chief of the Division of Pneumology and Allergology at the Ruhrlandklinik in Essen, Germany. He received his undergraduate training and his MD magna cum laude at the University of Freiburg. After graduating, he completed his residency and fellowship in internal and chest medicine in the Department of Professor Heinrich Matthys at the University Hospital in Freiburg. Professor Costabel's research interests lie in clinical and immunological studies in interstitial lung diseases, with a specific focus on clinical and research applications of bronchoalveolar lavage. In recent years, he was Principal Investigator of major clinical trials in IPF (N-acetylcysteine, etanercept, bosentan, interferon- γ , prifenidone). He is President of the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) and organised the World Congress on Sarcoidosis in Essen in 1997. He is also Chairman of the European BAL Group since 1998 and has co-organised several International Conferences on BAL. In 1992/1993 he spent a sabbatical of six months with Professor Takateru Izumi at the Chest Disease Research Institute of the University of Kyoto in Japan.

Professor Costabel has been actively involved with the European Respiratory Society (ERS) since its birth, having been Chair of the Occupational and Environmental Health Group and Secretary of the Assembly, and later Chair of the Bronchoalveolar Lavage Group. From 2002 to 2005 he was Head of the Clinical Assembly and member of the Executive Committee of the ERS, and in 2006 Chairman of the ERS Congress in Munich. Since 1990 he has served on the Editorial Board of the ERJ, first as an Associate Editor, then as an Assistant Chief Editor, and from 1994-1999 as the Chief Editor. He was Editor of the German journal *Pneumologie* from 2001 – 2005, has co-edited the European Respiratory Monograph "Sarcoidosis", and is currently on the board of Sarcoidosis, Seminars in Respiratory and Critical Care Medicine, and Current Opinion in Pulmonary Medicine, among others. He is the recipient of several honours and awards, including the Sarcoidosis Research Prize presented by the German Sarcoidosis Association. He is also the author of numerous scientific papers (275 PubMed listed publications) and chapters, and has edited several books.

Dr Paras Dalal is a Consultant Cardio-Thoracic Radiologist at the Royal Brompton and Harefield Foundation Trust and an Honorary Senior Lecturer at

SPEAKERS' BIOGRAPHICAL DETAILS

Imperial College. He is particularly interested in lung cancer imaging and in percutaneous ablations therapies for lung tumours, and is currently involved in various studies involving radiofrequency ablation, microwave ablation and cryotherapy.

Dr Jane Davies is a Reader and Honorary Consultant in Paediatric Respiratory Medicine and Gene Therapy at Imperial College London and the Royal Brompton Hospital. The focus of her research is cystic fibrosis, in particular the design and implementation of the clinical programme for the UK CF Gene Therapy Consortium. She is also PI for clinical trials of novel pharmacological approaches to CFTR correction and collaborates on research into the pathogenesis of CF and other chronic suppurative lung diseases.

Professor Peter Davies qualified at Oxford and St Thomas's Hospital in 1973. He was appointed a Consultant Respiratory Physician to Aintree Hospital and the Liverpool Heart and Chest Hospital, in 1988. He is author of over 100 peer reviewed papers and is editor of *Clinical Tuberculosis*, now in its fourth edition. In 2004 he was appointed Honorary Professor to Liverpool University.

Professor Dame Sally C Davies is the Director General (DG) of Research and Development and Chief Scientific Adviser for the Department of Health and NHS. Since May 1st Dame Sally has also been CMO (Interim). She has been actively involved in NHS R&D from its establishment and as DG she established the National Institute for Health Research (NIHR) with a budget of £1 billion. In the CMO role she is advising on the development of the Government's new Public Health Service.

Dame Sally led the UK delegations to the WHO Ministerial Summit in November 2004 and the WHO Forum on Health Research in November 2008. She spoke on R&D at the World Health Assembly May 2005 and is a member of the WHO Global Advisory Committee on Health Research (ACHR). She also chaired the Expert Advisory Committee for the development of the WHO research strategy, endorsed by the World Health Assembly in May 2010. She is a member of the International Advisory Committee for A*STAR, Singapore and the Caribbean Health Research Council Board and advises many others on research strategy and evaluation including the Australian NHMRC. Her own research interests focus on Sickle Cell disease.

Professor Marc Decramer is Professor of Respiratory Medicine and Chief of the Respiratory Division at the Katholieke Universiteit Leuven, Belgium. In the past, he has been Chairman of the Scientific Committee of the European Respiratory Society (ERS) and Chief Editor of the *European Respiratory Journal*. He is currently President of the ERS.

Professor Christopher Denton is Professor of Experimental Rheumatology at University College and

Consultant Rheumatologist at Royal Free Hospital, London. He leads a large multidisciplinary clinical scleroderma service at the Royal Free Hospital, managing more than 1200 patients. Professor Denton's laboratory research has focused on mediators of vasculopathy and fibrosis in connective tissue disease and preclinical models.

Dr Anthony De Soyza is a HEFCE Clinical Senior Lecturer working at Newcastle University and The Freeman Hospital where he runs a busy bronchiectasis service in addition to a COPD service. His research interests are non culture based diagnostics in CF and non CF bronchiectasis, the systemic aspects of both COPD and bronchiectasis as well as the interaction between pathogens and host immunity. He is also interested in network building in bronchiectasis and has set up a regional network of interested professionals (BRING). He leads the William Leech Centre for Respiratory Clinical Trials and has had great satisfaction in being a lead UK recruiter to bronchiectasis trials.

Professor Ken Donaldson is the Scientific Director of the ELEGI Colt Laboratory in the Queens Medical Research Institute, University of Edinburgh, where he is Professor of Respiratory Toxicology. He has published over 300 scientific papers on lung injury caused by inhaled particles and fibres and over 100 on nanoparticles.

Sir Neil Douglas is Professor of Respiratory and Sleep Medicine at the University of Edinburgh and an Honorary Consultant Physician at the Royal Infirmary of Edinburgh. He has published over 200 original papers, two books and 300 chapters and reviews on sleep and breathing, including the chapter on Sleep Apnoea in Harrison's textbook. He is an international authority on the causation, consequences and treatment of sleep apnoea. Previous roles included President of the British Sleep Society and Secretary of the British Thoracic Society. He was President of the Royal College of Physicians of Edinburgh from 2004–2010, the longest serving President of that College for 250 years, when his major focus was on training. In 2007, he chaired a Review Group to manage the crisis in the Medical Training Application System (MTAS) at the request of the Secretary of State for Health in England, Patricia Hewitt. Sir Neil is currently Chairman of the UK Academy of Medical Royal Colleges.

Dr Jeffrey M Drazen was born and raised in St Louis and majored in physics at Tufts University and graduated from Harvard Medical School in 1972. After serving his medical internship at Peter Bent Brigham Hospital in Boston, he joined the Pulmonary Divisions of the Harvard Hospitals. He served as Chief of Pulmonary Medicine at the Beth Israel Hospital, Chief of the combined Pulmonary Divisions of the Beth Israel and Brigham and Women's Hospitals, and then as Chief of Pulmonary Medicine at Brigham and Women's Hospital. Through his research, Dr Drazen defined the role of

SPEAKERS' BIOGRAPHICAL DETAILS

novel endogenous chemical agents in asthma, leading to four new licensed pharmaceuticals for asthma with millions of people on treatment worldwide. In 2000, he assumed the post of editor-in-chief of the *New England Journal of Medicine*. During his tenure, the Journal has published major papers advancing the science of medicine, including the first descriptions of SARS and modifications in the treatment of cancer, heart disease and lung disease, and it has been at the forefront of the worldwide effort to register all clinical trials. The Journal, which has over a million readers every week, has the highest impact factor of any journal publishing original research.

Dr Mark Elliott is Consultant Physician in Respiratory and General Medicine at St James's University Hospital, Leeds. He qualified from the University of Cambridge and Royal London Hospital in 1982. Dr Elliott trained in London and in 1993 was appointed as Consultant Physician at St James's University Hospital, Leeds. He has been responsible for developing the home sleep and assisted ventilation service, for acute in hospital NIV and weaning of patients with prolonged ventilator dependence. He has research interests in acute and chronic non invasive ventilation and sleep related abnormalities of breathing.

Professor David R Ferry is a medical oncologist based at New Cross Hospital, Wolverhampton. He is the BTOG-2 Chief Investigator and enters around 50 patients per year into lung cancer clinical trials. He has taken part in lung cancer trials testing targeted therapies including, sorafenib, ZD6467, aflibercept, cetuximab, R1507, pemetrexed gefitinib and the PARP inhibitor BSI 201.

Professor Andrew Fisher graduated from Nottingham University in 1993. He received research training as an MRC training fellow in Newcastle and Edinburgh from 1996–99 and graduated PhD in Lung Transplantation in 2001 from Newcastle University. He completed specialist training in Respiratory Medicine in the Northern Deanery in 2003 and was subsequently awarded a GlaxoSmithKline Senior Clinical Fellowship in 2004. His current post is Professor of Respiratory Transplant Medicine in the Institute of Cellular Medicine at Newcastle University and Honorary Consultant Respiratory and Transplant Physician at Freeman Hospital, Newcastle upon Tyne. He has recently taken on the role of Academic Director of the Institute of Transplantation in Newcastle, the first dedicated multi-organ transplant facility in the UK.

Dr David Fishwick is a Reader in Respiratory Medicine at the University of Sheffield, Co-Director of the Centre for Workplace Health, an Honorary Consultant Respiratory Physician at Sheffield Teaching Hospitals NHS Foundation Trust and the Chief Medical Officer at the Health and Safety Laboratory. He has an active clinical and research interest in all aspects of occupational lung disease.

Dr R Andres Floto is a Wellcome Trust Senior Fellow based in the Cambridge Institute for Medical Research,

University of Cambridge where his research focuses on understanding the regulation of antigen processing by macrophages and dendritic cells during infection (particularly with mycobacteria) and how it can be manipulated therapeutically. As an Honorary Consultant at Papworth Hospital, Cambridge, his clinical interests centre on cystic fibrosis (CF), non-CF bronchiectasis and non-tuberculous mycobacterial infections.

Dr Juliet Foweraker is a Consultant Microbiologist at Papworth Hospital, Cambridgeshire, UK. Her interests are in the microbiology of non-CF and CF bronchiectasis, lung transplant infections, and treatment and prevention of endocarditis. She is a member of two UK Cystic Fibrosis Trust working groups, for antibiotics and for microbiology laboratory standards.

Professor Nick Gay worked with Professor John Walker (Nobel Prize for Chemistry 1997) on the F1Fo ATPase for his PhD and then spent a postdoctoral period at the University of California San Francisco with Tom Kornberg. Since returning to the UK in 1987, the lab has worked on Toll signalling initially as a developmental system in *Drosophila* and more recently as key regulators of innate immunity. Professor Gay is currently Professor of Molecular and Cellular Biochemistry at the University of Cambridge and Tutor for Advanced Students at Christ's College, Cambridge.

Dr Paul Gill is a Consultant Liaison Psychiatrist working in Sheffield. He is Chair of the Faculty of Liaison Psychiatry at the Royal College of Psychiatrists and also Chairs the Accreditation Advisory Committee of the Psychiatric Accreditation Network (PLAN). He has extensive experience of working with patients with difficult asthma and optimising their clinical management.

Professor David Goldblatt is Professor of Vaccinology and Immunology and Head of the Immunobiology Unit at the Institute of Child Health, University College London as well as a Consultant Paediatric Immunologist at the Great Ormond Street Hospital for Children NHS Trust. He is the Director of Clinical Research and Development for the joint Institution where he is also Director of the National Institute for Health Research (NIHR) Specialist Biomedical Research Centre. He was recently appointed as Programme Director of the Child Health theme for the UCL Partners Academic Health Science Centre. He obtained his medical degree from the University of Cape Town, South Africa, his Paediatric qualifications from the Royal College of Physicians (London) and a PhD in Immunology from the University of London, United Kingdom.

Professor Goldblatt has a long-standing interest in the immune response to vaccines and infectious diseases in childhood and has an active research programme studying bacterial conjugate vaccines, the kinetics of immunological memory and immunity and infections in early life. He is involved in clinical trials and basic science research projects in the United Kingdom, Africa and SE

SPEAKERS' BIOGRAPHICAL DETAILS

Asia and collaborates with colleagues in Europe and the USA. He is a regular advisor to the World Health Organisation (WHO) on bacterial conjugate vaccines and is Director of the WHO Reference Laboratory for Pneumococcal Serology based at the UCL Institute of Child Health in London. He served as a member of the United Kingdom Department of Health Joint Committee on Vaccines and Immunisation for 10 years (1997–2007) and the MRC Infection and Immunity Panel, and is currently co-chair of the Wellcome Trust Immunology and Infectious Disease Funding Committee.

Dr Richard Harrison is Consultant Respiratory Physician in Lung Health at the University Hospital of North Tees. He trained in Liverpool and Southampton and was appointed as a consultant in 1984. He is a member of the BTS Lung Cancer and Mesothelioma SAG. Dr Harrison currently provides the EBUS service for the Northern Region and his special interests include medical thoracoscopy and the use of indwelling pleural catheters in malignant effusions.

Dr Nicholas Hart is a Clinical Research Consultant in Respiratory and Critical Care Medicine within Guy's and St Thomas' NHS Foundation Trust and Kings College London Comprehensive Biomedical Research Centre. In addition to providing clinical support for critical care, he provides support to the Lane Fox Respiratory Unit, which is the regional weaning and non-invasive ventilation unit specialising in providing long-term support for patients with neuromuscular, skeletal deformities, chronic obstructive airways disease and obesity-related respiratory failure. He is a co-author of over 30 peer-reviewed original articles. His research is focused on advanced physiological monitoring, ventilation and rehabilitation with his current projects assessing and monitoring respiratory muscle activity in acutely breathless patients, investigating different ventilatory strategies for patients with obesity-related respiratory failure, neuromuscular disease and COPD, and rehabilitation for patients during weaning, following critical illness and post lung cancer resection.

Dr Matthew Hatton is a Consultant Clinical Oncologist at Weston Park Hospital and Honorary Senior Lecturer at the University of Sheffield. His practice involves the non-surgical treatment of lung and breast cancer. He is a member of the NCRI Lung Cancer Study Group (chairing their LORD subgroup), CTAAC, Clinical and Translational Radiotherapy research group and chairs the UK Consortium for Stereotactic Radiotherapy in early lung cancer. His research interests include functional imaging for lung cancer radiotherapy and he is the principle investigator for a number of CHART based studies.

Dr Liam Heaney is based at Belfast City Hospital and runs a multi-disciplinary Regional Difficult Asthma Service. He chairs the Difficult Asthma Evidence Review Group for the BTS/SIGN Asthma Guidelines and sits on the National Steering Committee and BTS Asthma

SAG. He leads the BTS UK Difficult Asthma Registry and research interests include clinical difficult asthma assessment, mechanisms behind refractory asthma and viral/epithelial interactions in asthma.

Professor Tim Higenbottam's academic and clinical career was in Cambridge (1980–1995) and Sheffield (1995–2001). In Cambridge during the 1980s he worked on lung transplant surgery, and in Cambridge and Sheffield, study of the role of endothelial nitric oxide production in PAH was undertaken. In 2001 he moved to Respiratory and Inflammation R&D at AstraZeneca. His work centred on target identification for new therapies in COPD and the development of proof of concept study design for COPD therapies. Following a successful pharmacovigilance study of Iressa in Japan, Professor Higenbottam became a Senior Principle Scientist in AstraZeneca. In 2008 he joined Chiesi as Director of Corporate Clinical Development in Italy and is responsible for the clinical development of therapies for COPD, asthma and the special care disease of cystic fibrosis and neonatal RDS. This includes the highly successful new combination therapy Foster®.

Professor Higenbottam is a co-board member of the Severe Asthma UBIOPRED IMI project, a private public partnership to enhance therapy development in the EU. This is to stimulate academic industry interaction to enhance new therapy development. He is the Chairman of the Professional Standards Committee for the Faculty of Pharmaceutical Medicine, Royal College of Physicians and provides oversight of the CCT training for Pharmaceutical Medicine in the UK. He remains a visiting Professor of Medicine in the University of Sheffield, School of Medicine.

Dr Bernard Higgins is a Consultant Respiratory Physician in Newcastle, having previously trained in Manchester, Edinburgh and Nottingham. He has a particular interest in asthma, and is currently Chair of the BTS Specialist Advisory Group for Asthma and co-Chair of the British Asthma Guideline Steering Group.

Dr Adam Hill is a Consultant Chest Physician and Honorary Senior Lecturer at the Royal Infirmary and University of Edinburgh. He is the Respiratory Infection Lead and has a special interest in bronchiectasis, community acquired pneumonia and tuberculosis. He is involved in clinical and translational research and was on the committees for the BTS Bronchiectasis and Community Acquired Pneumonia Guidelines.

Professor Stephen Holgate is MRC Professor of Immunopharmacology at the School of Medicine in Southampton with research interests in the mechanisms and treatment of asthma. He is Chair of the MRC Population and Systems Medicine Board and Chair of the UK Respiratory Research Collaborative. In 2010 he was appointed as Chair Designate of REF Main Panel A (Medicine, Health and Life Sciences).

SPEAKERS' BIOGRAPHICAL DETAILS

Dr David Honeybourne is a Consultant Physician at Birmingham Heartlands Hospital. He is also Honorary Clinical Reader in Biological Sciences and Respiratory Medicine at the University of Warwick and Honorary Senior Clinical Lecturer in Medicine at the University of Birmingham. He is the Director of the West Midlands Adult Cystic Fibrosis Centre at Heartlands Hospital Birmingham. This centre has over 335 CF patients and moved into a purpose built unit in 2002. His main research interest is respiratory infection. He is an examiner for the Universities of Birmingham, Warwick and London. He is an editor of the Journal of Antimicrobial Chemotherapy and is the author of 130 papers, 75 abstracts and co-author of several books.

Professor Richard Hubbard is the GSK/BLF Professor of Respiratory Epidemiology at the University of Nottingham, based at Nottingham City Hospital. His research interests include the epidemiology of interstitial lung disease and asthma, drug safety, co-morbidity of respiratory disease, access to services and outcomes for people with lung cancer. He has clinical interests in interstitial lung disease and lung complications of bone marrow transplantation.

Dr Philip Ind is a Respiratory and General Physician at Hammersmith Hospital who trained initially in Clinical Pharmacology. He was appointed Consultant Physician in 1986 and Clinical Head of Department in 1996. His main research interest is in airway disease. He is a member of the BTS Specialist Advisory Group for Asthma and a Member of the Cardiovascular, Respiratory & Allergy Expert Group to MHRA.

Dr Sam Janes trained in respiratory medicine in North West Thames region and completed an MSc in Respiratory Medicine in 1999. He performed an MRC Training Fellowship and post-doctoral period working in the CRUK Lincoln's Inn Fields Institute with Fiona Watt working on integrin adhesion molecules and cancer cell survival. He then moved as an MRC Clinician Scientist to UCL leading a group interested in the role of stem cells in lung disease pathogenesis including cancer formation and treatment of lung disease using cell therapies in the Centre for Respiratory Research. He was awarded a Wellcome Senior Clinical Fellowship in June 2010 to work on therapies for lung cancers. He works as a Consultant for the NHS in Respiratory and General Medicine with a particular interest in lung cancer, mesothelioma, bronchoscopy and early lung cancer detection.

Dr Rupert Jones is a GP and Honorary Clinical Lecturer at the Peninsula Medical School, Plymouth. He is a GP with special interest in Plymouth PCT running oxygen and pulmonary rehabilitation services. His research interests include diagnosis of COPD, psychological factors in COPD, pulmonary rehabilitation, patient education and self-management.

Dr David Kiely is a Consultant Physician in Respiratory and General Medicine at Sheffield Teaching Hospitals.

He has a sub-speciality interest in pulmonary vascular disease and leads a nationally designated Pulmonary Hypertension Centre. He graduated from the University of Edinburgh and completed a period of post-graduate research investigating the cardiopulmonary interactions of hypoxia and hypercapnia and the role of vasoactive mediators in the pulmonary circulation. He completed his post-graduate training in Cambridge before moving to Sheffield in 2001.

Professor Bart N Lambrecht obtained his MD/PhD degree at the University of Ghent, Belgium in 1993 and 1999. After obtaining the MD/PhD degree under the mentorship of Professor Romain Pauwels, he moved to The Netherlands where he trained in Pulmonary Medicine. He became Professor of Pulmonary Medicine in 2005, holding a special chair in Immunopathology of the Lung at the pulmonary research programme of Erasmus University, Rotterdam, The Netherlands. After ten years in The Netherlands, he moved back to Belgium and was appointed Professor of Pulmonary Medicine at Ghent University, and is currently heading a group of 24 scientists dealing with the immunopathology of asthma and immunotherapy of cancer.

He is the author of over 100 papers dealing with the use of mouse models to study the pathogenesis of asthma and cancer related immunosuppression. In the last few years, he has received several awards, including the Odysseus Grant of the Flemish government, The Inbev-Baillet Latour Prize for Clinical Research, The Sabin Prize for Vaccine research, The Pharmacia Allergy Research Foundation Award 2004, The NWO Vidi Scholarship, The Schering Plough Respiratory 2000 Award, and the 1998 European Respiratory Society Annual Allergy and Immunology award. Among academic activities, he is a Young Academy member of the Royal Dutch Academy of Arts and Sciences (KNAW), advisory editor of The Journal of Experimental Medicine and associate editor of Mucosal Immunology. The interest of his research group is on the role of antigen presenting dendritic cells in the initiation of the pulmonary immune response that ultimately leads to sensitization to antigens, applied to allergic disease, respiratory viruses and cancer immunotherapy.

Dr Allan Lawrie is an MRC Career Development Award Fellow and head of the Pulmonary Vascular Research Group in the Department of Cardiovascular Sciences at the University of Sheffield. After completion of his PhD at the University of Sheffield he undertook a Post-doctoral Fellowship under the mentorship of Professor Marlene Rabinovitch at Stanford University. He returned to Sheffield at the end of 2004 to continue his studies into the pathogenesis of pulmonary hypertension.

Dr Wei Shen Lim is a Consultant Respiratory Physician at Nottingham University Hospitals, City Hospital Campus. His research interest is in respiratory infections. He is currently Chairman of the BTS Infection SAG and was Chairman of the BTS Community Acquired

SPEAKERS' BIOGRAPHICAL DETAILS

Pneumonia Guidelines Committee and joint BTS/BIS/HPA/DoH Pandemic Influenza Clinical Management Guidelines Committee.

Dr Marc Lipman is a HEFCE–NHS Clinical Senior Lecturer and Consultant in Respiratory and HIV Medicine at the Royal Free Hospital, London. He is Chair of the BTS TB Specialist Advisory Group, advisor to the Department of Health, a member of the Health Protection Agency TB Programme Board and the National MDRTB advisory service. His research interests focus on tuberculosis, respiratory infection and HIV.

Professor David Lomas was elected to the Professorship of Respiratory Biology at the University of Cambridge in 1998. He is an Honorary Consultant Respiratory Physician at Addenbrooke's and Papworth Hospitals and has a particular interest in α 1-antitrypsin deficiency, the serpinopathies and COPD.

Dr Toby Maher is a Consultant Respiratory Physician on the Interstitial Lung Disease Unit at the Royal Brompton Hospital. Prior to this, he was a Wellcome Trust Clinical Research Fellow at the Centre for Respiratory Research, UCL. His research interests include; biomarker discovery, clinical trials in fibrosing lung disease and studying the role of prostanoids and apoptosis in the pathogenesis of IPF.

Dr William Man is Consultant Chest Physician and National Institute for Health Research Clinician Scientist at the Royal Brompton and Harefield NHS Foundation Trust. His research interests include pulmonary rehabilitation and skeletal muscle dysfunction in COPD.

Dr Richard Marshall trained in respiratory and critical care medicine at UCL, with PhD and post-graduate training as a Wellcome Fellow. At GSK, he has lead research groups in translational medicine, clinical development and target biology. Currently, he is Head of the Fibrosis Discovery Performance Unit, responsible for R&D in the fibrosis area and also Head of External Discovery in Respiratory R&D responsible for collaborative partnerships and business development across biotech and academia. Externally, Dr Marshall has represented GSK on a number of public-private partnership initiatives.

Professor Michael A Matthay is a Professor of Medicine and Anesthesia at the University of California at San Francisco and a Senior Associate at the Cardiovascular Research Institute. He is Director of Critical Care Medicine Training in the Department of Medicine and Associate Director of the Intensive Care Unit. He received his AB from Harvard University in 1969 and his MD from the University of Pennsylvania School of Medicine in 1973. Dr Matthay received clinical training in Internal Medicine at the University of Colorado from 1973–76 and in pulmonary and critical care medicine from the University of California at San Francisco from 1977–78. He also received research

training from the Cardiovascular Physiology Laboratory, University of Colorado in 1976 and the Cardiovascular Research Institute from 1978–79.

Dr Matthay's basic research is focused on active ion and water transport mechanisms that account for the resolution of pulmonary oedema as well as mechanisms that account for alveolar epithelial repair after acute lung injury. The studies are carried out in several in vivo and in vitro models. Dr Matthay's clinical research is focused on the mechanisms that account for the pathogenesis and resolution of clinical acute lung injury and pulmonary oedema. More recently his research group has focused on mesenchymal stem cells and acute lung injury.

Dr Andrew Maynard is Director of the University of Michigan Risk Science Centre. A leading authority on the safe development and use of emerging technologies, he has testified before the US Congress, is a member of the World Economic Forum Global Agenda Council on the Challenges of Emerging Technologies, and serves on numerous review and advisory panels. An author of over one hundred scientific papers, reports and articles, Dr Maynard appears frequently in print and on television and radio, and writes regularly on science and society at <http://2020science.org>. He is a graduate of the University of Birmingham, and has a PhD in physics from the University of Cambridge.

Professor Bob Maynard leads the Air Pollution and Noise Unit of the Health Protection Agency. He is a medical physiologist and toxicologist and led the Department of Health's work on air pollution from 1990 to 2006. Prior to that, he led the Medical Division at the Chemical Defence Establishment at Porton Down. He has edited monographs on air pollutants, chemical warfare agents and the scientific foundations of trauma. He edited the World Health Organisation's Air Quality Guidelines for Europe in 1998. He was a co-organiser of a Royal Society meeting on nano-particles in 2005 and leads for the Health Protection Agency in this area. He holds an Honorary Chair in Public Health at Birmingham University and was awarded a CBE for his work on air pollution in 2000.

Dr Liz McDermott is a Consultant Immunologist in Nottingham with an interest in primary immune deficiency and autoinflammatory disease. She currently works closely with the local respiratory team to provide a combined immune deficiency/respiratory service. She is part of the respiratory/immune deficiency team within the National Ataxia Telangiectasia (AT) Clinic. Research interests include primary immune deficiency, AT and TRAPS (TNF Receptor Associated Periodic Syndrome).

Professor Ann Millar is Professor of Respiratory Medicine at the University of Bristol, having trained in London and Liverpool. She has clinical interests in diffuse parenchymal lung disease, acute lung injury and the immunocompromised lung. Professor Millar's research interests are in the mechanism regulating the outcome of acute and chronic lung injury.

SPEAKERS' BIOGRAPHICAL DETAILS

Professor Mike Morgan is a Consultant Respiratory Physician at the Department of Respiratory Medicine, Allergy and Thoracic Surgery at the University Hospitals of Leicester NHS Trust at Glenfield Hospital and Honorary Professor at the University of Leicester. He has previously worked at Birmingham Heartlands and the Brompton Hospitals. His career interests have included the assessment and management of respiratory disability particularly in COPD. He has published widely and was an author of the BTS and ERS/ATS statements on pulmonary rehabilitation. He is also a Council member and Vice President of the British Lung Foundation, the editor of Chronic Respiratory Disease and previously, Chairman of the Asthma UK Research Committee. He has been a member of the external reference group for the NICE COPD guidelines and the COPD NS. He is Chairman of the Executive of the British Thoracic Society.

Professor Mary J Morrell is Professor of Sleep and Respiratory Physiology, Imperial College London, Royal Brompton Hospital. Her research is focused on sleep related breathing disorders, and is supported by the Wellcome Trust, British Heart Foundation, and National Institute of Health Research.

Professor Nick Morrell is the British Heart Foundation Professor of Cardiopulmonary Medicine at the University of Cambridge School of Clinical Medicine, Addenbrooke's and Papworth Hospitals. His major research interest is in the molecular basis of pulmonary arterial hypertension and the translation of these studies into novel therapies. He is the Research Director of the Pulmonary Vascular Diseases Unit at Papworth Hospital.

Dr Ed Neville has been a Consultant Chest Physician in Portsmouth since 1983. He was Chairman of the Executive Committee of the British Thoracic Society from 2002 to 2005, having previously been BTS Secretary, and has sat on most other BTS committees. He is a former Director of Training (Linacre Fellow) at the Royal College of Physicians. His respiratory publications have mostly been in asbestos related pleural disease and sarcoidosis. He had major involvement in the original asthma guidelines and currently the pleural disease guidelines. His interest in medical education includes the development of curricula and assessment methodology. He is President-elect of the BTS.

Dr Rob Niven is a Senior Lecturer and Consultant Respiratory Physician at the University of Manchester and University Hospital of South Manchester. As a clinician he runs a supra-regional service for severe asthma. He has assessed over 600 severe asthma patients, with around 50% of these referrals being for patients on maintenance oral steroids. He is a core member of the UK National Severe Asthma Network, with over 650 patients entered onto a national database, with Manchester being the leading site.

As a researcher he has published over 70 peer reviewed papers and authored 5 book chapters. Areas of interest

have included occupational lung disease, environmental epidemiology and more recently clinical practice in severe asthma. He has innovated research into clinical practice in the fields of hypertonic saline for bronchiectasis as a therapy, awareness and diagnosis of dysfunctional breathing patterns, the role of antifungal therapy in severe asthma with fungal sensitisation and has been a chief investigator in the UK in the Bronchial thermoplasty trials.

In addition Dr Niven is a keen educator and leads the final year exams for the south Manchester site as well as being active in all aspects of education at undergraduate level.

Dr Paul W Noble is the Charles Johnson MD Professor of Medicine at Duke University Medical Centre and Chief of the Division of Pulmonary, Allergy and Critical Care Medicine. Dr Noble has a long-standing interest in the mechanisms that control lung inflammation and fibrosis in the absence of infection. His laboratory has focused on the role of the extracellular matrix glycosaminoglycan hyaluronan and its cognate receptors in lung injury, inflammation and repair.

Dr Ronan O'Driscoll is a Consultant Respiratory Physician in Salford. His research interests include asthma, COPD, bronchoscopy and oxygen therapy. He was the lead author of the European Respiratory Society Nebulizer Guideline in 2001 and the BTS Guideline for Emergency Oxygen Use in Adults in 2008.

Professor Luke O'Neill currently holds the Chair of Biochemistry at Trinity College Dublin. He obtained his PhD in Pharmacology from the University of London in 1988. He was a Medical Research Council Post-doctoral fellow at the Strangeways Research Laboratory, Cambridge until 1991, when he returned to Trinity College Dublin where he was appointed Lecturer in Biochemistry. He became a fellow at Trinity in 1996. In 2002 he was appointed Science Foundation Ireland Research Professor. He has won numerous awards for his research, notably the Royal Irish Academy Medal for Biochemistry, The Irish Society for Immunology Medal, the Royal Dublin Society/Irish Times Boyle Medal for Scientific Excellence and the Science Foundation Ireland Researcher of the Year Award 2009. He was elected a member of EMBO in 2005. He is a co-founder and director of Opsona Therapeutics. In 2008 he was appointed Chair of the Immunity and Infection panel of the European Research Council. His research is in the area of the molecular basis to inflammatory diseases, with a particular interest in pro-inflammatory cytokines and Toll-like receptors. Professor O'Neill has published over 180 papers and reviews on his research, in journals such as Nature, Science, Cell, Nature Immunology, Nature Medicine, Nature Genetics and PNAS. His contribution to the field of immunology in Ireland and internationally can be seen from the recent ranking of Ireland as third in the world in terms of citations per paper (1999–2009), where seven of his publications were ranking in the top nine from Ireland since 2006. He is on the editorial boards of six journals, including

SPEAKERS' BIOGRAPHICAL DETAILS

the Journal of Biological Chemistry and the Journal of Immunology.

Professor Martyn R Partridge is Professor of Respiratory Medicine at Imperial College London, UK, NHLI Division based at Charing Cross Hospital, and Honorary Consultant Respiratory Physician to Imperial Hospitals NHS Trust. His research interests are in the delivery of effective respiratory healthcare, with especial interest in evaluating novel methods of delivering care and patient centred approaches. Professor Partridge was (Honorary) Chief Medical Advisor to Asthma UK for 20 years and Chairman of the Trustees of the National Respiratory Training Centre (NRTC) (now part of Education for Health) from 1993 to 2008. From 1991 to 2003 he was a member of the executive committee of the Global Initiative for Asthma (GINA) and from 1992 to 2002, on the medical aerosols subcommittee of the United Nations Environment programme overseeing phase out of CFCs in inhalers. He has chaired a number of WHO initiatives. Professor Partridge was a member of the British Asthma Guidelines group from 1989 to 2008. He completed three years as Chairman of the British Thoracic Society in 2003 and was elected Vice President and then President of the Society in 2007–9. Professor Partridge is head of the Undergraduate Final Year for the Faculty of Medicine at Imperial College and was Lead Clinical Director of the North West London Comprehensive Local Research Network from 2008 to 2010. In 2009 he was appointed to Chair the UK Department of Health's Asthma Steering Group and Children's Asthma Sub Group and he serves on the Department of Health Respiratory Programme Board.

Dr Mark Pasteur is a Consultant Respiratory Physician in Norwich and has been a member of the BTS Standards of Care Committee and chaired the BTS guideline on non-CF bronchiectasis steering group.

Professor Ian D Pavord has been a Consultant Physician since 1995 and Honorary Professor of Medicine since 2005 at the Institute for Lung Health, Glenfield Hospital, Leicester, UK. He trained at University College London and Westminster Hospital, graduating in 1984. As a postgraduate he has worked in respiratory medicine at all grades and was a Lecturer in Respiratory Medicine at Nottingham University and a Visiting Fellow at the Firestone Regional Chest and Allergy Unit, McMaster University, Canada. His research interests include the non-invasive assessment of airway inflammation in asthma, cough, and chronic obstructive pulmonary disease.

Professor Pavord is Editor of *Thorax*, Chief Medical Officer of Asthma UK and a former Associate Editor of the *American Journal of Respiratory and Critical Care Medicine*. He is the author of more than 200 publications including four in the *New England Journal of Medicine* and eight in the *Lancet*. He gave the Cournand Lecture at the 2004 European Respiratory Society meeting, the

second UK based researcher to have been given this honour. He is married to a Consultant Haematologist and has three children and is a keen golfer with a handicap of four.

Professor Andrew Peacock is the Director of the Scottish Pulmonary Vascular Unit, which looks after all the patients with pulmonary hypertension in Scotland (population 5 million). He is also Professor in Medicine at the University of Glasgow (Respiratory Medicine). Professor Peacock trained at St Bartholomew's Hospital Medical College, London, Caius College Cambridge, Brompton Hospital, London, UK and at the University of Colorado Health Sciences Centre, CO, USA, where he studied the effect of high altitude on the pulmonary circulation of chickens! Hypoxia remains the main theme of his research because it combines the science of the pulmonary circulation with an unhealthy interest in mountains. His laboratory studies the effects of hypoxia on pulmonary vascular-cell proliferation and on the physiological responses of the human pulmonary circulation. He has been involved in many of the clinical trials of new therapies for pulmonary hypertension in the last years, and has spent time developing new end points in the assessment of patients with pulmonary vascular disease. He is Chair of the Pulmonary Circulation Group of the European Respiratory Society and the author of more than 150 papers, reviews and chapters on pulmonary vascular disease. He is co-editor with Lew Rubin of *Pulmonary Circulation* (2nd Edition): diseases and their treatments (3rd Edition in process).

Dr Linda Pearce is a Respiratory Nurse Consultant at West Suffolk Hospital and Clinical Lead for the Suffolk COPD Services. Her interest in respiratory health started as an occupational nurse and progressed through practice nursing. She completed her Doctorate in Nursing at Essex University and her thesis looked at non drug management of breathlessness in COPD.

Professor Michael Polkey is Consultant Physician in the Department of Sleep and Ventilation at the Royal Brompton Hospital and Professor of Respiratory Medicine at the National Heart and Lung Institute, London. His research interests include mechanisms of respiratory failure, systemic aspects of COPD and lung volume reduction surgery.

Dr Robert Primhak is a Consultant Paediatric Respiratory Physician at Sheffield Children's Hospital. He trained in paediatrics in Auckland, Newcastle, Toronto and Sheffield, and worked for two years as a paediatrician in Papua New Guinea. He was chair of the RCPCH Working Party on Sleep Physiology.

Dr Garth Rapeport is Managing Director of Respivot, a London-based drug discovery company focussed on new approaches to COPD, severe asthma and cystic fibrosis (CF). Respivot was co-founded with Dr Peter Strong (ex GSK) together with Professor Peter Barnes and Dr Kaz Ito, based at the National Heart and Lung

SPEAKERS' BIOGRAPHICAL DETAILS

Institute (NHLI), Imperial College, London. Dr Rapeport is also a non-executive director of Galapagos NV and is Honorary Principal Research Fellow at the National Heart and Lung Institute, Imperial College School of Medicine in London.

Dr Robert Rintoul is a Consultant Respiratory Physician with a special interest in lung cancer and mesothelioma at Papworth Hospital, Cambridge, UK. He undertook clinical training in Edinburgh and London and performed his doctoral research in Professor Tariq Sethi's laboratory in the University of Edinburgh. He is currently Lead Clinician for Thoracic Oncology at Papworth Hospital. He has a particular interest in developing novel techniques in diagnostics and staging. Part funded by the NIHR Cambridge Biomedical Research Centre and the Comprehensive Local Research Network, Dr Rintoul is a principal investigator for several translational and basic science research projects in lung cancer and mesothelioma. In collaboration with colleagues in Cambridge and beyond, he is building a research programme for the detection and management of pre-neoplasia. Dr Rintoul is a member of the NCRI Lung Clinical Studies Group and the Mesothelioma subgroup as well as being Chair of the Lung CSG SCEPTRE subgroup. He is also a member of the NICE Lung Cancer Guideline Development Group, BTS interventional bronchoscopy guideline and DH Lung Cancer and Mesothelioma Advisory Group.

Dr Matthew Robinson leads a number of programmes at MedImmune centred on innate immune cell biology in respiratory and autoimmune diseases. Previously, his post-doctoral research focused on Pattern Recognition Receptors, most noticeably defining the roles of novel C-type Lectins Receptors in host defence with Professor Reis e Sousa at CRUK.

Professor Ian Sabroe is Professor of Inflammation Biology at the University of Sheffield. His lab focuses on mechanisms of airway and vascular inflammation, with a particular interest in innate immunity and phagocyte biology. His clinical interests are severe asthma and pulmonary arterial hypertension.

Jane Scullion is currently a Respiratory Nurse Consultant at the University Hospitals of Leicester and SHA East Midlands LTC Clinical lead and shared post of Respiratory Clinical Lead. She is currently Chair of the Nurse Advisory Group for the BTS and a Trustee at PCRS and Respiratory Education UK.

Professor Ben Shaw trained in Birmingham, Edinburgh and Liverpool and is now Consultant in Neonatal and Respiratory Paediatrics at Liverpool Womens Hospital and the Royal Liverpool Children's Hospital, and Professor at Evidence-based Practice Research Centre, Edge Hill University. Previously he was Clinical Director of the Neonatal Unit at Liverpool Women's Hospital, R and D Director at Liverpool Women's Hospital and Associate Postgraduate Dean for Mersey Region. His

research interests are neonatal respiratory disease and medical education.

Dr Claire Shovlin is Senior Lecturer at Imperial College London and Honorary Consultant at Imperial College Healthcare NHS Trust. Dr Shovlin's early research training was in the laboratories of Professors Sir Martin Evans (Cambridge, 1984) and Michael Hayden (UBC, Vancouver, 1987). Her subsequent experience in pulmonary AVMs and hereditary haemorrhagic telangiectasia spans 18 years, including three years at the Department of Genetics, Harvard Medical School, and 11 years running a national service, reviewing more than 1,000 patients.

By 1998, she had recognised the substantial obstacles to the delivery of molecular medicines for rare diseases, and the potential value of more generic approaches. Using replicate prospective series to define the HHT/PAVM cohorts as models of thrombovascular risk, she has generated a reverse translational research programme in which clinical, cellular and second generation molecular approaches are delivering tangible health benefits to patients.

Dr Anita Simonds is a Consultant in Respiratory Medicine at the Royal Brompton Hospital with a special interest in non-invasive ventilation, home ventilation in adults and children, neuromuscular disorders and end stage lung disease.

Professor John Simpson is Professor of Respiratory Medicine at Newcastle University. His group is interested in mechanisms of innate immune regulation and dysfunction, with particular reference to nosocomial infection and acute lung injury. In parallel, the group seeks to develop novel therapeutic strategies for severe infective and non-infective lung injury.

Professor Sally Singh has worked in the field of pulmonary rehabilitation for several years; she is Head of Pulmonary and Cardiac Rehabilitation at the University Hospitals of Leicester NHS Trust and is Professor of Pulmonary and Cardiac Rehabilitation at Coventry University. She is the current Chair for the Pulmonary Rehabilitation Group for the ERS.

Dr Mark Slade graduated from Cambridge University in 1979 in theoretical physics. He worked in scientific book publishing as an editor before deciding to study medicine as a mature student at Guy's Hospital, beginning in 1986. He completed his training in medicine in Oxford, Cambridge, Sydney and Norwich, before being appointed to a consultant post in respiratory medicine in Oxford in 2000. Dr Slade specialises in lung cancer and mesothelioma, and more particularly in interventional bronchoscopy. He moved to Papworth Hospital in July 2008 and was appointed as Clinical Director of Thoracic Services in April 2009. Dr Slade represented Great Britain at the Olympic Games in sabre fencing in 1980,

SPEAKERS' BIOGRAPHICAL DETAILS

1984 and 1988, and has three Commonwealth silver medals for fencing.

Professor Alan Smyth is Professor of Child Health at the University of Nottingham and Honorary Consultant in Paediatric Respiratory Medicine at Nottingham University Hospitals NHS Trust. He is Director of the Nottingham Children and Young Person's Cystic Fibrosis Clinic, which provides care for 160 children. He also sees children with asthma, TB, HIV, specialist respiratory problems and general paediatric problems.

Professor Smyth is a member of the Nottingham Respiratory Biomedical Research Unit, and has a major research interest in novel ways of treating infection in cystic fibrosis. His group have ongoing projects looking at inhibition of bacterial communication. By way of contrast they are also looking at more effective ways of communicating with sick children.

He is also Director of the Trent Local Research Network, under the Medicines for Children Programme, and Co-ordinating Editor of the Cochrane Cystic Fibrosis and Genetic Disorders Group. When not working, he loves cycling, runs half marathons (increasingly slowly) and tries to keep up with his children.

Dr Kevin Southern completed his PhD, examining gene transfer as a therapy for CF, and then consolidated his research training with a MRC Research Fellowship at the University of North Carolina. He is currently Reader at the University of Liverpool, Editor for the CF and Genetics Disorders Cochrane Review Group and Chair of the European NBS Working Group.

Dr David Spencer is a Consultant in Respiratory Paediatrics in Newcastle. He trained in paediatrics in Edinburgh, London and the West Midlands before moving to Newcastle in 1996. His clinical and research interests include the consequences of community acquired pneumonia in children, non-CF bronchiectasis and the epidemiology of empyema in children.

Dr Duncan Stewart is the CEO and Scientific Director of the Ottawa Hospital Research Institute. His group has initiated Canada's first clinical trials using gene and cell therapy for cardiovascular disease, including therapeutic angiogenesis for end stage coronary artery disease and progenitor cell therapy for pulmonary hypertension.

Dr Alistair Story is a Consultant Nurse and Epidemiologist at the Health Protection Agency Centre for Infections in London. His main area of interest is the control and public health impact of infections among 'hard to reach' groups, especially homeless people, drug users and prisoners. He currently leads Find and Treat, a pan-London street outreach service supporting the detection, diagnosis and management of TB among hard to reach groups in London.

Dr Denis Talbot is a Reader in Cancer Medicine at the University of Oxford and has an active interest in clinical trials in thoracic oncology and the development of objective assessment of physician/patient communication skills. He is Regional Specialty Advisor for medical oncology, a member of the NCRI lung cancer group and of the CRUK Clinician Scientist Fellowship Appointment Board.

Professor Neil Thomson is the Professor of Respiratory Medicine at the University of Glasgow and Heads the Respiratory Medicine Section within the Institute of Infection, Immunity and Inflammation at the University of Glasgow. He is an Honorary Consultant based at Gartnavel General Hospital, Glasgow. He graduated from the University of Glasgow and undertook postgraduate training in Glasgow, London and McMaster University, Canada. He is a former member of the Committee for Safety of Medicine and a former Chair of the Scientific Committee of the British Lung Foundation and of the National Asthma Campaign Therapy Working Group. He has co-edited several textbooks on asthma and COPD. His current research interests include the interaction between smoking and asthma, biomarkers in airway disease and the assessment of novel treatments for asthma and COPD.

Mr David Waller graduated from Nottingham in 1985 and trained in cardiothoracic surgery in Sheffield, Leeds, Newcastle, Coventry and Birmingham. He has been a Consultant at Glenfield Hospital, Leicester since 1997. He has a special interest in mesothelioma, performing over 25 radical procedures annually and with over 25 peer reviewed publications on the subject. He is Chair of the NCRI mesothelioma subgroup and a member of the ERS/ESTS mesothelioma taskforce.

Dr Sarah Walmsley is a Wellcome Intermediate Fellow in the Academic Unit of Respiratory Medicine, the School of Medicine and Biomedical Sciences at the University of Sheffield. She has a research interest in the role of hypoxia and the HIF hydroxylase pathway in the regulation of neutrophilic inflammation.

Dr Chris Warburton is Consultant Physician and Clinical Director of the Aintree Chest Centre, Liverpool and is Chair of the BTS Occupational and Environmental Lung Health Specialist Advisory Group. The SAG's main aim is to promote training and understanding of occupational and environmental aspects of lung disease.

Professor Wisia Wedzicha is Professor of Respiratory Medicine at the UCL Medical School, University College London and the Royal Free Hospital. She qualified from Somerville College, Oxford University and St Bartholomew's Hospital Medical College, London University. She has a major interest in the causes, mechanisms and impact of COPD exacerbations and in the role of bacterial and viral infection at COPD exacerbation. She directs an active research group into COPD exacerbations and has published extensively on this topic. She chairs the Department of Health Home

SPEAKERS' BIOGRAPHICAL DETAILS

Oxygen Clinical User Group. She was a member of the Guideline Development Group for the revision of the NICE COPD guidelines, and is currently a member of the Programme Board for the COPD National Clinical Strategy. Until June 2010, she was Editor in Chief of Thorax, and is a member of the BMJ and AJRCCM advisory boards and on the editorial board of a number of international journals.

Dr Sophie West is a Consultant in Respiratory Medicine at the Freeman Hospital, Newcastle upon Tyne, where she is Head of the Regional Sleep Service. Her main research interests are obstructive sleep apnoea, insulin resistance and type 2 diabetes.

Professor Martin R Wilkins is Professor of Clinical Pharmacology, Head of the Division of Experimental Medicine, Imperial College London and Director of Clinical and Investigative Sciences within Imperial College Healthcare NHS Trust. He is a Consultant Physician within Imperial College Healthcare NHS Trust and has been the Director of the Sir John McMichael Centre for Clinical Research at the Hammersmith Hospital since its establishment in 2001.

Professor Robert J Wilkinson is a Wellcome Trust Senior Fellow in Clinical Tropical Medicine and Director of the University of Cape Town Clinical Infectious Diseases Research Initiative. He is also Professor of Infectious Diseases at Imperial College London, and MRC Programme Leader at the National Institute for Medical Research, Mill Hill, London. Professor Wilkinson trained in Cambridge, Oxford, London, Edinburgh, Sudan and the United States. His major research interest is the immunology of tuberculosis, particularly in the context of HIV infection. He is an author of the Oxford Handbook of Tropical Medicine and has published a number of original research and review articles on tuberculosis and other infectious diseases.

Dr Ian Woolhouse is a Consultant Physician in Respiratory and General Medicine at University Hospitals Birmingham NHS Foundation Trust. In 2007 he set up the first endobronchial ultrasound service in the Midlands. He took up the role of associate director to the National Lung Cancer Audit in 2009. He is clinical lead on the Improving Lung Cancer Outcomes Project which aims to reduce process and outcome variation for lung cancer patients in England.

EXHIBITORS' INFORMATION

Actelion Pharmaceuticals Ltd

Stand numbers 10 & 13

Actelion Pharmaceuticals Ltd is a biopharmaceutical company, focusing on the discovery, development and commercialisation of innovative treatments to serve high unmet medical needs. Please come and visit us at stands 10 & 13 for more information on pulmonary arterial hypertension and our products.

Tel: +44 (0)20 8987 3336

Email: Rachel.fortes@actelion.com

Website: www.actelion.com

Air Products

Stand number 12

Air Products is a global provider of home respiratory services. We serve 420,000 patients across the world through the provision of respiratory therapies, such as CPAP, oxygen, NIV, nebuliser and infusion services in their homes. In the UK, we provide the NHS Home Oxygen Service to over 52,000 patients across England and Wales. Our specialist teams serve patients with conditions ranging from chronic lung disease, asthma and emphysema to sleep apnoea. And we strive to improve their quality of life, by supporting clinicians through the provision of therapy equipment to patients in the home environment, offering 24/7 technical support and sharing therapy compliance data.

Tel: + 44 (0)800 373 580

Website: www.airproducts.co.uk/homecare

Airsonett

Stand number 43

Airsonett is a research based medical technology company with a unique technology which leads the development of preventative and secondary preventative treatment of allergic asthma as well as management of airborne bacteria and virus contamination. Airsonett has an extensive patent portfolio and is investing heavily in clinical research and product development. Airsonett was awarded the title Sweden's *MedTech Company of the Year 2009*.

Protexo® is a secondary preventative device which minimizes the exposure of allergen during night time. Protexo is recommended to patients with moderate to severe perennial allergic asthma (such as pet and mite allergies).

Tel: +46 431 402 530 (Headquarters in Sweden)
+44 (0)777 542 3322 (Brian Jones, UK Sales Office)

Email: brian.jones@airsonett.com

Website: www.airsonett.com

Association of Chartered Physiotherapists in Respiratory Care (ACPRC)

Stand number C59

ACPRC are a special interest group for physiotherapists, working to promote best physiotherapy practice in all areas of respiratory care. The ACPRC champions four specific areas within respiratory care: chronic disease, paediatrics, critical care and surgery/cardiothoracics.

We have over 800 members with expertise in all areas of respiratory physiotherapy and are closely linked with the Chartered Society of Physiotherapy.

We run annual study days, publish a peer reviewed journal and are a source of expertise for national and international projects.

Tel: +44 (0)207 831 8778

Website: www.acprc.org

The Association of Respiratory Nurse Specialists (ARNS)

Stand number C52

LEADING, INSPIRING, EMPOWERING

The Association of Respiratory Nurse Specialists (ARNS) exists to promote a higher level of respiratory nursing practice through leadership, education and professional development and to influence the direction of respiratory nursing care.

Tel: +44 (0)20 7228 3847

Email: info@arns.co.uk

Website: www.arns.co.uk

Association for Respiratory Technology and Physiology (ARTP)

Stand number C63

The ARTP is the sole professional organisation in the UK for practitioners working in clinical respiratory physiology and technology.

The ARTP provides the only national, professionally recognised, professional qualifications in Pulmonary Function Testing and Spirometry. An important function of the ARTP is the provision for Continuing Professional Development. The ARTP organises an Annual Conference and training courses on many respiratory topics including practical blood gas sampling, interpretation of lung function results, respiratory muscle assessment, sleep disorders and cardiopulmonary exercise testing. Additionally, ARTP coordinates spirometry training centres throughout the UK. The ARTP also write and publish textbooks in lung function testing and physiology.

The ARTP have recently launched ARTP Sleep to represent practitioners working in Sleep Medicine, and have written standards documents. The ARTP will shortly be launching an e-learning module in spirometry.

Tel: +44 (0)845 226 3062

Website: www.artp.org.uk

Asthma UK

Stand number C57

Asthma UK is the charity dedicated to improving the health and well-being of the millions of people with asthma in the UK. We work with people with asthma, healthcare professionals and researchers to develop and share expertise to help people increase their understanding and reduce the effect of asthma on their lives.

You can contact the Asthma UK Advice line team of asthma nurse specialists on:

Tel: +44 (0)800 121 62 44

EXHIBITORS' INFORMATION

Our Supporter and Information Team deals with queries about membership, donations and information, plus any general queries you have about Asthma UK.

Tel: + 44 (0)800 121 62 55

Email: info@asthma.org.uk

Website: asthma.org.uk

AstraZeneca Stand numbers 27, 28 & 39

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies, investing \$5.2 billion in medicines research and development in 2009, and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines.

Tel: +44 (0)1582 836 000

Website: www.AstraZeneca.co.uk

Atrium Stand number 19

Atrium was founded with the philosophy of providing the finest quality, most innovative and cost effective medical products available. This commitment to excellence and quality has earned Atrium the reputation as a leading edge medical device provider to the global healthcare community.

INDICATION BY DESIGN

With millions of chest drains sold to date worldwide, Atrium has discovered that one drain design does not necessarily fit all thoracic drainage indications. Atrium's innovative Indication By Design platform now sets a new bar for clinical performance, providing a full line of operating systems and specialty drainage products designed to cater to the needs of cardiac, thoracic and pediatric patients as well as a line of mobile drains that can get your patients ambulatory faster and safer. Atrium's complete family of chest drains are MRI compatible, latex-free, and feature multi-position hangers, a needleless access port for patient drainage sampling, automatic high negative pressure relief and knock-over nozzles to help reduce interchamber spills.

Tel: +44 (0)161 209 3675

Email: atriumuk@atriummed.com

Website: www.atriummed.com

Bedfont Scientific Ltd Stand number 44

BREATH ANALYSIS IS THE NEW BLOOD TEST

Bedfont Scientific Ltd is an award-winning worldwide market leader in breath gas analysers for medical applications.

Smokerlyzer handheld CO monitors are the global benchmark in smoking cessation, the NObreath FE_{NO} monitor is a revolutionary monitor for airway inflammation in asthma, and the Gastro+ is an indispensable hydrogen monitor for gastrointestinal disorders including lactose malabsorption.

With over 30 years' experience in its field, Bedfont is a small company with a big global presence. Bedfont's experienced research and development team

is passionate about finding quick, simple and non-invasive solutions for a variety of medical disorders.

Tel: +44 (0)1634 673 720

Email: ask@bedfont.com

Website: www.bedfont.com

BOC Healthcare Stand number 45

BOC Healthcare is a leading supplier of medical gases globally and in the UK. Our home oxygen service provides the best oxygen therapy and full support for patients of all ages with a wide variety of respiratory conditions (breathing problems). We currently supply oxygen therapy to approximately 10,000 patients living in the East of England.

BOC Healthcare is also involved in providing superior associated services to respiratory deficient patients. These services to patients of all ages and suffering from a variety of breathing conditions are supported by the latest innovative equipment and clinical assistance. To find out more please visit stand 45.

Tel: +44 (0)800 136 603

Email: healthcare.home-uk@boc.co.uk

Website: www.bochealthcare.co.uk

Boehringer Ingelheim GmbH and Pfizer Inc Stand number 9

Boehringer Ingelheim is one of the 20 leading pharmaceutical corporations in the world. As leader in COPD treatment, the company is committed to delivering high-quality respiratory care through the discovery of new respiratory medicines (SPIRIVA®) and delivery systems (RESPIMAT®), thus providing benefit for patients and healthcare providers.

Pfizer Inc discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known brands. Our innovative products improve the quality of life of people the world over and helps them enjoy longer, healthier, and more productive lives.

Tel: +44 (0)1344 424 600 (Boehringer Ingelheim)

+44 (0)1304 616 161 (Pfizer)

Websites: www.boehringer-ingelheim.com
www.pfizer.com

British Lung Foundation Stand number C51

The British Lung Foundation is the only UK charity working for everyone affected by lung disease. We focus our resources on providing support for people affected by lung disease today; and work in a variety of ways, including funding world-class research, to bring about positive change, to improve treatment, care and support for people affected by lung disease now and in the future.

Tel: +44 (0)20 7688 5555

Email: enquiries@blf-uk.org

Website: www.lunguk.org

EXHIBITORS' INFORMATION

British Thoracic Oncology Group (BTOG) **Stand number C60**

BTOG aims to improve the care of patients with thoracic malignancies through multidisciplinary education and clinical and scientific research.

BTOG represents all the disciplines involved in the care of lung cancer and mesothelioma throughout the UK. BTOG also aims to provide a Continuing Education Format for all professionals involved in the management of lung cancer and mesothelioma and to act as a body that could both help develop and give advice on thoracic oncology guidelines for patient care and to generate ideas for clinical trials and develop these ideas into full protocols.

Tel: +44 (0)116 250 2811

Email: dawn.mckinley@uhl-tr.nhs.uk

Website: www.BTOG.org

Cellestis Ltd **Stand number 20**

Cellestis Limited is a listed Australian biotechnology company that is a leader in the detection and control of tuberculosis, with the development of its breakthrough blood test: QuantiFERON®-TB Gold In-Tube (QFT™). Using its patented QuantiFERON technology, Cellestis develops diagnostics tests that measure immune function for diseases with an unmet medical need. QFT and other QuantiFERON products are sold directly in the US by Cellestis Inc; in Europe by Cellestis GmbH (Germany); and in Australia and Asia by Cellestis International Pty Ltd (Australia). QFT is also available through commercial partners in Japan, Europe, the Middle East and other countries worldwide.

Tel: +49 (0)6151 428 590

Email: Europe@cellestis.com

Website: www.cellestis.com

Chiesi Ltd **Stand numbers 30, 36 & 37**

A research-focused international company, developing and bringing innovative pharmaceutical solutions, which relieve and improve the quality of human life. An organisation that combines commitment and results with integrity, operating in a socially and environmentally responsible manner.

Established in the areas of respiratory, cardiovascular and musculoskeletal medicine, with a research pipeline focused on the treatment of respiratory disease and rare illnesses.

Tel: +44 (0)161 488 5555

Email: info@chiesi.uk.com

Website: www.chiesi.uk.com

Cryopal **Stand number 22**

Specialising in the homecare oxygen therapy system, CRYOPAL has been designing, manufacturing and distributing the FREELOX range of stationary reservoirs and portables for more than 30 years throughout the world. Its good range of homecare devices have been nicely designed to help active patients maintain a normal day to day life. To discover the full range of FREELOX, come and visit us at the BTS Winter Meeting (stand number 22), or through our website.

Tel: + 33(0)164 761 500

Website: www.laboutiquecryo.com

Department of Health **Stand number C49**

Under the Coalition Government the Department of Health now has five priorities:

- First, that patients must be at the heart of everything we do – as more than simply beneficiaries of care, but as participants in its design.
- Second, the NHS must be focused on achieving continuously improving outcomes for patients – not inputs or processes, but results.
- Third, we must empower clinicians – those responsible for patient care – to deliver those improvements.
- Fourth, if we are to improve overall health outcomes and make the demands on the NHS more sustainable, we must prioritise prevention and create a public health service.
- Fifth, we must reform social care alongside healthcare – and deliver closer integration in how services are commissioned and provided.

The primary purpose of the NHS must be: to improve the quality of care, and achieve outcomes that are amongst the best in the world.

Website: www.dh.gov.uk

Education for Health **Stand number C53**

Education for Health is the UK's leading education charity for health professionals working with patients with long term conditions and our education has been shown to measurably improve services and health outcomes. We believe education should be at the heart of service improvement and not as an add on. We find ourselves being asked to set the standard for effective education and asked to partner with health organisations across the globe to pioneer best practice learning experiences to materially and substantially benefitting patient care. We would welcome any opportunity to share this unique information, knowledge and expertise.

Historically our distance learning programmes have been paper based but in 2010 we have harnessed the enormous potential of the internet and digital technologies by developing dynamic, interactive e-learning programmes.

Tel: +44 (0)1926 836 849 (Rachel Clarke)

Email: r.clarke@educationforhealth.org

Website: www.educationforhealth.org

Fentons Solicitors LLP **Stand number 31**

Fentons Solicitors LLP is one of the country's leading claimant personal injury firms. We have a specialist occupational illness department with experienced solicitors dealing with mesothelioma, asbestos related lung cancer, asbestosis, pleural thickening, occupational asthma and byssinosis cases. We are happy to explain the complexities of the legal system, why some cases are successful and some are not and the importance of early referrals to specialist solicitors. Our team of specialists

EXHIBITORS' INFORMATION

is at stand 31 to discuss any issues you may have and answer your questions.

Tel: +44 (0)845 026 4749

Email: info@fentons.co.uk

Website: www.fentons.co.uk

Fisher & Paykel Healthcare Ltd UK **Stand number 6**

Fisher & Paykel Healthcare Ltd UK is a wholly owned subsidiary of Fisher & Paykel Healthcare New Zealand. Fisher & Paykel Healthcare has more than twenty years of expertise in heated humidification and temperature control. Our product range reflects the continuing technological development that is our aim, and which ensures we continue to provide our customers with innovative and reliable products that assist in providing the best patient care.

Tel: +44 (0)1628 626 136

Email: customerservice@fphcare.co.uk

Website: www.fphcare.co.uk

Forest Laboratories UK Ltd **Stand numbers 7 & 8**

Forest Laboratories UK Ltd has recently launched Nebusal™ (Sterile 7% hypertonic sodium chloride solution) for use in mobilisation of secretions in the lower respiratory tract in patients such as those with cystic fibrosis (CF), bronchiectasis, chronic obstructive pulmonary disease (COPD) and severe asthma. Forest also markets Colomycin (Colistimethate sodium) as a treatment option within cystic fibrosis, within the UK and Ireland.

Tel: +44 (0)1322 421 800

Website: www.forestlabs.com

GlaxoSmithKline **Stand numbers 17, 23 & 24**

GlaxoSmithKline have a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative medicines and products that help millions of people around the world.

We are one of the few pharmaceutical companies researching both medicines and vaccines for the World Health Organization's three priority diseases – HIV/AIDS, tuberculosis and malaria, and are very proud to have developed some of the leading global medicines in these fields.

Headquartered in the UK and with operations based in the US, we are one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market. But being a leader brings responsibility. This means that we care about the impact that we have on the people and places touched by our mission to improve health around the world.

It also means that we must help developing countries where debilitating disease affects millions of people and access to life-changing medicines and vaccines is a problem. To meet this challenge, we are committed to providing discounted medicines where they are needed the most.

As a company with a firm foundation in science, we have a flair for research and a track record of turning that research into powerful, marketable drugs. Every hour we spend more than £300,000 (US\$562,000) to find new medicines.

We produce medicines that treat major disease areas such as asthma, virus control, infections, mental health, diabetes and digestive conditions. In addition, we are a leader in the important area of vaccines and are developing new treatments for cancer.

Tel: +44 (0)800 221 441

Email: customercontactuk@gsk.com

Website: www.gsk.co.uk

Healthy Outlook® from the Met Office **Stand number C55**

Healthy Outlook® is a service provided by the Met Office which helps people with COPD to stay well and avoid hospital admissions. Traditionally the service has been offered in the winter months, however in 2010 in response to patient feedback, it will be a year round service. It warns them by an automated telephone call when environmental conditions are expected which could make their condition worse. The service encourages patient self-care and can alleviate some of the pressure on NHS resources.

Tel: +44 (0)870 900 0100

Email: Health@metoffice.gov.uk

Website: www.metoffice.gov.uk/healthyoutlook

Hitachi Medical Systems **Stand number 14**

EBUS guided TBNA – The new generation complementary to EUS-FNA

Hitachi's latest Endobronchial Ultrasound System (EBUS) combines high resolution ultrasound with high definition video imaging which together play a vital role in delivering accurate information for precise tumour staging. Safe, accurate and significantly less invasive for complete mediastinal staging.

Tel: +44 (0)844 800 4294

Website: www.hitachi-medical-systems.com

LAM Action **Stand number C62**

LAM Action is the UK charity for patients with lymphangioleiomyomatosis (LAM). Its primary aims are:

- To provide support and information for LAM patients and their families
- To educate health professionals about LAM and advance research into LAM

LAM is a rare multi-system disease, diagnosed mainly in women of childbearing age. It mainly affects the lungs, causing excessive growth of smooth muscle cells which progressively destroys lung tissue and erodes lung function. Currently, there is no cure for LAM and no effective treatment, so for many patients lung transplantation is the only means of survival.

Tel: +44 (0)115 823 1934 (Jan Johnson, LAM Coordinator)

Email: jan.johnson@nottingham.ac.uk

Website: www.lamaction.org

EXHIBITORS' INFORMATION

Lung Improvement Programme

Stand number C65

The Lung Improvement programme was officially launched on 1st November 2009 and is the latest programme to come under the growing NHS Improvement umbrella. Like the other NHS Improvement programmes, Lung Improvement will look to establish a robust and practical programme that will be closely aligned to QIPP policy and national strategy, and support both implementation and delivery.

The programme will initially cover chronic obstructive pulmonary disease (COPD), asthma and home oxygen services. It is an initiative to support the implementation of a National Strategy for England. The programme will work closely with the Department of Health respiratory team and in partnership with each Strategic Health Authority (SHA) and the SHA Clinical Leads for Respiratory Care.

Priorities and delivery for 2010/2011 – The programme objectives for 2010/11 are:

- To undertake local projects and testing to inform and accelerate local change using robust evidence, information management and service improvement and redesign methodologies
- To support clinical teams and the SHA respiratory clinical leads to deliver the National Strategy for England
- To align with other key national priorities such as Long Term Conditions, Right Care and the QIPP agenda
- Support the SHA clinical leads to develop communities of practice and to enhance existing respiratory networks at local level
- Identify early evidence of new models and pathways of care, and tested principles for COPD improvement, including their potential application across all respiratory services
- Disseminate information, resources and good practice examples that support the delivery of high quality respiratory services

Tel: +44 (0)116 222 5233
Email: phil.duncan@improvement.nhs.uk
Website: www.improvement.nhs.uk

Medela

Stand number 4

Medela has been established for over 45 years working in the areas of breastfeeding, neonatology and medical vacuum. In 2007 Medela launched the innovative Thopaz digital drainage system which enables surgeons and physicians to accurately quantify postoperative air leaks. Clinical experience has shown Thopaz reduced chest tube duration by 1.4 days and length of stay for pneumothorax patients by more than one day with between 20 and 75% patients discharged early depending on the type of procedure. In addition both patients and surgeons expressed a preference for Thopaz over traditional analogue drains.

Tel: +44 (0)870 950 5994
Website: www.medela.co.uk

Merck Sharp & Dohme Limited

Stand number I I

Today's MSD is a global healthcare leader who is working to help the world be well.

Through our medicines, vaccines, biologic therapies, and consumer and animal products, we collaborate with human and animal health professionals across the UK and in more than 140 countries to deliver innovative health solutions.

Beyond this, we have a commitment to increasing access to healthcare through far-reaching programmes that donate and deliver our products to people who need them.

Tel: +44 (0)1992 467 272
Website: www.msd-uk.co.uk

Mesothelioma UK Charitable Trust

Stand number C60

Mesothelioma UK is a resource centre dedicated to mesothelioma. A national free phone helpline that provides access to impartial, accurate and relevant advice specific to mesothelioma for patients, carers and health care professionals. For health care professionals, Mesothelioma UK provides numerous training and educational events, regular news bulletins, has established a National Mesothelioma Nurse Action Team and generally supports health care teams in the management of mesothelioma patients. Mesothelioma UK relies totally on donations to its own independent charity; Mesothelioma UK Charitable Trust.

Tel: +44 (0)800 169 2409
Email: mesothelioma.ukcharity@uhl-tr.nhs.uk
Website: www.mesothelioma.uk.com

Napp Pharmaceuticals Limited

Stand number 15

Napp Pharmaceuticals Limited is committed to building a respiratory portfolio in the UK. Napp holds the strong belief that people matter and caring about them counts, so we're proud to develop and market products to help relieve patients' symptoms and we strive to improve quality of life. Napp already has an established analgesic portfolio and a strong track record in innovation with plans to expand in the respiratory marketplace to begin a new commitment to respiratory medicine.

Tel: +44 (0)1223 424 444
Email: enquiries@napp.co.uk or
 medicalinformationuk@napp.co.uk
Website: www.napp.co.uk

The NHS Information Centre (The NHS IC)

Stand number C54

The NHS IC is England's central authoritative source of health and social care information for frontline decision makers. We release over 120 official and national statistics each year. We provide access to high quality comparative data and information for benchmarking and analysis to help local organisations plan and deliver better care.

The NHS IC Audit Support Unit manages the National Lung Cancer Audit in partnership with the Royal College of Physicians on behalf of Hqip. The audit provides public

EXHIBITORS' INFORMATION

information on the key outcomes concerning patients diagnosed with lung cancer or mesothelioma.

Tel: +44 (0)845 300 6016

Email: enquiries@ic.nhs.uk

Website: www.ic.nhs.uk

Novartis **Stand number 32 & 35**

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products.

The Respiratory Research Centre at Horsham in West Sussex is the Novartis worldwide headquarters for respiratory research, employing over 300 scientists with the site also being the global centre for gastro-intestinal research for Novartis.

Novartis UK employs over 3,500 people across 9 sites. In the UK, the Novartis sites are involved in manufacturing, packaging, customer service and marketing for products used in the UK and worldwide.

Tel: +44 (0)1276 692 255

Website: www.novartis.co.uk

Nutricia UK **Stand number 29**

Nutricia specialises in the delivery of advanced medical nutrition for the very young, the old and the sick. As well as being the largest specialist nutrition company in Europe, Nutricia is the market leader in the UK.

We supply high quality feeds, systems and support services to patients and health care professionals.

Through our Nutricia Homeward service, we deliver nutritional feeds, enteral feeding systems and nursing care directly to patients' homes.

One of Nutricia's latest innovations is a disease targeted nutritional supplement which has been shown to enhance physical capacity when combined with exercise in COPD patients.

Tel: +44 (0)1225 711 688

Email: resourcecentre@nutricia.co.uk

Website: www.nutricia.co.uk

Olympus KeyMed **Stand number 25**

A wholly-owned subsidiary of the Olympus Corporation of Japan, Olympus KeyMed is an important part of the global Olympus network, with specific responsibility for the development and manufacture of medical equipment and industrial products for distribution worldwide.

During the BTS Winter Meeting, Olympus KeyMed will be featuring the latest respiratory products on its stand, including a wide range of products for Endobronchial Ultrasound, flexible bronchoscopes, autoclavable semi-rigid thoracoscope, bronchoscopy accessories and the IBV Valve System, a new minimally invasive treatment for diseased lung in emphysematous patients or damaged lung resulting in air leaks.

Tel: +44 (0)1702 616 333

Website: www.olympus.co.uk

Oxford Immunotec **Stand number 18**

On stand 18, Oxford Immunotec will present the in vitro T-SPOT®.TB test for active and latent tuberculosis.

The T-SPOT.TB test is extremely sensitive and specific, accurately identifying TB in contact tracing scenarios, regular screening of healthcare workers, immigrants, prisoners and the immunosuppressed including HIV patients, cancer, transplant and pre anti-TNF alpha therapies. The test does not cross react with the BCG vaccination or other common mycobacteria.

The T-SPOT.TB test can be easily accessed through Oxford Diagnostic Laboratories National TB Testing Services.

Tel: +44 (0)1235 433 164

Email: odl@oxfordimmunotec.com

Website: www.tbtestingservices.com

Tel: +44 (0)1235 442 780

Email: info@oxfordimmunotec.com

Website: www.oxfordimmunotec.com

PARI Medical Ltd **Stand number 3**

PARI are Europe's leading manufacturer of nebuliser systems, with offices worldwide. For more than 100 years, PARI has been developing solutions for people suffering from respiratory diseases in the form of efficient, reliable nebuliser devices.

Precisely targeted and optimised for different age groups and target areas, the PARI product range can treat an enormous variety of conditions, including asthma, COPD and cystic fibrosis.

The PARI range also includes an anti-static spacer device – VORTEX – which gives a reliable dosage and will fit any MDI. Visit PARI at stand number 3.

Tel: +44 (0)1932 341 122

Email: infouk@pari.de

Website: www.parimedical.co.uk

Pentax **Stand number 26**

PENTAX has a long held reputation as a major innovator in the design and development of medical endoscopy equipment. Our products are used to help save lives and improve the health of others. We have unique and innovative technologies which enable doctors to speed up the diagnosis and treatment of life-threatening diseases. Technologies including SAFE-3000 Autofluorescence Bronchoscopy, Video Endobronchial Ultrasound (EBUS) and High Resolution EUS.

Tel: +44 (0)1753 792 723

Email: lifecare.sales@pentax.co.uk

Website: www.pentax.co.uk

Pfizer Vaccines **Stand number 16**

Pfizer, the world's leading biopharmaceutical company, applies science and global resources to improve health and well-being at every stage of life.

Our commitment to vaccines has a long heritage and spans well into the future. It stretches across a broad range of diseases and populations, including infants, children and adults.

Our innovative conjugate vaccines include Prevenar 13[®]▼, against pneumococcal disease and Meningitec[®], against meningitis C.

We are a reliable and trusted flu vaccine supplier to the NHS with a track record of partnering healthcare professionals to help deliver successful vaccination programmes in the UK.

Tel: +44 (0)1304 616 161

Website: www.pfizer.com

Pharmaxis **Stand number 38**

“Focused innovation in respiratory medicine”

Pharmaxis is a specialist pharmaceutical company committed to the research, development and commercialisation of human therapeutic products that address chronic respiratory and autoimmune diseases.

Our R&D activity has resulted in the successful development of mannitol as a diagnostic test for bronchial hyperresponsiveness. An osmotic agent is also currently being researched as a therapeutic mucoactive agent for potential indications including cystic fibrosis and bronchiectasis.

Website: www.pharmaxis.com.au

Philips Respironics **Stand number 1**

Philips Respironics, a global leader in the sleep and respiratory markets, is passionate about improving the quality of people's lives with solutions that are designed around the needs of our customers and their patients. For Philips Respironics, innovation is driven by gaining insight into the needs of the people who use our products in the areas of sleep management, oxygen therapy, non-invasive ventilation and respiratory drug delivery. This tradition of innovation combined with our ability to anticipate market needs has made Philips Respironics a name acknowledged worldwide as a pace-setter in the markets we serve.

Tel: +44 (0)800 1300 845

Email: rukcustomerservices@respironics.com

Website: www.philips.com/respironics

Primary Care Respiratory Society UK **Stand number C48**

The Primary Care Respiratory Society UK (PCRS-UK) is the UK-wide professional society committed to improving respiratory care in primary care. Registered as a charity, we are led by our members through a range of committees and faculties dedicated to meeting the vision of “optimal respiratory care for all”.

Providing education, policy support and research – We work across all areas of respiratory medicine in primary care; in particular COPD, asthma and respiratory-related allergy, and focus on:

- Offering a wide range of educational services to help you as a health professional – whether you are new to respiratory medicine, simply need to brush up your knowledge or are already an ‘expert’ – to provide quality care to your patients with respiratory disease

EXHIBITORS' INFORMATION

- Influencing policy and setting standards in respiratory medicine, relevant to primary care both nationally and locally
- Facilitating the development of primary care research and generation of evidence needed to support policy and education activities

Our resources and events are written and facilitated by experts who understand both primary care and respiratory care. They provide, not only a quick and easy way to keep up to date in respiratory medicine, but also an opportunity to further your own personal development and network with peers similarly interested in respiratory primary care.

More information about PCRS-UK, and how to join, can be found on our website.

Website: www.pcrs-uk.org/about/join.php

Primary Ciliary Dyskinesia (PCD) Family Support Group **Stand number C56**

The Primary Ciliary Dyskinesia (PCD) Family Support Group is a registered charity who:

- Provide support to patients with PCD and parents of children with the condition
- Bring PCD to the attention of the medical profession and the public
- Provide an up to date information service
- Raise money to promote research to aid diagnosis and treatment of children and adults with PCD

Tel: +44(0)1908 281 635

Email: chair@pcdsupport.org.uk

Website: www.pcdsupport.org.uk

Pulmonary Hypertension Association UK **Stand number C58**

The goal of the Pulmonary Hypertension Association UK is to provide support and information for people with PH, their families, and healthcare professionals working in PH. We hope to improve understanding of the condition and raise awareness of PH among the general public and healthcare professionals.

Tel: +44 (0)1709 761 450

Email: office@phassociation.uk.com

Website: www.phassociation.uk.com

Respiratory Education UK **Stand number C64**

At Respiratory Education UK our fundamental goal is to support patients and practitioners through the challenges now faced within the NHS.

This is achieved through a number of key objectives including the design and delivery of practical and academic study events; influencing respiratory practice via active research and promoting best practice through a number of respiratory related projects. COPD, Spirometry, NIV, Leadership, Commissioning and Consultation Skills are just some examples of the topics we cover, offering a number of named awards at diploma, degree and masters level. These are attainable within as little as one year.

EXHIBITORS' INFORMATION

We look forward to continuing to contribute towards the ongoing advancements in respiratory care through aiding the development of healthcare professionals across the country.

Tel: +44 (0)151 529 2598

Website: www.respiratoryeduk.com

Rocket Medical PLC **Stand Number 5**

As a UK design and manufacturing company, Rocket take pride in listening to our customers and making appropriate changes to the products to meet the ever changing ideas and to ensure patient safety.

Last year we launched the NEW Safety Seldinger Sets and procedure Trays and since then we have added the new fixation device along with the larger sizes. Visit our team on stand 5 and discuss new ideas in the pipeline, ideas that you may have for new products or improvements to existing products or just come along and say 'hello'.

Tel: +44 (0)191 419 6988

Email: homesales@rocketmedical.com

Website: www.rocketmedical.com

S-Med Ltd **Stand number 33**

S-Med Ltd will be showing the KarmelSonix Acoustic Respiratory Monitoring (ARM) Equipment at this year's BTS Winter Meeting. ARM offers advantages with respect to the capture, storage and analysis of respiratory sounds objectively and with no patient cooperation.

KarmelSonix provides a full range of products, from ambulatory to PFT Labs, A&E, Sleep Labs to ITU.

Come see how the PulmoTrack, Wholter and Wheezometers can help with both asthma and COPD diagnosis and management.

Tel: +44 (0)121 446 6953

Email: sales@s-med.co.uk

Website: www.s-med.co.uk

TB Alert **Stand number C61**

TB Alert – the UK's national tuberculosis charity
For over ten years TB Alert has been the only TB-specific charity working to address tuberculosis both in the UK and overseas. We work in both these arenas not only because they are inter-related, with global travel and migration patterns affecting TB rates in the UK, but also because there is much to be learned from one context that can be applied to the other.

Our Vision is the control and ultimate eradication of TB
Our Mission is to increase access to effective treatment for all

Tel: +44 (0)1273 234 029

Email: info@tbalert.org

Websites: www.tbalert.org and www.thetruthabouttb.org

Teva UK Limited **Stand numbers 40 & 41**

Teva UK Limited is one of the biggest pharmaceutical companies in the UK. We're proud to be part of the Teva Pharmaceutical Industries group, and we make medicines that help improve lives.

We estimate that on average every second, of every day, over 200 tablets or capsules supplied by us are taken

by patients all around the UK. In fact, we like to think of ourselves as the nation's medicine cabinet.

We supply medicines to pharmacies and hospitals, from painkillers to antibiotics, and cholesterol reducers to lifesaving injectable medicines to fight cancer. Our specialities are generic medicines, which are usually medicines whose patents have expired; and respiratory medicines, especially inhalers to relieve the symptoms of asthma.

Tel: +44 (0)1977 628 500

Website: www.tevauk.com

UK Medical **Stand number 42**

UK Medical is the UK distributor of the PleurX catheter for the home management of recurrent pleural effusion and malignant ascites. PleurX is an excellent option for patients with trapped lung and those that have failed talc pleurodesis. Furthermore, PleurX is also indicated as an alternative to talc slurry or thoracoscopic talc insufflation as a first line pleurodesis option.

With UK Medical's commitment to providing the highest level of training and support and over thirty published clinical papers supporting its use, PleurX is an evidence-based option that you can offer your patients with confidence.

Tel: +44 (0)114 268 8880

Email: info@ukmedical.com

Website: www.ukmedical.com

Uptake Medical™ Corporation **Stand number 21**

Uptake Medical™ Corporation is dedicated to improving the lives of patients suffering from emphysema. Uptake is developing Bronchoscopic Thermal Vapor Ablation (BTVA). BTVA is a bronchoscopic lung volume reduction technology intended to improve patients' lung function and quality of life to help them breathe better and live better.

Tel: + 00 1 949 275 5172 (Mike Numamoto, Vice President, Marketing)

Email: miken@uptakemedical.com

Website: www.uptakemedical.com

Vitalograph **Stand number 34**

Vitalograph is respected around the world by secondary care practitioners as a leading provider of high performing respiratory screening, diagnostic and monitoring devices. Vitalograph products and services are also widely trusted in primary care, occupational health and clinical trial environments.

Our commitment to innovation ensures that our wide range of spirometers, electronic and mechanical peak flow meters and consumables remains at the cutting edge of respiratory performance and reliability.

New products include:

- Vitalograph In2itive, a lightweight handheld spirometer that combines the benefits of full spirometry, data integration and mobility with connectivity to Spirotrac V
- ALPHA Touch, a portable spirometer with printing and PC connectivity

EXHIBITORS' INFORMATION

Tel: +44 (0)1280 827 110
Email: sales@vitalograph.co.uk
Website: www.vitalograph.co.uk

Wisepress Medical Bookshop Stand number 46

Wisepress.com, Europe's leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 250 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers, some up to 40% off the publisher list prices.

Tel: +44 (0)20 8715 1812
Email: bookshop@wisepress.com
Website: www.wisepress.com